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ABSTRACT
Protein post-translational modifications (PTMs) are important for a variety of reasons, as
PTMs confer the final protein product and biological functionality onto a nascent protein chain.
Two of the most common PTMs are glycosylation and disulfide bond formation.  Both
glycosylation and disulfide bond formation contribute to a range of cellular processes, including
protein folding and stabilization.  Mass spectrometry (MS) has shown to be an essential
technique to study PTMs, especially when tandem mass spectrometry (MS/MS) experiments are
performed.  In the characterization of PTMs using MS/MS, different fragmentation techniques
are often used.  Regardless of the dissociation method that is employed, MS/MS data
interpretation is a tedious and lengthy procedure.  To render this analysis more efficient, the use
of automated tools is necessary.
In this work, collision induced dissociation (CID) MS/MS experiments were carried out
in order to create a set of fragmentation rules applicable to any N-linked glycopeptide.  These
rules were then used to develop an algorithm to power publicly available software that accurately
determines glycopeptide compositions from MS/MS data.  This program greatly reduces the time
it takes researchers to manually assign the identity of an N-linked glycopeptide to an acquired
CID spectrum.  In addition, electron transfer dissociation (ETD) experiments were performed in
order to devise a computational approach that works to determine precursor charge state directly
from MS/MS data of peptides containing disulfide bonds.  Lastly, alternate fragmentation
patterns found to be detected in MS/MS data of glycopeptides containing labile monosaccharide
residues such as sialic acid, are discussed. These patterns, along with other trends noticed after
extensive analysis of N-linked glycopeptide CID spectra, were then used to propose future
updates to the GPG analysis tool.
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CHAPTER 1
INTRODUCTION
The work described in Chapter 1 encompasses an original (first author) publication:
Woodin, et al. Software for automated interpretation of mass spectrometry data from
glycans and glycopeptides. Analyst. 2013, 138, 2793-2803.
1.1 POST-TRANSLATIONAL MODIFICATIONS
1.1.1 Overview of Post-Translational Modifications. There are currently hundreds of
known protein post-translational modifications, commonly referred to as PTMs, that have been
classified among the archaea, prokaryotes, and eukaryotes.1, 2, 3, 4, 5 Some of the more frequent
PTMs are acetylation, glycosylation, phosphorylation, and disulfide bond formation.1, 4, 6, 7
Collectively, these modifications work to regulate protein structure and function, and various
cellular processes.1, 2, 7, 8, 9 The development and progression of cancer and other diseases are
also shown to be influenced by protein PTMs.10, 11 In eukaryotic organisms, glycosylation and
disulfide bond formation are two of the most prevalent modifications that a protein undergoes
after translation. As it stands, it is estimated that over 50 % of a eukaryote’s cells are
glycosylated and contain disulfide bonds.4, 12 Furthermore, both glycosylation and disulfide
bond formation have been heavily implicated in the design of safe and effective protein
pharmaceuticals.6, 13, 14
1.1.2 Characterization of Protein PTMs. Many methods of instrumental and
biochemical analysis have been used to study protein PTMs, including glycosylation and
disulfide bond formation, with varying degrees of success. Some examples reported in the
literature are: Edman degradation, crystallography, nuclear magnetic resonance (NMR), circular
dichroism (CD), and mass spectrometry (MS).15, 16, 17, 18, 19,  20 Currently, mass spectrometry is
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the most utilized analytical route in the sequencing of proteins containing PTMs.16, 21 In contrast
to other spectroscopic methods such as NMR and crystallography, MS experiments allow for the
accurate detection and characterization of these modifications using only a small volume of
sample.22 Furthermore, liquid chromatography mass spectrometry (LC-MS) permits the
interrogation of PTMs when heterogeneous protein mixtures are considered.22, 23, 24 To this end,
LC-MS analysis of proteins and peptide PTMs in complex biological matrices is now routinely
performed.22, 23
1.1.3 Analysis of Protein PTMs by Mass Spectrometry. In the identification of protein
PTMs, MS experiments have shown to be useful in mapping their location, and correlating that
information with biological functionality.22, 24 This has been accomplished using various types
of mass spectrometers.16, 18, 21, 22, 23, 25 Regardless of the type of mass measurements performed,
there are three main components to an MS instrument.22
1) An ion source to generate ions.
2) A mass analyzer to separate ions, based on their m/z.
3) A detector to quantify each ion’s abundance.
For the study of biomolecules, electrospray ionization (ESI) and matrix-assisted
desorption ionization (MALDI) are the two most common methods used to generate ions.16, 21, 22,
26 A variety of mass analyzers may be coupled to these ionization sources.16, 21, 22 ESI is
routinely coupled to LC-MS systems with both low resolution, and high resolution, analyzers.22,
23 Depending on the type of mass analyzer, the method of detection for the ions varies, although
in most instruments ions are detected when they make physically contact with the detector,
which often occurs in electron multipliers.21, 25
In order to distinguish isobaric peptide compositions using mass spectrometry, including
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those containing post-translational modifications (e.g. glycosylated or disulfide-bonded
peptides), tandem mass spectrometry (MS/MS) experiments are usually required.  The
fragmentation profiles obtained within tandem mass spectra allow a precursor’s identity to be
determined in cases where a number of potential compositions have the same nominal mass; that
is, when their in silico mass calculations differ by less than the instrument’s accepted error
range.27, 28
To increase the efficiency at extracting relevant PTM information, researchers have
developed an arsenal of analysis tools and computer software programs to automate both MS and
MS/MS data interpretation.29, 30, 31 Figure 1 provides an illustration of this analytical process.
Figure 1. In the characterization of glycosylation PTMS, glycopeptide analysis provides
location information to identify where the modification resides along the amino acid sequence.
After the appropriate MS scans are performed, the use of computer software and automated
analysis tools substantially increases the amount of data that can be processed for a given amount
of time, as compared to data analyzed manually.29
1.1.3.1 Electrospray Ionization Mass Spectrometry. The application of ESI in
characterization of biomolecules by MS has greatly advanced the field of proteomics. The wide
applicability of electrospray ionization mass spectrometry (ESI-MS) to large molecules has
enabled the amino acid sequencing of proteins, including those with PTMs.23, 26, 32, 33,  34, 35, 36 In
ESI-MS, a sample is introduced into the source by way of a stainless steel capillary needle (ESI
needle), which is heated to a temperature between approximately 200 and 500 oK.34, 35, 37, 38
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Droplets containing the charged analyte are formed during the ESI process, which can be
performed in positive or negative mode.16, 21 For proteins and peptides, this analysis is typically
performed in positive ion mode, due to the ability of the amino groups along the primary
sequence to undergo protonation.24
In positive mode ESI-MS, charge separation of the positively and negatively charged
species (these contain the analyte) occurs as the potential applied across the heated capillary
attracts the positively charged species.35, 37 Subsequently, repulsive forces accumulate as the
growing number of positively charged species are pushed closer and closer in space. A fine
spray of droplets containing the charged analyte is formed once the repulsive forces become
greater than the force of the analyte’s surface tension.34, 35, 37 Many theories are proposed for the
physical process of droplet formation, including Coulombic fission and solvent evaporation
mechanisms.37 The theories on droplet formation, along with other details of the ESI process,
are extensively reviewed in the literature.35, 37
Certain factors render ESI-MS analysis more challenging, such as the introduction of
salts or other impurities into a sample, or when analytes with large differences in ionization
energy are present in a mixture.21 In these instances, other ionization techniques such as MALDI
may be more appropriate to use.39
1.1.3.2 Fourier Transform Ion Cyclotron Resonance Mass Spectrometry. Fourier
transform ion cyclotron resonance mass spectrometry (FT-ICR MS) was invented in 1974 by
Alan Marshall and co-workers.40, 41 FT-ICR MS is one type of mass analyzer that provides
highly accurate mass information.21, 22, 23, 40, 41, 42 For peptides and their associated PTMs, FT-
ICR provides powerful MS analysis capabilities.23, 43, 44 The mass error measured between the
actual and experimental m/z values for an analyte is typically below 10 parts per million (ppm)
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when data is acquired on an FT-ICR MS instrument.41 High resolution FT-ICR MS data is
achieved by measuring the cyclotron frequency of ions as they pass through a fixed magnetic
field,40, 41, 42 which is different than the physical contact required for detectors in most other MS
instruments.45
Although the MS1 data provided by FT-ICR is of high resolution, it is still not sufficient
to unequivocally determine a precursor’s composition when two or more possible structures
share the same neutral mass.27, 28
1.1.4 Analysis of Protein PTMs by Tandem Mass Spectrometry. The most common
method of fragmentation coupled to ESI-MS is collision induced dissociation (CID),22 whereas
electron transfer dissociation (ETD) is a relatively new method of tandem mass spectrometry
used to study peptides.46 Both methods result in cleavage along the amino acid backbone of a
peptide, though by different mechanisms.22 In comparison to CID, which cleaves a peptide
between the carbonyl and amine groups of adjacent amino acids,22 ETD cleaves non-specifically
along the amide bond of amino acids.47, 53, 54 ETD allows most labile PTMs to remain intact,
while CID produces a signature loss of these modifications.47 The two dissociation mechanisms
provide complementary results to one another, and each offers distinct advantages in the
characterization of PTMs.22, 56 That is, the best fragmentation technique is unique to the PTM, as
well as the desired information the researcher is trying to obtain.
1.1.4.1 Collision Induced Dissociation Tandem Mass Spectrometry. Collision
induced dissociation, also referred to as collisionally activated dissociation (CAD), was first
evidenced in the mass spectra of Sir J. J. Thomson.57, 58 CID is a type of gas phase ion/neutral
pair activation where product ions are generated when a precursor is fragmented indirectly by the
transfer of vibrational energy from an inert gas.53, 57, 58, 59 The deposit of energy onto an ion
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during activation is dependent upon the relative collision energy of the ion/neutral pair that is
colliding, which dictates the maximum amount of kinetic energy that is available for transfer of
internal energy onto the ion.53, 57 One of the useful features of CID is that it is generally
universally applicable to analytes; that is, all molecules have a collision cross section.57
The trajectory properties (kinematics) for these ion collisions have been previously
described in detail.53, 59 Equation 1 shows the available kinetic energy of an ion/neutral pair in
which the velocity of the neutral species is broadly considered to be negligible, where KECOM
indicates the kinetic energy of transfer to the colliding complex, mn and mi stand for the mass of
the neutral target and precursor ion, respectively, and KE is the kinetic energy of the ion.57
Although the transfer of energy for these reactions is dependent upon a variety of factors, it can
generally be classified as high-energy or low-energy CID.53, 57
Equation 1.
The vibrational excitement of analyte ions that occurs in CID results in the dissociation of
amide bonds along a peptide’s backbone, and subsequent cleavage between the carbonyl and
amine groups of contiguous amino acids.22 Product ions that result from this type of cleavage
are termed b- and y-type ions.22 The product ions detected in CID MS/MS data may then be
used to sequence and identify a peptide or protein, and map the location of any chemical or post-
translational modification that the protein may possess.22, 56
CID MS/MS is particularly useful in the investigation of protein glycosylation, especially
in cases where mass information alone does not support an unambiguous assignment of a
glycopeptide’s composition.  Specifically, the identity of a glycopeptide bearing multiple
KECOM = KE
mn
mn + mi
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monosaccharide residues can be readily determined from CID experiments using information
extracted from the MS/MS data.28
1.1.4.2 Electron Transfer Dissociation Tandem Mass Spectrometry. During ETD
MS/MS, fragmentation on positively charged ions is induced by transferring electrons from a
radical anion.46, 50 Unlike the ion/neutral pair activation that occurs in CID, ion/ion pair
activation is the basis for ETD fragmentation.22 ETD Reagents such as fluoranthene provide the
radical anions necessary for this transfer of electrons to occur.46, 50
ETD MS/MS experiments generate peptide-containing product ions by cleaving non-
specifically along the amide bond of amino acids.22 In this way, ETD is analogous to electron
capture dissociation (ECD).  These product ions are referred to as c- and z-type ions.22, 47
Consequently, ETD allows labile PTMs to remain intact.  This is in direct contrast to CID, which
produces a signature loss of labile modifications.22, 47 To this end, ETD has proven value in the
study of proteins with PTMs difficult to characterize using CID.46 These include labile
modifications of low molecular weight, such as phosphorylation and O-linked GlcNAcylation.47
ETD has also shown to be beneficial in the study of proteins modified by disulfide
bonds.46 For disulfide-bonded peptides, previous work has revealed that ETD preferentially
cleaves the disulfide bond between the two joined peptides,48, 50, 60, 61 leaving a pattern of
characteristic product ions that is different in comparison to peptides containing other post-
translational modifications.60 While CID is useful for obtaining product ions that produce
signature losses of labile modifications, such as those resulting from glycosylation, it generally
will not cleave a disulfide bond.60 Finally, ETD has been shown to impart more extensive
peptide sequence coverage.47
8
1.2 PROTEIN GLYCOSYLATION
1.2.1 Overview of Glycosylation. The addition of monosaccharide residues onto a
protein or lipid, known as glycosylation, serves an important function in many cellular signaling
and communication events, including those involving host-pathogen interactions.62, 63, 64, 65 It has
long been understood that protein-carbohydrate interactions play a participatory role in many
processes affecting disease progression.62, 65, 66, 67, 68 Furthermore, experimental evidence
demonstrates that the identity of the attached glycans change during these events.67, 69, 70, 71 For
example, aberrant glycosylation is often present in individuals experiencing cancer, diabetes, and
inflammation.65, 69, 70, 71, 72 Accordingly, accurate characterization of a glycoprotein’s glycan
substituents has been shown to be crucial in the development of potential biomarkers, protein-
based vaccine candidates, and pharmaceutical treatments.66, 70, 73, 74
1.2.2 Glycosylation Heterogeneity. Unlike DNA replication and protein transcription,
glycosylation is a “non-template”- driven process,66, 75 where the sugar residues form a multitude
of arrangements.66, 73 The monosaccharides that comprise the glycan may be long or short,
branched or linear, and linked in a variety of ways, creating a large degree of variability.64, 66, 73
This heterogeneity is described in two ways: Glycan differences at different sites of attachment
(macroheterogeneity), or within the same site (microheterogeneity).73 The large amount of
heterogeneity presents a challenging obstacle to researchers attempting to elucidate structural, as
well as compositional, information on a protein’s glycan population, especially when samples are
mixtures of proteins.
1.2.3 Types of Protein Glycosylation. Over half of all proteins expressed are predicted
to be glycosylated.12 In addition to the established forms of protein glycosylation, including N-
linked, O-linked, and C-linked forms,62, 76, 77, 78 rarer configurations such as S-linked
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glycosylation,79 are also being discovered. Although a variety of types exist, the two most
common types of glycosylation are N-linked and O-linked.62, 68, 80
In N-linked glycosylation, the addition of a glycan may occur at the asparagine residue
when the consensus sequence Asn-Xaa-Ser/Thr occurs, where Xaa is any amino acid except
proline.73, 78, 81 The inclusion of this pattern is a fundamental requirement for N-linked
glycosylation to occur, though it is not a guarantee that a glycosylation site will be occupied.81
With O-linked glycosylation, the glycan addition may occur at any Ser or Thr residue within the
protein sequence,65, 72 though a very low percentage of these sites are actually occupied.12 In
contrast to N-linked glycans, O-linked glycans have less defined sequence patterns, 73, 78, 82 and
may consist of several distinct core arrangements.72 For these reasons, both the prediction and
determination of O-linked glycosylation characteristics have advanced slower than N-linked
glycosylation analysis.72
1.2.4 Characterization of Protein Glycosylation. A variety of biochemical and
instrumental techniques may be used to probe a glycoprotein’s features.  To obtain glycan
structural information, enzymatic sequencing and carbohydrate-binding protein (lectin) arrays
are often employed.80 Likewise, analyses by more utilitarian methods rooted in the separation of
carbohydrates, including capillary electrophoresis (CE), high-performance anion-exchange
chromatography (HPAEC), and mass spectrometry, are also common.80, 83, 84 As it stands, mass
spectrometry is considered to be the preferred route of analysis for the identification of protein
glycoforms, whether attached or released.72
1.3 GLYCOSYLATION ANALYSIS BY MASS SPECTROMTERY
In the study of protein glycosylation, mass spectrometry has shown to be a powerful tool,
as successful interrogation of glycan composition and structure has largely been achieved
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through MS experiments.78, 83, 84 To simplify assignment of mass spectra and other data, each
monosaccharide residue of a glycan is represented by a symbol with a unique combination of
color and shape.  These symbols, and the abbreviation of each associated sugar, are shown in
Table 1.
Table 1. Monosaccharide Residue Symbols and Abbreviations.
Monosaccharide Abbreviation1 Mass Symbol
Fucose Fuc 146.0579
Mannose Hex 162.0528
Galactose Hex 162.0528
N-Acetylglucosamine HexNAc 203.0794
Sialic Acid Neu5Ac 291.0954
1 Mannose and galactose may also be abbreviated as Man and Gal, respectively.  However, typical MS data does
not distinguish between isomeric structures; therefore, the more general abbreviation of Hex is often used.
There are two main strategies for elucidating protein glycosylation information using MS
techniques: 1) Characterization of a protein’s glycans after they are released from glycoproteins
and 2) Characterization of glycopeptides after proteolytic digestion of a glycoprotein.72, 78, 83 The
study of released glycans is particularly useful when rapid analysis of glycan composition is
desired.  Though N- and O-linked glycan populations can be studied independently through the
use of different cleavage procedures,72, 73 no information on where the individual glycans were
attached along the protein is obtained when the glycans are cleaved a priori.  In order to obtain
glycosylation site-specific information for individual glycoforms, the second method,
glycopeptide analysis, which requires digestion of the protein using a protease such as trypsin, is
necessary.78, 83, 85 This method is generally advantageous because it provides information about
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both glycan composition and the site of the glycan’s attachment.83 Despite the associated
challenges, techniques that allow for complete profiling of a peptide’s glycan population have
advanced greatly in the past decade, especially with respect to site-specific glycopeptide
analysis.
To examine protein glycosylation by either of these techniques, a number of resources,
including databases providing information on known glycan structures or site of occupancy, as
well as collections of experimental data, are currently available.86, 87, 88, 89, 90, 91, 92, 93 For instance,
researchers needing to identify occupied N-linked glycosylation sites on a specific protein can
access UniProtKB,86 while those wanting statistics specific to proteins modified by O-GlcNAc
could visit dbOGAP.93 Although this repertoire of information is greater for proteins modified
by N- and O-linked glycan types, databases that contain entries on C-glycosylated proteins, such
as dbPTM,87 are available as well.  A current list and description of these database resources are
provided in Table 2.
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1.3.1.1 Characterization of High Resolution MS Oligosaccharide Data. Often, the
easiest way to identify a protein’s glycan population is by enzymatically cleaving the glycan
substituents and analyzing the monosaccharide residues directly.85 N- and O-linked glycans
from the same protein can be independently characterized in this manner, as in the method
described by Goetz et al. where β-elimination is used to release O-linked glycans, which are
simultaneously permethylated.94 Once cleaved, automated analysis tools to assist in the
determination of glycan composition from MS data may be used.
One such tool developed to analyze MS data of glycans is Cartoonist, as described by
Goldberg et al.95 This program works to increase the speed of compositional determination in
permethylated N-linked glycans from matrix-assisted laser desorption/ionization mass
spectrometry (MALDI-MS) data through identification and annotation of matrix-assisted laser
desorption/ionization time-of-flight (MALDI-TOF) spectra.95 The most likely glycan
compositions are selected using precursor mass information.95 Cartoonist automatically labels
MALDI peaks with cartoons of the most probable oligosaccharide structure, as determined by
the program’s algorithm, from a library of 300 generated mammalian N-linked glycans.95
Recently, Goldberg et al. extended this concept by developing an automated tool for the analysis
of O-linked glycans from MS/MS data,96 as described below in MS/MS approaches for glycan
analysis.  To date, neither program is publicly available.
Another software solution useful for the identification of glycans from MS data is
SysBioWare, described by Vakhrushev et al.97 SysBioWare takes raw MS1 data that a user
uploads and performs baseline adjustment and denoising, wavelet analysis, and peak detection
before grouping isotopes of detected peaks.97 The isotopic grouping is also performed
automatically, which enables the program to deduce monoisotopic m/z values and precursor
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Table 2. Glycosylation Databases.
Database Link to Database Type Description
UniProtKB http://www.uniprot.org/ N-glycos.
O glycos.
C-glycos.
Contains annotation of N-, O-, and C-
linked glycosylation, as well as glycation.
Both mammalian and non-mammalian
entries are provided.
dbPTM http://dbptm.mbc.nctu.edu.tw/ N-glycos.
O-glycos.
C-glycos.
Contains a combinational repertoire of
protein PTMs from other databases,
including experimentally obtained data on
site of modification.
GlycomeDB http://www.glycome-db.org/ N-glycos.
O-glycos.
C-glycos.
Contains over 30,000 carbohydrate
structures from all major taxonomies,
representing a variety of glycosylation
types.
GlycoSuiteDB http://glycosuitedb.expasy.org/
glycosuite/glycodb
N-glycos.
O-glycos.
Contains over 9400 entries on curated
and annotated glycans from a variety of
organisms.
O-GlycBase http://www.cbs.dtu.dk/databases/
OGLYCBASE/
O-glycos.
C-glycos.
Contains over 2000 entries of protein
glycosylation sites, the majority of which
are O-linked.
UniPep http://www.unipep.org/ N-glycos. Contains over 1500 entries of N-linked
glycosylation sites found in human
proteins.
GlycoBase http://glycobase.univ-lille1.fr/base/ N-glycos. Contains HPLC elution positions for 2-
AB labeled N-glycans from LC-MS data
and exoglycosidase sequencing.
dbOGAP http://cbsb.lombardi.georgetown.edu/
hulab/OGAP.html
O-glycos. Contains over 1100 entries on sites
modified by O-GlcNAcylation.
1.3.1 Automated Analysis of Released Glycans. In both MS and MS/MS experiments,
glycans are frequently investigated independently of the glycoprotein they comprise. To
facilitate the profiling of carbohydrates from either data type, a number of automated analysis
tools have been described in the literature.
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charge states without the need of manual input by the user.97 Monosaccharide compositions are
then determined by the software on the basis of mass.97 Currently, the SysBioWare program is
being updated to include analysis of MS/MS data for glycans as well.98 SysBioWare is not
freely available to the public at this time.
Similar to SysBioWare is GlycoWorkbench.  GlycoWorkbench evaluates glycan
compositions (which are proposed by the user) by searching the spectral peak list of user-input
MS data for matches between calculated theoretical glycan masses and corresponding m/z
values.99 The GlycanBuilder tool, designed to interface with GlycoWorkbench, enables the
drawing of glycan structure representations, with all stereochemical information on the
monosaccharides depicted as specified by the user.100 Both analysis tools, GlycanBuilder and
GlycoWorkbench, are available online free of charge, as described in Table 3.
GlycoSpectrumScan, another freely available program, was developed by Deshpande et
al. and works to identify N-and O-linked glycoforms using MS1 data.101 This software is capable
of analyzing both singly or multiply charged ions directly from raw data, and accepts the input of
both ESI and MALDI spectra.101 GlycoSpectrumScan also determines the relative abundance of
N-and O-linked glycoforms that are identified for each glycosylation site.101 However, the user
must enter the N- and/or O-linked glycan compositions potentially present in the sample, as well
as the in silico peptide masses of the digested glycoprotein.101 GlycoSpectrumScan is available
online (see Table 3).
1.3.1.2 MS/MS Approaches for Glycan Characterization. Until recently, when
automated software tools and scoring algorithms became available, the identification of accurate
glycan or glycopeptide assignments from MS/MS data was a key bottle-neck, due to the need for
extensive manual data analysis.  STAT, designed by Gaucher et al., is one of the first automated
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tools for the determination of glycan composition using tandem MS.102 STAT is designed for
glycans of up to ten monosaccharide residues, and has the ability to quickly analyze relevant N-
glycan compositions.102 STAT also lists the most likely structures in order of probability to
provide a ranking system when more than one candidate glycan matches the fragmentation
profile of the data being analyzed.102 Unfortunately, this program is no longer publicly
accessible.
An early analysis tool capable of evaluating O-linked glycan fragmentation is the
OSCAR algorithm.103 OSCAR, as developed by Ashline et al., is specifically designed for the
annotation of permethylated O-linked oligosaccharides from MSn data.103 OSCAR is part of a
collection of software tools termed Glyspy, which is not currently accessible to the public.103
Although innovative, the use of OSCAR is limited to direct infusion experiments, as the software
does not effectively process data from LC-MS methods.103
A program contemporary to OSCAR and also developed to handle glycan MS/MS data is
StrOligo.104 This instrument-specific program was designed by Ethier et al. for the
determination of N-linked glycan structures from matrix-assisted laser desorption/ionization
tandem mass spectrometry (MALDI MS/MS) data.104 In published research, StrOligo
successfully assigned the correct glycan structure in 24 out of 28 cases.104 Although the results
of these two programs are promising, neither program is freely accessible online.
Several alternative glycan analysis tools are freely available online.  One of the earliest
of these was reported by Lohmann et al. in 2004.105 The authors describe the web tools
GlycoFragment and GlycoSearchMS, which were developed for glycan structural
determination.105 The theoretical fragmentation patterns of carbohydrate structures are
calculated using GlycoFragment, which displays theoretical b- and y-fragments as well as c-, z-,
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a- and x-ions.105 GlycoSearchMS works to analyzes experimental glycan data by comparing it
against a library of theoretical spectra from N-linked and O-linked glycan fragmentation entries
extracted from SweetDB.105 The GlycoFragment program has been validated on both N-linked
and O-linked glycan classes, and, used in conjunction with GlycoSearchMS, enables researchers
to determine the most probable glycan composition according to the information from the
combined algorithms.105, 106 Both GlycoFragment and GlycoSearchMS are freely available. See
Table 3 for more information.
Another heavily used, free, online tool for glycoform analysis is GlycoWorkbench, which
has shown to be a resourceful tool not only for analysis of MS1 data, as mentioned previously,
but in the identification of glycans from MS/MS data as well.99 To utilize the glycan
fragmentation analysis feature, a user must first input/define the possible glycan compositions
and spectral peak list.99 The software then calculates expected glycan fragmentation and relative
m/z values, and annotates peaks of the uploaded data with the most probable identity (shown in
red to distinguish it), of all compositions tested.99 As previously stated, GlycoWorkbench is
available for free online.
In addition to the freely available tools mentioned above, several other MS/MS analysis
tools for glycans are available to researchers, either for purchase or by special request to the
tools’ developers.  Two of these are GlyCH and Glyquest.107, 108 GlyCH was developed by Tang
et al. to perform automated interpretation of oligosaccharide tandem mass spectra.107 The
algorithm has a scoring function built in to allow researchers to compare compositions when
more than one is determined to be possible.107 The GlyCH algorithm, which has so far been
tested on released N-glycans, is also capable of de novo analysis, providing no more than ten
monosaccharide residues comprise the glycan chain.107 Although not freely accessible online;
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the program is available upon request from the authors.107 More recently, Gao et al. developed
Glyquest, an automated analysis program that takes a different approach to determine
compositions of intact N-linked glycans.108 This software utilizes a database in conjunction with
an integrated search engine to determine the composition of peptide-attached N-glycans from
CID MS/MS data.108 After the program algorithmically identifies the molecular weight of the
protonated peptide within a given spectrum; candidate N-glycan compositions are selected and
fragmented in silico to generate a theoretical spectrum that is then compared to the experimental
spectrum.108 The glycan compositions with fragmentation profiles that are most similar to the
experimental fragmentation are determined to be the most probable candidates.108 Glyquest is
not freely available to the public.
SimGlycan is another program that can be used to increase throughput of glycan
analysis.109, 110 More information is available online (http://www.premierbiosoft.com/).  This
commercial tool is useful for determining glycan structures from MS/MS data obtained on many
different mass spectrometers, once an acquisition file is converted into mzXML format.110 A
user uploads an MS/MS data file, and the software utilizes a built-in database with theoretical
fragmentation profiles of nearly 10,000 glycan structures to provide the most likely structural
candidates.109 One unique feature of SimGlycan is that no filtering of biologically relevant
structures is provided, which can be advantageous for identifying novel glycan structures, but
disadvantageous in that it returns a user many structures which are not pertinent.109 However,
for purchase programs such as SimGlycan are expensive, which potentially limits their use.
A more recent program developed specifically for the compositional interpretation of O-
linked glycan fragmentation is CartoonistTwo, as described by Goldberg et al.96 CartoonistTwo
was designed using CID data acquired on an FTICR-MS, and validated using data from a test set
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of 34 spectra acquired from Xenopus egg jelly.96 Unfortunately, the program is not freely
accessible to the public.
A summary of those glycan MS and MS/MS data analysis tools that are currently
available online is shown below, in Table 3.
Table 3. Online Tools to Facilitate Glycan Characterization from MS and MS/MS Data.
MS Analysis Tool Link to Analysis Tool Concept and Data Type
GlycoWorkbench http://download.glycoworkbench.org/ Identifies and annotates MS and
MS/MS data with appropriate glycan
compositions or fragments.
GlycanBuilder http://live.glycanbuilder.org/ Drawing tool interfacing with
GlycoWorkbench that displays different
stereochemical representations of glycans.
GlycoSpectrumScan http://www.glycospectrumscan.org. Quantitatively identifies N- and O-linked
glycoforms within a protein using LC-MS
data.
GlycoFragment http://www.glycosciences.de/
tools/GlycoFragments/fragment.php4
Identifies and displays the main product
ions expected for oligosaccharide
MS/MS data.
GlycoSearchMS http://www.glycosciences.de/database/
start.php?action=form_ms_search
Compares experimental MS/MS data to
product ions calculated from an extensive
library of N-and O-linked glycans.
SimGlycan http://www.premierbiosoft.com/
glycan/index.html
Predicts the structure of glycans from
MS/MS data by matching spectra to a
built-in database.
1.3.2 Automated Analysis of Glycopeptides. For researchers performing site-specific
glycosylation analysis, the initial step toward accomplishing the characterization of attached
glycoforms at unique sites within a digested protein is to identify potential glycosylation sites
within that protein.  The tools to facilitate this step are described in Table 2. In addition to these,
programs that utilize algorithms to predict the likelihood of site-occupancy by examination of the
amino acid residues surrounding the potential glycosylation site have also been developed.111, 112,
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113, 114, 115, 116, 117, 118, 119 These prediction tools, along with a description and link to each tool, are
provided in Table 4.
Table 4. Glycosylation Site Prediction Tools.
Database Link to Database Prediction Tool Type Overview
EnsembleGly http://turing.cs.iastate.edu/EnsembleGly/ N-glycos.
O-glycos.
C-glycos.
Uses ensemble learning to
predict N-, O-, and C-linked
sites, as well as O-glycan types.
GlySeq http://www.glycosciences.de/tools/glyseq/ N-glycos.
O-glycos.
Uses the PDB and SwissProt to
perform statistical analysis of
glycosylation sites.
GPP http://comp.chem.nottingham.ac.uk/glyco/ N-glycos.
O-glycos.
Algorithmically predicts
occurrence for N- and O-linked
glycosylation.
NetNGlyc http://www.cbs.dtu.dk/services/NetNGlyc/ N-glycos. Uses consensus sequence to
predict N-linked glycosylation
in human proteins.
NetCGlyc http://www.cbs.dtu.dk/services/NetCGlyc/ C-glycos. Predicts sites in mammalian
proteins for C-mannosylation
attachment.
NetOGlyc http://www.cbs.dtu.dk/services/NetOGlyc/ N-glycos. Predicts mucin-type GalNAc O-
glycosylation in mammalian
proteins.
CKSAAP_OGlysite http://bioinformatics.cau.edu.cn/zzd_lab/
CKSAAP_OGlysite
O-glycos. Predicts mucin-type O-
glycosylation sites in
mammalian proteins.
OGPET http://ogpet.utep.edu/ O-glycos. Predicts occurrence of mucin-
type O-linked glycosylation in
eukaryotic proteins.
YinOYang http://www.cbs.dtu.dk/services/
YinOYang/
O-glycos. Predicts O-β-GlcNAc
attachment sites in eukaryotic
proteins.
DictyOGlyc http://www.cbs.dtu.dk/services/
DictyOGlyc/
O-glycos. Predicts sites for O-GlcNAc
attachment in Dictyostelium
discoideum proteins.
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1.3.2.1 Experimental Data Requirements.  After the resultant glycopeptides are 
obtained from the proteolytic digest, two types of data are generally used to accurately 
characterize the identity of a glycopeptide.  First, high resolution MS data of the glycopeptide is 
used to infer possible glycopeptide compositions; second, tandem MS data is acquired to 
distinguish between isomers and isobars.
27
  In Figure 2, a schematic of this work-flow is 
provided.  
  
 
 
Figure 2.  Flow chart outlining the use of MS and MS/MS data for glycopeptide identification.
29 
 
 
1.4 AUTOMATED MS and MS
n
 ANALYSIS OF GLYCOPEPTIDES 
1.4.1 N-Linked Glycopeptides.  Although N-linked glycoforms share a common core 
structure, the rest of the glycan follows one of three distinct arrangements.  Based on the 
arrangement pattern, N-linked glycans compositions are classified into three main types, those 
with: 1) High mannose type glycans 2) Complex type glycans and 3) Hybrid type glycans.
73, 78, 80
  
This information is useful when deciphering glycopeptide compositions from MS experiments, 
specifically from CID MS/MS data.
28
 
Generate Candidate Glycopeptide 
Compositions for Peak of Interest 
Digest Glycoprotein      
into Glycopeptides 
Analyze Fragmentation to  
Identify Correct Candidate  
MS Data Protease MS/MS Data 
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1.4.1.1 N-Linked Glycopeptide Characterization from MS Data. A variety of
automated and semi-automated analysis tools have been created to aid in the interpretation of N-
linked glycopeptide MS data. The key objective of these tools is to provide glycopeptide
compositions that are consistent with the high resolution MS data.  Researchers then typically
use MS/MS analysis to determine which of the compositions is correct for each given ion. Three
of these tools are accessible to the public: GlycoMod (http://web.expasy.org/glycomod/),
GlycoPep DB (http://hexose.chem.ku.edu/glycop.htm), and the previously mentioned
GlycoSpectrumScan.101, 120, 121 GlycoMod, the earliest and most heavily used tool, accepts a
protein sequence, possible monosaccharide building blocks, and experimental mass data as
inputs, and it calculates all possible glycopeptide compositions that fall within the mass
tolerance.120 One restriction in the capacity of GlycoMod to analyze glycopeptide data is the
inability to handle multiply charged precursors.120
Programs such as GlycoPep DB and GlycoSpectrumScan were designed to overcome
some of the limitations in GlycoMod.  GlycoPep DB, developed by Go et al. limits its output by
restricting the potential glycans in the glycopeptide to a database of biologically relevant
glycoforms that have been previously identified in MS data.121 It also accepts precursor ions in
multiple charge states.121 The disadvantage of using this approach, however, is that if the glycan
in the spectrum is not in the GlycoPep DB database, then the software will not be effective at
providing the correct assignment for the peak.121 GlycoSpectrumScan is a more recent program,
developed by Deshpande et al., that also interprets MS data on both N- and O-linked
glycopeptides.101 Like GlycoPep DB, this program has the ability to handle input for both singly
and multiply charged data.101 GlycoSpectrumScan is described in detail below for O-linked MS
data analysis.  Regardless of which tool is used for assigning the high resolution data, these
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assignments must be supported by MS/MS data, to provide high confidence assignments.27
1.4.1.2 N-Linked Glycopeptide Characterization from MS/MS Data. Each common
N-linked glycan type (complex, hybrid, or high mannose) has a signature fragmentation profile
that is present when a glycopeptide is subjected to MS/MS experiments.28, 85 These characteristic
fragmentation profiles are useful for determining the correct identity of an N-linked glycopeptide
when isobaric candidate compositions are possible.28 However, as manual interpretation of these
data are challenging, software is required to speed analysis time.
Of the automated tools used to analyze glycopeptides, many are software expansions of
programs that were developed previously to analyze released glycans.  One disadvantage of
expanding glycan analysis tools to glycopeptides is that these tools generally lack capabilities for
analyzing and scoring the peptide component of glycopeptides.  SimGlycan is one such example.
Available for purchase, SimGlycan has been updated to perform fragmentation analysis for
glycopeptides, in addition to glycans.109, 110 As stated previously, SimGlycan uses a database of
over 9,000 glycan structures that could be consistent with the MS/MS data to identify the most
appropriate composition for the acquired spectrum.110 SimGlycan may be purchased online
(http://www.premierbiosoft.com/).
Many other publicly available tools to elucidate glycosylation profiles of glycopeptides
have emerged out of glycan analysis software.  GlycoWorkbench and Glyco-Peakfinder both
work to annotate glycan fragmentation in glycopeptide data, although the peptide portion of the
glycopeptide must be determined by some means other than the use of these tools.99, 122 On the
positive side, Glyco-Peakfinder is useful for de novo calculation and annotation of glycan
fragment ions within tandem mass spectra.122 Users may allow constraints on the
oligosaccharide such as size and attachment of other substituents (such as acetate, phosphate, and
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sulfate), and the program is capable of annotating multiply charged ions (- 4 to + 4).122
Additionally, glycan fragmentation is analyzed across multiple charge states, and across multiple
charge carriers (cationic carriers), within the same spectrum.122
A completely different approach is used in GlycoPep ID.123 GlycoPep ID is a web-based
tool developed by Go et al. to interpret MS/MS data of glycopeptides and to identify the peptide
component of glycopeptides through analysis of expected product ions.123 The URL to access
this program is listed in Table 5. Although this program is useful for identification of the peptide
portion of the glycopeptide in complex LC-MS samples, it does not contain a scoring algorithm
to identify the most probable glycopeptide match.123
Software with the ability to score potential compositions is especially useful to
researchers.  Often, more than one glycan or glycopeptide composition could correspond to a
given spectrum within the accepted range of mass tolerance.  Therefore, programs that have a
scoring function to evaluate each of those possible matches, and return which of them is the most
likely structure, greatly improve the efficiency of glycosylation analysis.  For tools that lack this
feature, a user must spend time manually determining which of the mathematically possible
predictions is the best match for the data.
Some alternative, unique strategies have been developed with the goal of scoring MS/MS
data against potential glycopeptide compositions, such as those described using Peptoonist,
Medicel Integrator, the Branch-and-Bound algorithm, GlycoMaster, Sweet Substitute, and
GlyDB.124, 125, 126, 127, 128, 129 Unfortunately, none of these programs are currently publicly
available.
To address the need for publicly accessible tools specifically designed to interpret and
score fragmentation of glycopeptides, GlycoMiner was developed by Ozohanics et al.130 In the
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analysis of 3132 spectra, the software was reported to have found 338 that corresponded to
MS/MS data of glycopeptides (versus peptides).130 Designed using quadrupole time-of-flight
(Q-TOF) data, this program is capable of assigning glycopeptide compositions when both the
peptide and glycan components portions are unknown.130 However, GlycoMiner is only capable
of performing compositional analysis when the spectra are of good quality.130 The program fails
when spectral quality is low, as evidenced by the software’s identification of glycan composition
in only 196/338 glycopeptide spectra.130 Although this tool is a great advancement towards
automated interpretation of glycopeptide MS/MS data, GlycoMiner often generates multiple
plausible compositions and fails to rank the correct glycopeptide as the top candidate.130 In
addition, the program requires spectra containing a low S/N, as well as the presence of
glycopeptide oxonium marker ions, which are not typically present in data collected on ion trap
instruments.130 Available online, GlycoMiner is free to download and use; see Table 5.
Similar to GlycoMiner, GlycoPeptide Search (GPS) is a recently developed program by
Chandler et al. for the determination of glycopeptide composition from CID data.131 Designed
for purified glycoprotein samples analyzed by liquid chromatography tandem mass spectrometry
(LC-MS/MS), GPS utilizes GlycomeDB, a glycan database in conjunction with the peptide file,
which is supplied by the user, to produce an Excel file of glycopeptide matches based on
fragmentation evidence.131 To generate the peptide-glycan pairs, GPS must find both low mass
oxonium, and N-glycan core-containing, product ions.131 GPS is freely available online, as
well.131 For further information, see Table 5.
The targeted MS/MS approach utilizing the computational tool GlypID recently
described by Wu et al. aims to characterize N-linked glycopeptides through the combined use of
MS1 and MS2 information extracted from LC-MS/MS experiments.132 One of the benefits to the
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method is that no prior knowledge of the potential glycosylation or identity of the glycopeptide is
necessary.132 Instead, GlypID assigns a cluster of glycopeptides in the “same family”
(microheterogeneities) based on observed mass.132 In addition, the approach utilizes an isotope
deconvolution algorithm to assign ion charges along with monoisotopic ions.132 This
information is then added to the inclusion list of “prioritized precursor ions” for the MS/MS
analysis that follows.132 Next, the resultant CID data is searched for the longest series of
glycosidic bond cleavage series.132 These product ions are used to determine the oligosaccharide
sequence tag, which is used to verify whether or not the spectrum is from a glycopeptide.132 A
score is assigned to the CID spectrum based on this sequence tag.132 MS data is used to evaluate
and score the relative probability of a glycopeptide by examining the clusters of peptide
glycoforms, or those glycopeptides with the same peptide backbone that co-elute within a
specific time range.132 The glycoform is then identified using the mass of the attached N-linked
glycan, though the most current version of GlypID allows the entry of user-defined glycan
compositions as well.132 A limitation to the program is that when low resolution data is used,
there is a significant increase in the number of false-positive identifications of glycopeptide
microheterogeneities within a cluster.  Although the new targeted MS/MS approach has been
optimized for FT MS instrumentation and data, the original GlypID algorithm was designed
using LC-MS ion trap data.133 A publicly accessible version of the computational tool is
currently available online, free of charge to users (see Table 5).
Mayampurath et al. recently modified the GlypID algorithm with a scoring function that
works to determine glycopeptide composition from high-energy C-trap dissociation (HCD)
MS/MS data.134 The new software tool, GlypID 2.0, uses high resolution MS1 data along with
CID and HCD scan information to improve the accuracy of N-linked glycopeptide
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identification.134 Like the original GlypID, GlypID 2.0 can also score CID spectra independently
on MS systems that do not contain the HCD instrument option.134 GlypID 2.0 is freely available
to download, as listed in Table 5.
Woodin et al. have also developed a freely accessible web-based tool, GlycoPep Grader
(GPG), to assign glycopeptide composition from MS/MS data in an automated fashion.28 This
tool is specifically designed for data collected in an ion trap mass spectrometer, and it features a
novel algorithm that enables users to identify the correct glycopeptide composition from a pool
of candidate compositions of the same nominal mass.28
GPG utilizes the MS/MS data by calculating, scoring, and searching for the expected
product ions of potential glycopeptide candidate compositions.28 The algorithm scores the
glycopeptide candidate composition through detection of two types of product ions: 1) Ions that
contain the peptide portion and some portion of the pentasaccharide core, or [peptide + core
component] ions, and 2) Ions formed via neutral loss of monosaccharide residues from the
precursor ion, or [precursor – monosaccharide] ions.28 The algorithm that powers GPG has been
shown to assign the correct glycopeptide candidate after performing the MS/MS peak list search
with a very high degree of accuracy.28
One advantage to the algorithm behind GPG is that the precursor ion’s charge state is
included in the input data, so all product ions can be searched for within their appropriate charge
state.28 Secondly, no spectral transformation (to singly charged ions) needs to be performed
prior to using the program, as GPG automatically searches for product ions in a charge-specific
fashion, bypassing the need for additional processing software.28 A disadvantage of the program
is that the user must utilize a separate program, such as GlycoMod, to obtain potential matches
for the high resolution MS data, prior to assigning the MS2 data with GPG.28 GPG can be found
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online, and is free to use.
A summary of programs that assist in N-linked glycopeptide characterization from
MS/MS data is listed in Table 5.
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Table 5. Freely Available N-linked Glycopeptide Analysis Tools.
Database Link to Database Overview
GlycoMod http://web.expasy.org/glycomod/ GlycoMod determines potential glycopeptide
compositions, on the basis of mass
information, from MS data.
GlycoPep DB http://hexose.chem.ku.edu/glycop.htm GlycoPep DB deduces possible biologically
relevant glycan compositions from MS data of
glycopeptides with a “smart search”
GlycoSpectrumScan http://www.glycospectrumscan.org. GlycoSpectrumScan searches LC-MS data to
identify glycopeptides and determine
glycoform location.
GlycoWorkbench http://download.glycoworkbench.org/ GlycoWorkbench annotates glycopeptide
MS/MS data through fragmentation analysis
and scoring of only the glycan portion.
Glyco-Peakfinder http://glyco-peakfinder.org/ Glyco-Peakfinder performs de novo analysis of
glycopeptides, after a peptide sequence is input
by a user, using glycan fragmentation profiling.
GlycoPep ID http://hexose.chem.ku.edu/
predictiontable2.php
GlycoPep ID analyzes MS/MS glycopeptide
data from complex mixtures by identifying the
peptide portion based on expected product ions.
GlycoMiner http://www.chemres.hu/ms/
glycominer/tutorial.html
GlycoMiner identifies glycopeptides in qTOF
MS/MS data, and assigns composition for
quality spectra containing specific marker ions.
GPS http://edwardslab.bmcb.georgetown.edu/
software/GlycoPeptideSearch.html
GPS generates glycopeptide compositions,
utilizing a glycan database, after searching and
matching LC-MS/MS data of purified proteins.
GlypID http://www.cbs.dtu.dk/services/
DictyOGlyc/
GlypID identifies glycopeptides from LC-
MS/MS experiments using a combination of
MS1 and MS2 data.
GlypID 2.0 http://mendel.informatics.indiana.edu/
~chuyu/glypID/software.html
GlypID 2.0 uses CID and HCD MS/MS data to
deduce monosaccharide composition, as well as
glycan type and location, for N-glycopeptides.
GPG http://glycopro.chem.ku.edu/
GPGHome.php
GPG scores glycopeptide candidates after
searching MS/MS data for each candidate’s
predicted product ions.
1.4.2 O-Linked Glycopeptides. The analysis of O-linked glycoforms is particularly
challenging, as no single consensus sequence exists to predict the site of glycan attachment.68, 80,
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135 Further adding to the difficulty of analysis, factors that affect the efficiency of glycosylation
at N-linked sites are different than those affecting O-glycosylation efficiency.  For example, the
presence of aromatic residues near an O-linked site inhibits glycosylation; whereas the presence
of an aromatic residue near an N-linked site increases the likelihood of site-occupancy.82
1.4.2.1 Mucin-Type O-Linked Glycosylation. The most prevalent form of O-linked
glycosylation to occur in eukaryotic organisms is mucin-type O-glycosylation, which occurs
where glycans are attached to a protein by the addition of α-N-acetylgalactosamine (GalNAc)
residues to the hydroxyl group of Ser/Thr side chains (commonly referred to as the Tn
antigen).63, 68 Though still in the infancy stage, analysis tools have recently been created to assist
researchers in the determination of O-linked glycoforms, many of which are mucin in type, from
MS data.
1.4.2.2 O-Linked Glycopeptide Characterization from MS Data. Recently,
Deshpande et al. advanced the MS data analysis of N- and O-linked glycopeptides with the
advent of the GlycoSpectrumScan program.101 GlycoSpectrumScan is designed to analyze LC-
MS data of intact glycopeptides from proteolytic digests.101 The program utilizes MS1 data to
determine glycopeptide composition, along with the relative distribution of glycoforms at each of
the sites.101 In addition, the algorithm behind the program offers a few distinct advantages in that
it handles multiply charged ions, making it amenable to both MALDI and ESI data, and is
currently freely available online (www.glycospectrumscan.org.).101
GlycoX and GlycoMod, described earlier in the analysis of N-linked glycopeptides, are
capable of O-linked glycopeptide data interpretation as well.120, 136 Unlike GlycoMod
(http://web.expasy.org/glycomod/), GlycoX is not publicly available, though it is available upon
request from the authors.136 GlycoWorkbench, also described previously, performs automation
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of O-linked glycopeptide MS1 data to elucidate the most likely composition from an
experimental peak list in the same manner as for N-linked glycopeptide spectra.99
GlycoWorkbench is freely available online (http://download.glycoworkbench.org/).
1.4.2.3 O-Linked Glycopeptide Characterization from MS/MS Data. Currently, there
is no freely available stand-alone program designed to automate the analysis of O-linked
glycopeptide CID MS/MS data through evaluation of both unknown portions of a glycopeptide,
the peptide and glycan.  The GlycoWorkbench program is capable of annotating glycans in CID
fragmentation data of glycopeptides.99 However, as described for the MS/MS characterization of
N-linked glycopeptides, the identity of the peptide portion must already be known, as
GlycoWorkbench solely evaluates the fragmentation of the glycan-containing portion of a
glycopeptide.99
There are promising advances being made in the compositional determination of
glycopeptides using ETD fragmentation techniques,72, 84 or a combination of CID and ETD,
particularly in the study of O-linked species.137 A recent method described by Darula et al. in
which MS1, CID, and ETD data are used in conjunction with Protein Prospector v5.3 for the
identification of SA1-10GalGalNAc-containing O-linked glycopeptides enriched from bovine
serum, demonstrates the potential for automated analysis through a combination of these
techniques and database searches.137 However, this process is only semi-automated, and
restricted to samples containing simple carbohydrate structures.137 Hopefully, the compositional
information gained between the two complementary fragmentation methods of CID and ETD
will enable researchers to gain insight into creating automated programs to speed the analysis of
O-linked MS/MS glycopeptide data as well.
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1.5 PROTEIN DISULFIDE BOND FORMATION
1.5.1 Overview of Disulfide Bonds. Protein disulfide bonds result when two cysteine
residues are covalently joined through oxidation.1, 4, 7 The formation of native disulfide bonds in
a protein is necessary to achieve proper folding, stability and conformation.1, 8, 9, 14, 15 In addition,
disulfide bonds directly contribute to many biological functions by participating in cellular
regulation or catalysis events.1, 9, 15 Furthermore, dysregulation of enzymes that are involved in
the formation of disulfide bonds have been reported in some diseases.15 Aberrations of disulfide
bond structure for proteins showing altered expression or activity have also been reported in
damage caused by oxidative stress events.5, 15
The formation of disulfide bonds within a protein is paramount to the production of
functional biopharmaceuticals. Often, treatments are designed using proteins containing
modifications, and utilize recombinant protein technology.6, 13, 15, 138, 139 For many of these, E.
coli has been used to express the associated recombinant proteins.  This is problematic, as
disulfide bond scrambling and misfolding are often reported for proteins produced by E. coli.139
The folding of the final protein product is critical to its biological function.
Consequently, there is a need to obtain timely, accurate and concise data so the quality of protein
therapeutics can be assessed. To this end, thorough scrutiny into the pattern and integrity of each
associated protein’s disulfide bond arrangements become necessary. According to Trivedi et al.,
the demand for this characterization is rapidly increasing,14 due to a rising trend in the use of
protein-based drugs.
1.5.2 Types of Disulfide Bonding. There are two main types of protein disulfide
arrangements that are commonly found in proteins and peptides: Interchain and intrachain type
bonds.18 Interchain type bonds occur when the disulfide bond is comprised of cysteine residues
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from more than one protein or protein subunit, and intrachain type bonds occur when the 
cysteine residues are within the same protein or protein subunit.  Figure 3 provides a 
visualization of interchain disulfide bonding.  In Fig. 3, two discrete subunits of a single protein 
are shown with their participating thiols orientated in close proximity to form an interchain 
disulfide bond upon oxidation of each cysteine’s sulfhydryl group. 
 
 
 
 
 
 
Figure 3.  Interchain disulfide bonding between two subunits from the same protein.  The 
disulfide bond linking the oxidized cysteine residues is shown in red.  
 
 
For peptides, interchain type bonding refers to disulfides that form between two or more 
unique peptides, and intrachain type bonding indicates that the cysteine residues forming the 
disulfide reside along the amino acid sequence of a single peptide.
18, 50, 140
  
1.5.3 Characterization of Protein Disulfide Bonds.  To investigate the formation and 
integrity of protein disulfide bonds, a variety of spectroscopic and biochemical techniques may 
be exploited.  Before the advent of appropriate MS instrumentation, NMR and crystallography 
were commonly used to characterize disulfide connectivity.
141, 142
  Unfortunately, both NMR and 
crystallography experiments require large amounts of high purity samples, which are often 
difficult to obtain.  Edman degradation is another traditional method used to investigate protein 
disulfide bond patterns; however, this method requires that samples be of ultra-high purity.
18
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1.5.4 Disulfide-Bonded Peptide Analysis by Mass Spectrometry. In the
characterization of peptides containing intact disulfide bonds, a variety of MS methods have
shown to be effective, including MALDI-TOF and ESI-FT-ICR.18, 23 However, as ETD is a
relatively new fragmentation technique, the availability of mass analyzers that can be coupled to
ETD is not near the number that can be coupled to CID. To date, limited instruments are
equipped with the ability to perform ETD MS/MS analysis.55 Of these MS systems, not all
provide high resolution MS1 scans.23, 55 With low resolution mass spectrometers, it is often
necessary to assign charge state independent of the MS1 data. In these instances, the charge state
of disulfide-bonded precursors needs to be determined using a different approach.
1.5.5 Disulfide-Bonded Peptide Analysis by Tandem Mass Spectrometry. MS
analysis of peptides containing intact disulfide bonds has been advanced by the advent of
recently developed MS/MS fragmentation techniques, such as infrared multiphoton dissociation
(IRMPD), ECD, and ETD.56, 142 Although all three techniques have proven to be powerful tools
for profiling species that are difficult to analyze by CID, IRMPD and ECD are much more costly
than ETD.22 As mentioned previously, disulfide bonds are readily cleaved in ETD MS/MS.  This
is a particularly informative characteristic of disulfide-bonded peptide ETD data, as detection of
the product ions arising from the individual peptide chains have proven useful for identifying the
composition of the intact disulfide-bonded precursor.
1.5.5.1 Automated MS/MS Data Analysis of Disulfide-Bonded Peptides. ETD
fragmentation was first described in 2004,22 and computational tools to assist in the analysis of
resultant MS/MS data have not yet advanced to the level seen for CID MS/MS data.143, 144, 145, 146,
147, 148 In particular, analysis tools that work to determine the charge state of precursor ions in
low resolution ETD fragmentation data, where charge state assignments are not apparent from
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isotopic distribution, are needed.  Although a few automated peptide ETD MS/MS analysis
programs have been created, these software were not developed or tested using disulfide-bonded
peptides, and are either not freely available or difficult for persons not trained in the use of
complex software to use.149, 150, 151
1.6 CONCLUDING REMARKS
Mass spectrometry is often the method of choice for elucidating protein post-translational
modifications. The generation of automated MS and MS/MS analysis tools to assist in the
characterization of PTMs is emerging as an effort to facilitate more rapid analysis of data
collected on proteins and peptides that contain them.  Specifically, analytical approaches and
automated tool development for the investigation of protein glycosylation and disulfide bond
formation, two of the most common PTMs, are discussed herein.
For the study of protein glycosylation, there are two main approaches used by
researchers: Glycan analysis and glycopeptide analysis.  The least challenging mode of analysis
is to release the glycans from a glycoprotein and analyze them independently. However, the
most informative approach is to utilize a protease and cleave the glycoprotein into glycopeptides,
thereby retaining information on where each glycan is attached within the protein sequence.
Similar to glycopeptide analysis, MS/MS experiments can be used to identify and map
the location of disulfide bonds on a protein after it has been enzymatically cleaved into peptides.
A key difference for proteins containing disulfide bonds is that the cysteine residues are not
reduced prior to proteolytic digestion, in order to retain the disulfide linkages.
Current research shows that although progress has been made in the development of
software for peptides containing glycans or disulfide bonds, there are still crucial deficiencies
that must be overcome before MS analysis of these and other PTMs is fully automated.
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1.8 SUMMARY OF SUBSEQUENT CHAPTERS
Chapter 2 describes a set of fragmentation rules that predict product ion formation in the
tandem mass spectra of peptides post-translationally modified by glycosylation. These rules
were developed after extensive analysis of the dissociation patterns detected in experimental N-
CID MS/MS data collected on these complex species. Prior to MS analysis, model glycoproteins
were digested by trypsin to yield glycopeptides comprised of various N-linked glycan
arrangements. The fragmentation rules developed from these studies are applicable to all N-
linked glycopeptides, regardless of the type of monosaccharide residues that comprise the
glycans. Finally, these rules were used to devise an algorithm that would be the basis for
MS/MS data analysis software.
Chapter 3 encompasses the development and testing of glycopeptide software, GlycoPep
Grader (GPG).  The GPG software incorporates the original algorithm that was created from the
CID studies on N-linked glycopeptides.  Specifically, the analysis tool evaluates MS/MS data for
the presence or absence of predicted products to elucidate N-linked glycopeptide composition.
GPG was first tested on the collection of CID spectra from the fragmentation studies (training
data set) before it was applied to a protein that was not part of the original algorithm design
(validation data set).  For both data sets, GPG detected the correct composition from a pool of
candidate glycopeptides of nearly identical mass (actual and decoy) in every test performed.
Chapter 4 describes an MS/MS analysis tool for the determination of precursor charge
state from peptides containing another common PTM, the inclusion of disulfide bonds.  Proteins
with a variety of disulfide bond patterns were digested using a protease, in the absence of a
reducing agent, in order to yield disulfide-bonded peptides.  These peptides were then analyzed
by ETD MS/MS to develop a method for the determination of precursor charge state directly
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from the fragmentation data.  Finally, the devised computational approach was automated with 2
straight-forward and easy-to-use computational tools that a user may easily reproduce in Excel.
Chapter 5 outlines future updates to the GPG software with the goal of improving the
score separation between the correct, or actual glycopeptide composition, and the decoy
candidates.  After scoring hundreds of CID spectra, alternative fragmentation patterns were noted
for complex/hybrid type glycopeptides bearing labile terminal residues.  In addition, other
proposed updates to GPG scoring for all complex/hybrid type glycopeptides are also discussed.
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CHAPTER 2
COLLISION INDUCED DISSOCIATION BEHAVIOR OF
N-LINKED GLYCOPEPTIDES
The work described in Chapter 2 encompasses an original (first author) publication:
Woodin, et al. GlycoPep Grader: A web-based utility for assigning the composition of
N-linked glycopeptides. Anal. Chem. 2012, 84, 4821-4829.
ABSTRACT
In order to accurately determine glycopeptide composition using mass spectrometry
(MS), fragmentation information is necessary.  For N-linked glycopeptide precursor ions
fragmented by collision induced dissociation tandem mass spectrometry (CID MS/MS), the
dissociation profiles obtained are uniquely correlated to a glycopeptide’s glycan substituent.
This information, along with precursor m/z, allows composition to be deduced with high
accuracy.  However, manual interpretation of these spectra is both challenging and laborious, and
limited programs exist to assist in the characterization of glycopeptides from CID data.
Developing a set of fragmentation rules is paramount toward designing the necessary algorithms
to successfully automate this MS/MS analysis.
In this work, experimental MS studies on N-linked glycopeptides were performed in
order to create a set of fragmentation rules to act as the basis of a novel glycopeptide MS/MS
scoring algorithm. Liquid-chromatography tandem mass spectrometry (LC-MS/MS) was done on
glycopeptides generated from tryptic digestion of RNase B, asialofetuin, and transferrin to
determine common product ions for the different types of N-linked glycopeptides that exist.
Resultant CID spectra, along with the large body of literature on MS/MS data of glycopeptides,
were then used to define a set of fragmentation rules applicable to all N-linked glycopeptides,
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regardless of type.  These rules incorporate differences in fragmentation that were found to be
present for different glycopeptides, and dependent on the monosaccharide arrangement of the
glycan substituent.  Next, the set of fragmentation rules were incorporated into a novel scoring
algorithm that deciphers glycopeptide composition from MS/MS data.  Specifically, the
algorithm searches a CID spectrum for characteristic product ions predicted to be present for
specified N-linked glycopeptide candidates and identifies the most likely composition of both the
peptide and the attached glycan.
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2.1 INTRODUCTION
In the human body alone, over half of all proteins expressed are predicted to be
glycosylated.1 Cellular communication events such as signaling, targeting and transport are also
known to be proudly impacted, even dependent, upon the types of glycosylation present for a
given protein.2, 3 , 4, 5, 6, 7, 8, 9 It should come as no surprise then that a variety of adverse
physiological conditions, such as inflammation and diabetes, and numerous disease states,
including cancer, typically present alongside an aberration of glycans on those proteins
affected.10, 7, 8, 9, 11, 12 In order to develop effective pharmaceuticals for the treatment of those
afflicted with such disorders, accurate glycan profiling of those involved glycoproteins is
necessary.  One of the most common ways to accomplish this is through the use of mass
spectrometry (MS) experiments.13, 14, 15, 16, 17, 18
The use of MS for the interrogation of protein glycosylation is accomplished by two main
routes: 1) Analysis of released glycans, and 2) Analysis of glycopeptides.13, 16 Although insight
on glycan composition and relative abundance is achieved using either approach, glycopeptide
analysis is most advantageous in that it provides location evidence for each individual glycan
residing on a peptide.16, 17 In the study of glycopeptides, the use of tandem mass spectrometry
(MS/MS) is especially important.  Information from MS/MS experiments allow a glycopeptide’s
composition to be determined in cases where MS1 data alone is not sufficient to do so: When the
experimental mass of the precursor ion, within a specified error range, correlates to more than
one possible structure.19
Several distinctive features render MS/MS by collision induced dissociation (CID)
amenable to glycopeptide analysis. One is that CID MS/MS permits glycopeptide data to be
readily distinguished within a protease digest, even though glycopeptides are generally present in
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low concentration as compared to peptides.20 This is due to the characteristic marker ions that
are detected in, and diagnostic of, spectra pertaining to them.  These low mass oxonium ions (m/z
204, m/z 163, m/z 292, m/z 366 and m/z 657) allow for the identification of glycopeptide spectra
even when complex samples are considered, and also serve as an indicator for which
monosaccharide residues comprise the attached glycan.20, 21, 22, 23, 24 The existence of these
marker ions is indicative of which terminal monosaccharide residues comprise the carbohydrate
portion, but not adequate to decipher overall glycopeptide composition.  To this end, tedious
evaluation of the entire CID spectrum for product ions encompassing multiple aspects of a
glycopeptide precursor’s fragmentation is necessary.
Glycopeptides have been shown to dissociate during CID MS/MS on the basis of their
attached glycan arrangement.20, 24, 25 It is through the study of these distinct fragmentation
profiles that allow a glycopeptide to be accurately correlated to their tandem mass spectra.
However, no set of comprehensive fragmentation rules have been reported for glycopeptide data
thus far.  As a result, researchers must rely on careful manual analysis in order to assign
glycopeptide composition to a given CID spectrum. Although this analysis is now routinely
performed, it remains a complex and difficult task, as two unknowns that must be identified are
present: The peptide portion, and the glycan portion.16
Due to these challenges, analysis programs to aid in the interpretation of glycopeptide
MS/MS data are limited.  Current research efforts toward improved automation are discussed in
Chapter 3 (Introduction) of this dissertation. In order to develop effective algorithms to power
these automated glycopeptide tools, a set of rules that accurately describes their fragmentation
profiles must be developed. These rules must be applicable to all N-linked glycopeptides, and
therefore incorporate the unique properties for each of the potential carbohydrate substituents
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that comprise them.
Herein, we describe CID MS/MS experiments performed on glycopeptides of various
glycan types.  After a large collection of spectra was obtained, they were extensively analyzed in
order to develop a set of fragmentation rules to develop an initial algorithm to expedite the
analysis of CID data collected for any N-linked glycopeptide.  Finally, these fragmentation rules
were utilized to construct an initial algorithm to serve as the basis for the automated computer
analysis tool described in Chapter 3 of this dissertation.
2.2 EXPERIMENTAL
2.2.1 Materials and Reagents. Bovine asialofetuin, bovine ribonuclease B (RNase B),
human apo-transferrin (transferrin), urea, dithiothreitol (DTT), iodoacetamide (IAM), formic
acid, acetic acid, Sepharose® CL-4B, HPLC grade ethanol, and HPLC grade 1-butanol were
purchased from Sigma Aldrich (St. Louis, MO). HPLC grade methanol (CH3 OH) and HPLC
grade acetonitrile (CH3 CN) were purchased from Fisher Scientific (Fairlawn, NJ). Ammonium
bicarbonate (NH4HCO3) was purchased from Fluka (Milwaukee, WI) and sequencing grade
modified trypsin was from purchased Promega (Madison, WI). Ultrapure water was obtained
from a Millipore Direct-Q® UV 3 system (Billerica, MA) with a resistance greater than 18 MΩ.
2.2.2 Preparation of RNase B, Asialofetuin, and Transferrin Glycopeptides. To
obtain glycopeptide samples, approximately 300 µg of each protein was dissolved in 50 mM
NH4HCO3 (pH 8.0) containing 4-6 M urea for denaturation. Disulfide bonds were reduced by
the addition of 15 mM DTT and incubation at room temperature for 1 hr. Samples were then
alkylated by allowing 25 mM IAM to react with the reduced glycoproteins at room temperature
in the dark, for an additional period of 1 hr. The alkylation reaction was quenched through the
addition of 40 mM DTT. Next, trypsin was added in a 1:30 (w/w) protease to protein ratio and
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incubated at 37 °C for 18 hr. The protease digestion was stopped by the addition of 1 µL
concentrated acetic acid for every 100 µL solution.  After digestion, RNase B and asialofetuin
samples were subjected to glycopeptide enrichment by an in-solution extraction method as
described by Rebecchi et al.26 These samples were then analyzed by direct infusion, as
described below. The transferrin sample was not enriched, as it was analyzed by LC-MS, also
described below.
2.2.3 Direct Injection Mass Spectrometry. RNase B and asialofetuin samples were
reconstituted after glycopeptide enrichment using solvent consisting of 1:1 (v/v) ultrapure
water/methanol in 0.5 % acetic acid, to a final concentration of 10 µM immediately prior to
direct injection of the glycopeptide samples onto an ESI-LIT-FTICR mass spectrometer
(ThermoScientific, San Jose, CA) containing a 7 Tesla actively shielded magnet.  Samples were
injected at a flow rate of 1 µL/min, and data was collected in positive ion mode.  Optimization of
the spray voltage was performed to achieve maximum signal.  The carrier gas, N2, was set to 10
psi and the capillary temperature was set to 200 °C. A 2 Da isolation window was used to select
precursor ions for MS/MS experiments.  Activation time was set to 30 ms, activation qz was set
to 0.250, and activation energy was set to 30 %, as defined by the instrument software.  Thirty
scans, each with 10 microscans, were averaged during the collection of MS/MS data.
2.2.4 Liquid Chromatography and Mass Spectrometry. Transferrin glycopeptides
were subjected to LC-MS experiments.  High resolution MS and MS/MS data were acquired on
an ESI-LIT-FTICR-MS (ThermoScientific, San Jose, CA) containing a 7 Tesla actively shielded
magnet.  The mass spectrometer was directly coupled to a Dionex UltiMate capillary LC system
(Sunnyvale, CA) equipped with a FAMOS well plate autosampler.  The mobile phase for solvent
A was comprised of 99.9 % H2O + 0.1 % formic acid and the mobile phase for solvent B
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consisted of 99.9 % CH3CN + 0.1 % formic acid.  Transferrin glycopeptides (5 µL at 3 µg/µL)
were injected onto a C18 column (300 µm i.d. x 5 cm, 3 µm particle size, CVC MicroTech,
Fontana, CA).  The flow rate was set to 5 µL/min.  Solvent conditions were as follows: 5 min at
5 % B, a 50 min. linear increase to 40 % B, a 10 min linear increase to 90 % B, 10 min. at 90 %
B, and re-equilibration of the column.  To prevent sample carryover, a 30 min wash cycle
followed by a blank run was performed between each sample.  The capillary offset voltage was
47 V, capillary temperature was 200 °C, and the spray voltage on the ESI source was set to 2.8
kV.  Mass spectrometry data were collected in a data dependent manner.  The five most intense
ions were selected for collision induced dissociation (CID) in the linear ion trap using 30 %
collision energy, and a dynamic exclusion window of 3 min was included.
2.2.5 Manual Data Analysis. To identify the glycopeptides from these samples in the
MS data, a prediction table of theoretical m/z values corresponding to glycopeptide compositions
for each of the three proteins was prepared.  The amino acid sequences from RNase B,
asialofetuin, and transferrin were obtained from Uniprot (www.uniprot.org) and their sequences
were imported into Protein Prospector (http://prospector.ucsf.edu/prospector/mshome.htm)
where tryptic peptides containing Cys residues were modified with carbamidomethylation, and a
theoretical tryptic digest was performed to consider up to two tryptic miscleavages.  The masses
of the peptides that contained potential N-linked glycosylation sites were added to the masses of
the known glycan compositions for each glycosylation site, in order to obtain glycopeptide
masses.  These masses were converted into m/z values corresponding to the glycopeptides in
multiple charge states.  The MS/MS data for RNase B, asialofetuin, and transferrin were then
searched to identify spectra that corresponded to the correct m/z value for a given glycopeptide
composition.  The MS/MS data were carefully (manually) evaluated, to verify the glycopeptide
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assignment.
2.3 RESULTS AND DISCUSSION
N-linked glycopeptides of different types have been shown to generate unique
dissociation profiles during MS/MS experiments.25 In order to develop a set of rules that can be
used to predict the expected product ions applicable these various compositions, three model
glycoproteins with differing N-glycan moieties were utilized during these experimental studies.
These include the well-characterized RNase B, asialofetuin, and transferrin glycoproteins, the
properties of which are shown in Table 1.
Table 1. Glycopeptides Analyzed by CID MS/MS.
Glycoprotein Mass (Da) Length (AA) # N-glycan Sites1 N-Glycan Type
RNase B 16,461 150 1 High Mannose
Asialofetuin 38,419 359 3 Complex
Transferrin 77,064 698 2 Sialylated Complex
1 N-linked glycosylation sites, excluding N-linked glycation.
2.3.1 Collision Induced Dissociation (CID) Studies. Representative data from
glycopeptides of RNase B, asialofetuin, and transferrin, are shown in Figures 1 and 2. These
data show typical fragmentation patterns for glycopeptides in the following categories: A) High
mannose type, B) Complex or hybrid type and C) Complex type structures containing the more
labile residues of sialic acid and/or fucose. The CID spectra of these glycopeptides illustrate that
many of the same types of product ions are detected in the glycopeptide MS/MS data, regardless
of the attached glycan composition. Specifically, product ions containing the peptide and
portions of the pentasaccharide core are found in all these spectra and most other spectra in the
training set, regardless of the glycan type. Herein, those peptide-containing product ions are
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referred to as the [peptide + core component] ions.
It has been shown previously that the same [peptide + core component] ions are present
in CID spectra of glycopeptides.23 From the MS/MS data we obtained, the [peptide + core
component] product ions were also found to be present in multiple charge states, when the
charge state of the precursor ion was greater than one, as shown in Figure 1.  For all three model
glycopeptides, these product ions were detected in both the precursor’s charge state and the next
lowest charge states, as shown by Figure 1A – C.  This finding is consistent with previous
reports by Lebrilla and co-workers.27
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Figure 1. MS/MS data from model N-linked glycopeptides used to generate CID fragmentation
rules with those product ions common to all appended glycans. A high mannose glycopeptide
from RNase B is shown in A; a sialylated complex glycopeptide from transferrin is shown in B;
and a complex glycopeptide from asialofetuin is shown in C.  The spectra in A – C show the
peptide-containing, or [peptide + core component], product ions detectable for all N-linked
glycopeptides (regardless of the glycan attached).
The second predominant type of product ion detected in the glycopeptide data were
neutral losses of terminal monosaccharides from the glycopeptide precursor ion. In contrast to
the [peptide + core component] fragmentation, neutral losses from the precursor ion observed for
the three model glycoprotein types were found to be unique to each candidate’s carbohydrate
composition. These ions, herein referred to as the [precursor – monosaccharide] product ions,
were used to develop fragmentation rules specific to glycopeptides with different glycan
substituents.  The fragmentation rules for both types of product ions serve as the basis for a novel
algorithm and computer analysis tool that is described in Chapter 3 of this dissertation.
An example highlighting the glycan-specific fragmentation for glycopeptides is
illustrated in Figure 2.  In Figure 2A, a CID spectrum collected on a high mannose type
glycopeptide shows sequential mannose losses, and the neutral loss of this residue as the
predominant fragmentation for high mannose containing glycopeptides is well established.25, 28, 29
These ions are typically present in the spectrum in the same charge state as the precursor ion.
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Figure 2. MS/MS data from model N-linked glycopeptides used to generate CID fragmentation
rules with those product ions specific to the composition of an appended glycan. A high
mannose glycopeptide from RNase B is shown in A; a sialylated complex glycopeptide from
transferrin is shown in B; and a complex glycopeptide from asialofetuin is shown in C.  The
spectra in A – C show those product ions that result from neutral losses of monosaccharides,
[precursor – monosaccharide], found to be unique to each N-glycan type.  (Diagnostic neutral
losses specific to each glycan type are shown in color, while other neutral losses that are not
useful in determining the glycan type are shown in gray.)
For complex or hybrid bi- and tri-antennary structures containing no labile fucose or
sialic residues, (such as the representative glycopeptide in Figure 2B), the predominant neutral
losses were found to be dependent on the total number of HexNAc vs. Hex monosaccharide
residues. If there are more HexNAc residues than Hex residues, the key diagnostic loss most
commonly observed in the training set was shown to be loss of two HexNAc from the
glycopeptide precursor ion. In comparison, those compositions containing more Hex residues
than HexNAc residues showed a key diagnostic loss corresponding to the loss of [Hex +
HexNAc] from the precursor ion.  In addition, a glycopeptide marker ion at m/z 366 is present in
the CID spectra of these compositions.  Figure 2B shows an example where the [Hex + HexNAc]
loss is readily detected. These characteristic fragmentation patterns were found to be essential
for verifying the glycan portion of a glycopeptide.
Finally, for MS/MS data collected on glycopeptides containing labile residues such as
sialic acid or fucose, the predominant [precursor – monosaccharide] product ion is the neutral
loss of these labile residues from the glycopeptide precursor. For example, in Figure 2C, loss of
sialic acid is detectable as a major product ion. Often, these ions are detected in both the
precursor ion’s charge state, and in the charge state below that of the precursor ion. While data
for only a glycopeptide containing sialic acid is shown in this chapter, glycopeptides containing
at least one fucose residue generally follow the same trend, since fucose is also a more labile
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monosaccharide.  This idea was verified during the validation of the software program described
in Chapter 3 of this dissertation, where analysis of fucosylated glycopeptide data is shown.
Although other neutral losses corresponding to the [precursor – monosaccharide] product
ion types are often present in CID spectra collected on the glycopeptides, (these ions are in gray
in the above figure) they were not shown to be unique enough to discriminate among various
potential glycan substituent compositions.
2.3.2 N-Linked Glycopeptide Fragmentation Rules. After extensive analysis of CID
spectra collected on RNase B, asialofetuin, and transferrin glycopeptides, a set of fragmentation
rules to be applied for N-linked glycopeptide MS/MS data was developed. Separate
fragmentation rules are implemented for the glycan portion of the glycopeptide, depending on
which types of glycans are present in the candidate composition.  The eight possible glycan
categories include: 1) High mannose type glycans without appended fucose; 2) High mannose
glycans that also contain fucose; 3) Complex or hybrid structures containing sialic acid (defined
as any glycan that is not in groups 1 or 2, does not contain any fucose residues, but contains
sialic acid); 4) Complex or hybrid type structures containing sialic acid and fucose residues
(defined as any glycan that is not in groups 1 or 2, and contains both sialic acid and fucose
residues); 5) Complex or hybrid type structures that contain fucose and multiple terminal
HexNAc residues; (defined as any glycan that is not in groups 1-4, does not contain sialic acid,
and has at least one fucose residue and a greater number of HexNAc than Hex residues); 6)
Complex/hybrid type structures that contain fucose and terminal Hex residues (defined as any
glycan that is not in groups 1-5, does not contain sialic acid, has at least one fucose residue, and
has a greater number of Hex than HexNAc residues); 7) Complex/hybrid type structures with
multiple terminal HexNAc residues but no sialic acid or fucose; (which is the same as group 5
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glycans, except no fucose is present); and 8) Complex/hybrid type structures that lack sialic acid
or fucose and contain terminal Hex residues (which is the same as group 6 glycans, except no
fucose is present).
The glycan classification system described above was developed to account for the fact
that glycopeptides with these different glycan components fragment differently and have
different diagnostic ions identifying them, as shown herein. This approach is also supported by
recently published research that shows the types of product ions in tandem mass spectra of
glycopeptides vary, depending on the unique glycan substituents present.25 Figure 3 displays the
product ions detected for each of the glycan class types devised on the basis of their
fragmentation characteristics.
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A. [Peptide + Core Component] Ions             B. [Precursor – Monosaccharide] Ions        
 
 
 
Figure 3.  Schematic of (A) [peptide + core component] and (B) [precursor – monosaccharide] 
product ions expected for each of the eight group types, described in the text.  In (A), the six 
different [peptide + core component] product ions detected for a glycopeptide, regardless of 
glycan type, are displayed.  In (B), the monosaccharide neutral losses evaluated for group 1 are 
shown in the purple oval; for group 2, the relevant losses are shown in both the purple oval and 
the yellow circle; group 3, the relevant losses are shown in the blue oval; group 4, in the blue 
oval and yellow circle; group 5, in the orange oval and yellow circle; group 6, in the green oval 
and yellow circle; and group 7 and group 8 neutral losses are presented by the orange oval, and 
the green oval, respectively.  
 
 
2.3.3 Initial Algorithm Development.  After the fragmentation rules were created, as 
illustrated by Fig. 3, they were incorporated into a set of instructions, or algorithm, to be used to 
determine glycopeptide composition from a given CID spectrum.  These rules were based on the 
detected product ions found to be present in each of the devised glycan categories.  In the 
development of this algorithm, a variety of normalization thresholds were manually evaluated 
using the normalization function in the XCalibur software (Thermo-Scientific).   
Normalization levels for [peptide + core component] product ions were applied by setting 
the relative abundance threshold to specified percentages.  Extensive testing of 1 %, 2 %, and 3 
% relative abundance normalizations were performed.  A relative abundance threshold of 2 % 
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was found to work best for most spectra, however; 3 % was found to be better for those
spectra containing a high amount of noise whereas 1 % was found to be ideal for very
clean spectra with a strong signal-to-noise ratio.
For the [precursor – monosaccharide] product ions, the normalization rubric
applied was more complex.  The product ions formed by each of the precursor neutral
losses were found to be present in varying intensities.  As such, different relative
abundance thresholds are applied to each unique monosaccharide loss.  However, these
normalization values are still based on the quality of MS/MS data and are automatically
adjusted based on the peptide normalization values which are selected.  Details of these
normalization values are given in the original complete algorithm, as shown in Table 2.
Table 2. Original Complete Algorithm Developed from Glycopeptide Fragmentation Rules.
INPUTS
Spectra = MS/MS data
PrecursorIon = m/z of precursor ion
Candidate Glycan & Peptide Formulas
ChargeState = charge state of precursor ion
PeptideSearchNormalization = spectra record abundance at {1% | 2% | 3%}
CONVENTIONS
DecrementedChargeState = charge state - 1
Spectra[m/z] = m/z value of a record in spectra
Spectra[Minima] = lowest m/z value in spectra
Spectra[Maxima] = highest m/z value in Spectra
CandidateHexNAc = number of HexNAc residues in candidate's glycan
CandidateHex = number of hexose residues in candidate's glycan
CandidateFuc = number of fucose residues in candidate's glycan
CandidateNeu5Ac = number of sialic acid residues in candidate's glycan
For all matching and scoring calculations, a match between SearchCandidate and Spectra is true only if:
(Spectra [m/z] - 1) <= SearchCandidate <= (Spectra [m/z] + 1)
and TotalRawPeptideScore and TotalRawGlycanScore are incremented only if:
(Spectra[Minima]) <= SearchCandidate <= (Spectra[Maxima])
SPECTRA NORMALIZATION SELECTION
A. Normalize spectra to 1%, 2%, or 3% for peptide-glycan searches:
Remove Spectra records whose relative abundance is less than or equal to PeptideSearchNormalization.
B. Normalize spectra for precursor-glycan searches:
Remove Spectra records whose relative abundance is less than or equal to the below corresponding thresholds:
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If 1% PeptideSearchNormalization:
Block A1, A2: PrecursorIonSearchNormalization = 2%
Block A3, B, C, D: PrecursorIonSearchNormalization = 6%
Block E: PrecursorIonSearchNormalization = 4%
Block F: PrecursorIonSearchNormalization = 0%
If 2% PeptideSearchNormalization:
Block A1, A2: PrecursorIonSearchNormalization = 3%
Block A3, B, C, D: PrecursorIonSearchNormalization = 10%
Block E: PrecursorIonSearchNormalization = 6%
Block F: PrecursorIonSearchNormalization = 0%
If 3% PeptideSearchNormalization:
Block A1, A2: PrecursorIonSearchNormalization = 4%
Block A3, B, C, D: PrecursorIonSearchNormalization = 18%
Block E: PrecursorIonSearchNormalization = 8%
Block F: PrecursorIonSearchNormalization = 0%
1. Calculate the neutral masses of the candidates' peptides and glycans.
PeptideMass = (masses of constituent amino acids) + 18.01056
2. Grade peptide-containing peaks.
2A. Look for each of these candidates at ChargeState:
Y0 = (PeptideMass + (ChargeState * 1.0073)) / ChargeState
Y1 = (PeptideMass + (ChargeState * 1.0073) + HexNAc) / ChargeState
Y1 = (PeptideMass + (ChargeState * 1.0073) + 203.0794) / ChargeState
Y2 = (PeptideMass + (ChargeState * 1.0073) + HexNAc + HexNAc) / ChargeState
Y2 = (PeptideMass + (ChargeState * 1.0073) + 203.0794 + 203.0794) / ChargeState
Y3 = (PeptideMass + (ChargeState * 1.0073) + HexNAc + HexNAc + Hex) / ChargeState
Y3 = (PeptideMass + (ChargeState * 1.0073) + 203.0794 + 203.0794 + 162.0528) / ChargeState
Y4 = (PeptideMass + (ChargeState * 1.0073) + HexNAc + HexNAc + Hex + Hex) / ChargeState
Y4 = (PeptideMass + (ChargeState * 1.0073) + 203.0794 + 203.0794 + 162.0528 + 162.0528) / ChargeState
Y5 = (PeptideMass + (ChargeState * 1.0073) + HexNAc + HexNAc + Hex + Hex + Hex) / ChargeState
Y5 = (PeptideMass + (ChargeState * 1.0073) + 203.0794 + 203.0794 + 162.0528 + 162.0528 + 162.0528) /
ChargeState
If match, ActualRawPeptideScore += 1.  Regardless of match, TotalRawPeptideScore += 1.
2B. For ChargeStateIterator from DecrementedChargeState to 1, recursively look for each of these candidates:
Y0 = (PeptideMass + (ChargeStateIterator * 1.0073)) / ChargeStateIterator
Y1 = (PeptideMass + (ChargeStateIterator * 1.0073) + HexNAc) / ChargeStateIterator
Y1 = (PeptideMass + (ChargeStateIterator * 1.0073) + 203.0794) / ChargeStateIterator
Y2 = (PeptideMass + (ChargeStateIterator * 1.0073) + HexNAc + HexNAc) / ChargeStateIterator
Y2 = (PeptideMass + (ChargeStateIterator * 1.0073) + 203.0794 + 203.0794) / ChargeStateIterator
Y3 = (PeptideMass + (ChargeStateIterator * 1.0073) + HexNAc + HexNAc + Hex) / ChargeStateIterator
Y3 = (PeptideMass + (ChargeStateIterator * 1.0073) + 203.0794 + 203.0794 + 162.0528) / ChargeStateIterator
Y4 = (PeptideMass + (ChargeStateIterator * 1.0073) + HexNAc + HexNAc + Hex + Hex) / ChargeStateIterator
Y4 = (PeptideMass + (ChargeStateIterator * 1.0073) + 203.0794 + 203.0794 + 162.0528 + 162.0528) /
ChargeStateIterator
Y5 = (PeptideMass + (ChargeStateIterator * 1.0073) + HexNAc + HexNAc + Hex + Hex + Hex) /
ChargeStateIterator
Y5 = (PeptideMass + (ChargeStateIterator * 1.0073) + 203.0794 + 203.0794 + 162.0528 + 162.0528 + 162.0528) /
ChargeStateIterator
If match, ActualRawPeptideScore += 2.  Regardless of match, TotalRawPeptideScore += 2.
2C. Look for the Y1 candidate at DecrementedChargeState.
If match and relative abundance is > 25%, add 4 to ActualRawPeptideScore.  Regardless of match, add 4 to
TotalRawPeptideScore.
2D. PeptideScore = ActualRawPeptideScore / TotalRawPeptideScore
3. Grade precursor loss peaks.
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A. Is CandidateHexNAc = 2 and CandidateHex = {1 - 9}? If yes, continue from A1. If no, continue from B.
A1. For LossMultiplier from 1 to CandidateHex, recursively look for loss of (LossMultiplier * Hex) from
PrecursorIon at ChargeState:
SearchCandidate = PrecursorIon - ((LossMultiplier * 162.0528) / ChargeState)
If match, ActualRawGlycanScore += 2.  Regardless of match, TotalRawGlycanScore += 2.
A2. Initialize MatchFound to true, increment LossMultiplier from its last value at A1, and while MatchFound is true,
look for loss of (LossMultiplier * Hex) from PrecursorIon at ChargeState:
SearchCandidate = PrecursorIon - ((LossMultiplier * 162.0528) / ChargeState)
If match, ActualRawGlycanScore -= 2, LossMultiplier += 1.
A3. Is CandidateFuc > 0?  If yes, continue from A4.  If no, continue from G.
A4. Look for loss of (Fuc) from PrecursorIon at DecrementedChargeState:
SearchCandidate = ((PrecursorIon * ChargeState) - 1.0073 - 146.0579) / DecrementedChargeState
If match, ActualRawGlycanScore += 2.  Regardless of match, TotalRawGlycanScore += 2.
A5. For LossMultiplier from 1 to CandidateFuc, recursively look for loss of (LossMultiplier * Fuc) from
PrecursorIon at ChargeState:
SearchCandidate = PrecursorIon - ((LossMultiplier * 146.0579) / ChargeState)
If match, ActualRawGlycanScore += 4.  Regardless of match, TotalRawGlycanScore += 4.
A6. Continue from G.
B. Is CandidateNeu5Ac > 0 and CandidateFuc > 0?  If yes, continue from B1.  If no, continue from C.
B1. Look for loss of (Neu5Ac + Fuc) from PrecursorIon at ChargeState:
SearchCandidate = PrecursorIon - ((291.0954 + 146.0579) / ChargeState)
If match, ActualRawGlycanScore += 4.  Regardless of match, TotalRawGlycanScore += 4.
B2. Continue from C.
C. Is CandidateNeu5Ac > 0?  If yes, continue from C1.  If no, continue from D.
C1. Look for loss of (Neu5Ac) from PrecursorIon at DecrementedChargeState:
SearchCandidate = ((PrecursorIon * ChargeState) - 1.0073 - 291.0954) / DecrementedChargeState
If match, ActualRawGlycanScore += 2.  Regardless of match, TotalRawGlycanScore += 2.
C2. For LossMultiplier from 1 to CandidateNeu5Ac, recursively look for loss of (LossMultiplier * Neu5Ac) from
PrecursorIon at ChargeState:
SearchCandidate = PrecursorIon - ((LossMultiplier * 291.0954) / ChargeState)
If match, ActualRawGlycanScore += 4.  Regardless of match, TotalRawGlycanScore += 4.
C3. Continue from D.
D. Is CandidateFuc > 0 ?  If yes, continue from D-1A.  If no, continue from D-2.
D-1A. Look for loss of (Fuc) from PrecursorIon at DecrementedChargeState:
SearchCandidate = ((PrecursorIon * ChargeState) - 1.0073 - 146.0579) / DecrementedChargeState
If match, ActualRawGlycanScore += 2.  Regardless of match, TotalRawGlycanScore += 2.
D-1B. For LossMultiplier from 1 to CandidateFuc, recursively look for loss of (LossMultiplier * Fuc) from
PrecursorIon at ChargeState:
SearchCandidate = PrecursorIon - ((LossMultiplier * 146.0579) / ChargeState)
If match, ActualRawGlycanScore += 4.  Regardless of match, TotalRawGlycanScore += 4.
D-1C. Is CandidateNeu5Ac > 0?  If no, continue from D-1D.  If yes, continue from G.
D-1D. Subtract pentasaccharide core ([HexNAc]2Hex[3]) from glycan.  Of the remaining sugars, are there at least 2
more HexNAc than Hex residues?  If yes, continue from D-1D-1A.  If no, continue from D-1D-2A.
D-1D-1A. Look for loss of (Fuc + HexNAc) from PrecursorIon at DecrementedChargeState:
SearchCandidate = ((PrecursorIon * ChargeState) - 1.0073 - 146.0579 - 203.0794) / DecrementedChargeState
If match, ActualRawGlycanScore += 4.  Regardless of match, TotalRawGlycanScore += 4.
D-1D-1B. Look for loss of (Fuc + HexNAc) from PrecursorIon at ChargeState:
SearchCandidate = PrecursorIon - ((146.0579 + 203.0794) / ChargeState)
If match, ActualRawGlycanScore += 4.  Regardless of match, TotalRawGlycanScore += 4.
D-1D-1C. Is CandidateFuc > 1?  If yes, continue from D-1D-1D.  If no, continue from D-1D-1E.
D-1D-1D. Look for loss of ((CandidateFuc * Fuc) + HexNAc) from PrecursorIon at ChargeState:
SearchCandidate = PrecursorIon - (((CandidateFuc * 146.0579) + 203.0794) / ChargeState)
If match, ActualRawGlycanScore += 4.  Regardless of match, TotalRawGlycanScore += 4.
D-1D-1E. Look for loss of ((CandidateFuc * Fuc) + (2 * HexNAc)) from PrecursorIon at ChargeState:
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SearchCandidate = PrecursorIon - (((CandidateFuc * 146.0579) + (2 * 203.0794)) / ChargeState)
If match, ActualRawGlycanScore += 2.  Regardless of match, TotalRawGlycanScore += 2.
D-1D-1F. Continue from G.
D-1D-2A. Look for loss of (Fuc + Hex) from PrecursorIon at ChargeState:
SearchCandidate = PrecursorIon - ((146.0579 + 162.0528) / ChargeState)
If match, ActualRawGlycanScore += 4.  Regardless of match, TotalRawGlycanScore += 4.
D-1D-2B. Is CandidateFuc > 1?  If yes, continue from D-1D-2C.  If no, continue from D-1D-2D.
D-1D-2C. Look for loss of ((CandidateFuc * Fuc) + Hex) from PrecursorIon at ChargeState:
SearchCandidate = PrecursorIon - (((CandidateFuc * 146.0579) + 162.0528) / ChargeState)
If match, ActualRawGlycanScore += 4.  Regardless of match, TotalRawGlycanScore += 4.
D-1D-2D. Look for loss of (Fuc + Hex + HexNAc) from PrecursorIon at DecrementedChargeState:
SearchCandidate = ((PrecursorIon * ChargeState) - 1.0073 - 146.0579 - 162.0528 - 203.0794) /
DecrementedChargeState
If match, continue from D-1D-2D-1A.  If no match, continue from D-1D-2D-2A.
D-1D-2D-1A. Add 4 to ActualRawGlycanScore.  Add 4 to TotalRawGlycanScore.
D-1D-2D-1B. Continue from F1.
D-1D-2D-2A. Look for loss of (Fuc + Hex + HexNAc) from PrecursorIon at ChargeState:
SearchCandidate = PrecursorIon - ((146.0579 + 162.0528 + 203.0794) / ChargeState)
If match, ActualRawGlycanScore += 4.  Regardless of match, TotalRawGlycanScore += 4.
D-1D-2D-2B. Continue from F1.
D-2. Is CandidateNeu5Ac > 0?  If no, continue from E.  If yes, continue from G.
E. Subtract pentasaccharide core ([HexNAc]2Hex[3]) from glycan.  Of the remaining sugars, are there at least 2
more HexNAc than Hex residues?  If yes, continue from E-1A.  If no, continue from E-2A.
E-1A. Look for loss of (HexNAc) from PrecursorIon at DecrementedChargeState:
SearchCandidate = ((PrecursorIon * ChargeState) - 1.0073 - 203.0794) / DecrementedChargeState
If match, ActualRawGlycanScore += 4.  Regardless of match, TotalRawGlycanScore += 4.
E-1B. Look for loss of (HexNAc) from PrecursorIon at ChargeState:
SearchCandidate = PrecursorIon - (203.0794 / ChargeState)
If match, ActualRawGlycanScore += 4.  Regardless of match, TotalRawGlycanScore += 4.
E-1C. Look for loss of (2 * HexNAc) from PrecursorIon at ChargeState:
SearchCandidate = PrecursorIon - ((2 * 203.0794) / ChargeState)
If match, ActualRawGlycanScore += 2.  Regardless of match, TotalRawGlycanScore += 2.
E-1D. Continue from G.
E-2A. Look for loss of (Hex) from PrecursorIon at ChargeState:
SearchCandidate = PrecursorIon - (162.0528 / ChargeState)
If match, ActualRawGlycanScore += 4.  Regardless of match, TotalRawGlycanScore += 4.
E-2B. Look for loss of (Hex + HexNAc) from PrecursorIon at DecrementedChargeState:
SearchCandidate = ((PrecursorIon * ChargeState) - 1.0073 - 162.0528 - 203.0794) / DecrementedChargeState
If match, continue from E-2B-1A.  If no match, continue from E-2B-2A.
E-2B-1A. Add 4 to ActualRawGlycanScore.  Add 4 to TotalRawGlycanScore.
E-2B-1B. Continue from F1.
E-2B-2A. Look for loss of (Hex + HexNAc) from PrecursorIon at ChargeState:
SearchCandidate = PrecursorIon - ((162.0528 + 203.0794) / ChargeState)
If match, ActualRawGlycanScore += 4.  Regardless of match, TotalRawGlycanScore += 4.
E-2B-2B. Continue from F1.
F1. Look for Hex-HexNAc marker ion (366).
If match, ActualRawGlycanScore += 2.  Regardless of match, TotalRawGlycanScore += 2.
3F2. Go to G.
3G. GlycanScore = ActualRawGlycanScore / TotalRawGlycanScore
4. GlycopeptideScore = (PeptideScore * 0.67) + (GlycanScore * 0.33)
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2.4 CONCLUDING REMARKS
Numerous CID experiments on glycopeptides containing various N-linked glycan
types were performed.  Two main types of product ions were subsequently identified
from the resultant of MS/MS data, one of which was found to be present in all of the
glycopeptide data studied, and one of which was found to be unique to the arrangement
of the attached glycan.  These product ions are referred to as [peptide + core component]
ions and [precursor – monosaccharide] ions, respectively.  After studying the collection
of spectra, a set of fragmentation rules to be applied to each of the eight devised glycan
type categories was developed.  These fragmentation rules were then incorporated into an
algorithm that functions to predict two types of product ions from CID data of varying
spectral quality.  The algorithm was eventually turned into a publicly available automated
analysis tool, which is described in Chapter 3 of this dissertation.
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CHAPTER 3
GLYCOPEP GRADER: A WEB-BASED UTILITY FOR ASSIGNING THE
COMPOSITION OF N-LINKED GLYCOPEPTIDES
The work described in Chapter 2 encompasses an original (first author) publication:
Woodin, et al. GlycoPep Grader: A web-based utility for assigning the composition of
N-linked glycopeptides. Anal. Chem. 2012, 84, 4821-4829.
ABSTRACT
GlycoPep Grader (GPG) is a freely available software tool designed to accelerate the
process of accurately determining glycopeptide composition from tandem mass spectrometric
data.  GPG relies on the identification of unique dissociation patterns shown for high mannose,
hybrid, and complex N-linked glycoprotein types, including patterns specific to those structures
containing fucose or sialic acid residues.  The novel GPG scoring algorithm scores potential
candidate compositions of the same nominal mass against MS/MS data through evaluation of the
Y1 ion and other peptide-containing product ions, across multiple charge states, when applicable.
In addition to evaluating the peptide portions of a given glycopeptide, the GPG algorithm
predicts and scores product ions that result from unique neutral losses of terminal glycans. GPG
has been applied to a variety of glycoproteins, including RNase B, asialofetuin and transferrin,
and the HIV envelope glycoprotein, CON-S gp140ΔCFI. The GPG software is implemented
predominantly in PostgreSQL, with PHP as the presentation tier, and is publically accessible
online. Thus far, the algorithm has identified the correct compositional assignment from multiple
candidate N-glycopeptides in all tests performed.
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3.1 INTRODUCTION
Among all co/post-translational modifications, glycosylation is widely regarded as both
the most frequent and most complex that proteins undertake.1, 2, 3, 4 It is well-documented that
glycosylation regulates a variety of intra- and extra-cellular processes.3, 4, 5, 6, 7, 8, 9 Cellular
communication and transport events,5, 6 and mechanisms of protein folding,3, 5, 6 degradation,3, 5
and enzymatic interaction,7 have all been shown to be regulated by glycosylation, the majority of
which are N-linked in type.1 As such, the availability of mass spectrometry (MS) tools to speed
the identification of glycosylation profiles is critical to the elucidation of their physiological
importance.3, 8, 10, 11, 12
Typically, glycosylation analysis using mass spectrometry (MS) techniques is
accomplished using one of two approaches:  Glycan analysis and glycopeptide analysis.12 The
most information-rich of these methods is glycopeptide analysis, as glycosylation characteristics
at individual sites of glycan attachment are readily identifiable.2, 12 High resolution MS data is
used to determine potential candidate compositions for mass spectral peaks that are suspected or
known to be from glycopeptides.  Computer-based programs such as Glycomod 13 and GlycoPep
DB 14 calculate glycopeptide candidate compositions on the basis of mass information, as do a
number of custom-generated databases.15, 16 Unfortunately, a large amount of mass redundancy
is typically encountered in glycopeptide analysis.  Many different combinations of glycan
composition + peptide composition are isobaric,15 so multiple candidate compositions frequently
correspond to the same nominal mass.  Therefore, while high resolution MS data is useful for
predicting possible glycopeptide candidate compositions, it alone is not sufficient to identify
glycopeptides unambiguously.  As a result, MS/MS experiments are often necessary to correctly
assign glycopeptide compositions.  When the analyses of these data are performed manually, the
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process is laborious, time-consuming, and requires significant expertise.3, 4, 17
A few unique strategies have been developed to automate the process of scoring MS/MS
data against potential glycopeptide compositions.  These include programs described in
references 18, 19, 20, 21, 22.  However, none of these analysis tools are freely accessible to the
public.18, 19, 20, 21, 22. In terms of those tools that are publicly available for glycopeptide analysis,
many have been designed to predominantly analyze the fragmentation of glycans.23, 24 Although
these tools are capable of analyzing glycopeptides, the peptide component must be known in
advance, which severely limits their utility for analysis of unknown glycopeptides.23, 24
GlycoWorkBench 23 and Glyco-Peakfinder 24 both utilize this approach for the annotation of
glycans in glycopeptide data.  A completely different approach is utilized by GlycoPep ID, a
web-based tool developed by Go et al.25 GlycoPep ID interprets MS/MS data of glycopeptides
to identify the peptide component of glycopeptides through analysis of expected product ions,
but the key disadvantage of this program is that it does not include a scoring function.25
The most promising publicly accessible tool specifically developed to interpret and score
MS/MS data of glycopeptides is GlycoMiner, developed by Ozohanics et al.26 This program was
designed to analyze qTOF data, and is capable of identifying and assigning glycopeptide
compositions when both the peptide and glycan portions are unknown.  Although this program is
a great advancement in the automation of glycopeptide MS/MS analysis, GlycoMiner often
generates multiple plausible compositions and fails to rank the correct glycopeptide as the top
candidate, instead listing it as one of the most probable compositions.26 In addition, the program
requires the presence of low-mass marker ions, which are generally not present in data collected
on ion trap instruments.  The program also requires the MS/MS data to be transformed into
singly charged ions, prior to analysis.  This transformation is often not possible when analyzing
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low resolution MS/MS data, such as that from an ion trap mass spectrometer. Finally,
GlycoMiner requires MS/MS data containing a low S/N.26
GlycoPep Grader, which aims to expedite the characterization of N-linked glycopeptides
by evaluating both the glycan and peptide portions through a series of devised fragmentation
rules, was developed in an effort to overcome the limitations of the currently available tools.
The novel algorithm calculates and scores any given glycopeptide candidate composition by
searching MS/MS data for two types of product ions: 1) Those containing the peptide portion,
[peptide + core component] ions, and 2) Those resulting from neutral losses of terminal
monosaccharides, [precursor – monosaccharide] ions.  The use of GlycoPep Grader in
determining glycopeptide compositions is not contingent upon any spectral requirements, such
the presence of specific marker ions.  In addition, the GPG algorithm analyzes MS/MS data in a
charge-state dependent fashion, bypassing the need for transformation of spectra to singly-
charged ions.  These features have resulted in a highly accurate automated analysis tool that
deciphers glycopeptide compositions.  GPG is freely available online; it can be accessed at
http://glycopro.chem.ku.edu/GPGHome.php.
3.2 EXPERIMENTAL
3.2.1 Materials and Reagents. Details regarding the materials and reagents, along with
the experimental protocols for sample preparation and MS analysis of RNase B, asialofetuin, and
transferrin glycopeptides can be found in the experimental section of Chapter 2 of this
dissertation.
3.2.2 Production of CON-S gp140ΔCFI Glycoprotein. CON-S gp140ΔCFI envelope
glycoprotein was obtained by our lab from the Duke Human Vaccine Research Institute
(Durham, NC) after it was constructed, expressed and purified using methods previously
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stated.27, 28, 29
3.2.3 Preparation and LC-MS of CON-S gp140ΔCFI Glycopeptides. Purified
envelope glycoprotein samples were prepared by Go et al. as stated in the literature.27 Briefly,
300 μg aliquots of glycoprotein were denatured by the addition of 6 M urea in 100 mM Tris
buffer (pH 7.5) with 3 mM EDTA.  The denatured proteins were then reduced and alkylated by
incubation in 15 mM DTT at room temperature for 1 hr.  Immediately after, 40 mM IAM was
allowed to react with each denatured sample at room temperature in the dark for an additional 1
hr.  To neutralize excess IAM, a second portion of DTT was added to achieve a final
concentration of 50 mM DTT.  After reduction and alkylation, the samples were diluted to 2 M
urea prior to adding trypsin at a protein/enzyme ratio of 30:1 (w/w).  The protease was allowed
to react at 37 °C overnight, followed by a second trypsin digestion under the same conditions.
HIV Env glycopeptides were then subjected to LC-MS and identified by Go et al., as
described.27 Finally, the resultant collection of CID spectra was scored using GPG.
3.2.4 Development of a Glycopeptide Training Data Set. In order to develop the GPG
algorithm, a set of “known” glycopeptides and their MS/MS data were required; the training set
included glycopeptides from RNase B, asialofetuin and transferrin, as these are well
characterized samples.30, 31, 32 To identify the glycopeptides from these samples in the MS data, a
prediction table of theoretical m/z values corresponding to glycopeptide compositions for each of
the three proteins was prepared.  The amino acid sequences from RNase B, asialofetuin, and
transferrin were obtained from Uniprot (www.uniprot.org) and their sequences were imported
into Protein Prospector (http://prospector.ucsf.edu/prospector/mshome.htm) where tryptic
peptides containing Cys residues were modified with carbamidomethylation, and a theoretical
tryptic digest was performed to consider up to two tryptic miscleavages.  The masses of the
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peptides that contained potential N-linked glycosylation sites were added to the masses of the
known glycan compositions for each glycosylation site, in order to obtain glycopeptide masses.
These masses were converted into m/z values corresponding to the glycopeptides in multiple
charge states.  The MS/MS data for RNase B, asialofetuin, and transferrin were then searched to
identify spectra that corresponded to the correct m/z value for a given glycopeptide composition.
The MS/MS data were carefully (manually) evaluated, to verify the glycopeptide assignment.
3.2.5 The Glycopeptide Validation Data Set. In order to test the GPG software, a
validation set of glycopeptide compositions that were not used in the fragmentation studies or
algorithm development was necessary.  The validation set for these studies comprised data from
a glycoprotein, CON-S gp140ΔCFI, which had been previously analyzed in our laboratory.27
Data from this protein was selected because prior analyses demonstrated that all the necessary
glycoform types were present as glycopeptides (including high mannose and complex/hybrid
structures with and without sialic acid and fucose.)  Additionally, since the protein has more than
25 glycosylation sites, a wide variety of glycosylated peptide sequences were also available.
Furthermore, all the MS/MS data on this protein had been previously analyzed manually, as
described elsewhere.27
3.2.6 Software Platform. GlycoPep Grader is a Web service implementation of our
algorithm, encapsulating data submission and analysis as a computational session. This
transaction-processing approach protects our Web service against the thankless perils that come
with providing anonymous data acceptance and computational services on the Internet, while
simultaneously ensuring the correctness of the computation. The graphical user interface (GUI)
code is built to conform to ECMAScript and W3C DOM standards, and we chose the open-
source, globally distributed Mozilla Firefox Web browser as the reference platform for the GUI
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presentation. The computational engine is implemented on common Web server and database
software, with a variety of implementation-specific optimizations for computationally-intensive
hotspots in the algorithm. These optimizations include deep logic reordering, pre-calculations of
elicited constants, and pre-compilations of common loops. Finally, we use AJAX technology
(Asynchronous Javascript And XML) to achieve state continuity and provide a responsive,
interactive experience to the user.
Prior to using GlycoPep Grader, the user must first successfully complete a simple math
problem embedded in a CAPTCHA (completely automated public Turing test to tell computers
and humans apart). This security step helps prevent automated abuse of the Web server.
GlycoPep Grader then accepts user input, including candidate glycopeptide compositions, the
m/z and charge state of the precursor ion, and MS/MS data (which the user provides in a .CSV
file). The Web service performs server-side validation of the submitted data for type, format,
size, and range correctness. Once the data obtains correctness approval, the computational
engine performs its analysis of the glycopeptide candidates against the spectral data. When the
analysis is complete, the computational engine assembles and returns the results to the GUI code
listening on the user's Firefox Web browser.
3.2.7 Generation and Input of Glycopeptide Candidate Compositions. After the
MS/MS peak list file (along with the corresponding charge state and m/z of the precursor ion) is
uploaded to GPG in .CSV file format, peptide compositions are input manually by listing the
amino acid sequence of each glycopeptide candidate ion vertically on a separate line.  The
glycopeptide candidate compositions are obtained by the user through freely accessible programs
such as GlycoMod 13 or GlycoPep DB 14, or custom-generated databases.15, 16 The GPG analysis
tool then quickly calculates and searches for the [peptide + core component] product ions that it
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predicts to be present for each of the peptide portions entered.  In the next window, the glycan
portions for each of the candidate glycopeptides are manually entered in the same order using the
following format, where n = the number of each monosaccharide residue and Neu5Ac = sialic
acid: [HexNAc]n[Hex]n[Neu5Ac]n[Fuc]n.  After GPG evaluates the uploaded MS/MS peak list
for product ions expected to be present for each glycan, a final score is displayed in the output
for each of the user-entered glycopeptide compositions.
3.2.8 False Discovery Rate Determination and Scoring of Candidate Compositions.
Decoy candidate compositions for all data sets were generated using an in-house database where
a decoy polypeptide of 50,000 amino acid residues, Titin, was multiplexed to a biologically
relevant library of approximately 200 glycans.  (These glycans are the same ones used in the on-
line tool, GlycoPep DB.14)  All selected decoy candidate compositions have a calculated neutral
mass that is within 50 ppm of the FT-ICR MS monoisotopic peak value of the glycopeptide
precursor ion for the CID spectrum tested.  The decoy glycopeptide compositions, along with the
correct glycopeptide composition assignment, were used to determine the false discovery rate of
the GPG tool.
3.3 RESULTS AND DISCUSSION
GlycoPep Grader (GPG) was designed to analyze N-linked glycopeptide CID data.
RNase B, asialofetuin, and transferrin were chosen as model glycoproteins for the initial testing
of the GPG software tool, as well as for the development of the novel algorithm that powers
GPG, because they are well characterized and contain various glycoform types.  Detailed
information on the glycosylation characteristics of the glycopeptides used for the testing and
validation of the GPG software tool, is included below in Table 1.
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Table 1. Glycopeptides Analyzed for Training and Validation Data Sets.
Glycoprotein Mass (Da)                 Length (AA)         # N-glycan Sites N-Glycan Type
RNase B1 16,461 150 1 High Mannose
Asialofetuin1 38,419 359 3 Complex
Transferrin1 77,064 698 2 Sialylated Complex
CON-S gp140∆CFI2 ~140,000 610 21 Highly Diverse
1 Training Data Set
2 Validation Data Set
3.3.1 Novel GPG Scoring Algorithm. A detailed version of the scoring system, as it
stands currently, is available at http://glycopro.chem.ku.edu/GPGHome.php.  The original
scoring algorithm is also available in Chapter 2 of this dissertation.  The same peptide-containing
product ions are detected in a CID spectrum of an N-linked glycopeptide, regardless of the type
of glycan substituent attached.  Therefore, for GlycoPep Grader (GPG) scoring of each peptide
portion, the [peptide + core component] product ions are calculated for the candidate
glycopeptide beginning with the [naked peptide] and continuing through the [peptide + intact
pentasaccharide core] for a total six possible [peptide + core component] product ions: 1. [naked
peptide], 2. [peptide + HexNAc], 3. [peptide + 2HexNAc], 4. [peptide + 2HexNAc + Hex], 5.
[peptide + 2HexNAc + 2Hex], and 6. [peptide + 2HexNAc + 3Hex].  The GPG algorithm uses
the presence of these ions to score the peptide portion of the candidate glycopeptide composition.
The Y1 ion, which contains the peptide and one HexNAc residue from the pentasaccharide core,
has been shown to be a highly abundant ion in MS/MS data collected on glycopeptides.  This
product ion is also considered a very indicative identifier of a glycopeptide’s peptide portion,33
so the GPG algorithm weights this ion more heavily and scores it on the basis of its intensity as
well.  Each of these ions is then searched for in the MS/MS data in multiple charge states.  The
scoring algorithm for these ions does not change, regardless of the N-linked glycopeptide type.
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A separate GPG scoring scheme is implemented for the glycan portion of a glycopeptide,
depending on which type of glycan is present in each candidate composition.  These eight glycan
categories and the diagnostic product ions expected to be detected for each are described in
Chapter 2 of this dissertation as well.
In addition to determining which diagnostic ions should be scored for each of the
candidate glycopeptide compositions, we have implemented noise-reduction and intensity-based
scoring components into the algorithm.  A baseline noise correction is applied before the
automatic “spectral match searching” is performed in order to limit false positive peak matches
arising from noise.  In preliminary testing, a cut-off of 2 % has been found to be ideal for most
spectra, but the algorithm allows the user to vary this cut-off, so that spectra of differing quality
(noise levels) can be scored using different thresholds for noise reduction.
The relative abundance of the [precursor – monosaccharide] product ions is also taken
into account when determining whether or not a peak corresponding to a particular m/z is
actually from the neutral loss being evaluated, with varying threshold limits being applied
according to the composition of the monosaccharide resides in the neutral loss being scored.  For
example, as fucose and sialic acid are more labile than Hex or HexNAc residues, the threshold
applied to the detection of product ions resulting from cleavage of these residues is much higher
than the threshold applied to the scoring of product ions that arise from the cleavage of Hex and
HexNAc residues.  This feature was implemented to reduce the possibility of false positive
matches.  Detailed information on the normalization thresholds used in the scoring scheme can
be found in the complete algorithm, located in Chapter 2 of this dissertation.
3.3.2 Candidate Composition Scoring by GPG. After algorithm development, MS/MS
data of glycopeptide spectra from RNase B, asialofetuin, and transferrin were scored using the
84
GPG software.  The resultant collection of CID spectra obtained during the fragmentation studies
described in Chapter 2 of this dissertation is referred to herein as the training data set.  For each
case, the known composition of the glycopeptide was scored against at least three decoy
compositions, which were generated as described in the experimental section.  Glycopeptide data
from a variety of precursor charge states were scored.
In Figure 1, an example of the candidate composition scoring by GPG is shown for a CID
spectrum collected from a high mannose type glycopeptide from RNase B.  The same spectrum
is shown in Figure 1A, B, and C.  However, each panel shows a different candidate composition
for this spectrum and includes the results of how GPG scored each composition.  The correct
composition is in 1A, while two decoy compositions are shown in Figure 1B and 1C.  The
[precursor – monosaccharide] product ions searched by GPG are calculated based on the
candidate composition.  For candidate A, which contains a high mannose glycan, GPG predicts
the sequential loss of mannose residues from the precursor ion and evaluates the [precursor –
monosaccharide] product ions by searching the MS2 peak list for the m/z values corresponding to
sequential losses of individual hexose residues.  Candidate compositions B and C are both
classified as complex or hybrid glycans without sialic acid or fucose, so the same set of
fragmentation rules applies for the glycan component in these two spectra.  In addition to
variations in the glycan scoring, each spectrum is scored differently for the [peptide + core
component] ions, because each spectrum has a different candidate peptide composition.  As a
result, GPG returns separate scores for the candidate compositions in B and C, even though the
glycan portions are similar.  The calculations for the different types of fragmentation ions are
weighted by the software, with [peptide + core component] product ions accounting for 67 % and
[precursor – monosaccharide] product ions accounting for 33 % of the score.  GPG reports a
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final score of 97 % for the correct glycopeptide assignment (candidate composition A), 20 % for
the first decoy glycopeptide assignment (candidate composition B) and 27 % for the second
decoy glycopeptide assignment (candidate composition C).
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Figure 1. CID data of an RNase B glycopeptide from the training data set.  (A) GPG scoring of
the correct glycopeptide composition: 97 %.  (B), (C) Scoring of two decoy compositions of the
same nominal mass:  20 % and 27 %, respectively.  Exact neutral masses of candidate
compositions shown in (A), (B), and (C) are, in order: 2419.9945, 2419.9733, and 2419.9978.
The X on arrows in spectra indicate the absence of a product ion that was predicted to be present
by GPG for a given candidate composition.  A relative abundance threshold of 2 % was used for
[peptide + core component] product ion matching to decrease false positives from noise.
A second example of spectra scored by GPG is presented in Figure 2.  The MS/MS data
shown here is a sialylated glycopeptide from transferrin. In this case, different types of
[precursor – monosaccharide] product ions are searched, as different glycans are present in the
candidate and decoy compositions.  GPG scoring of the actual transferrin glycopeptide, on which
the CID spectrum was obtained, is shown in Figure 2A.  In Figure 2B and 2C, the same spectrum
is shown, along with two decoy glycopeptide compositions that have the same nominal mass as
the correct composition.  To score each spectrum, the [precursor – monosaccharide] product ions
searched by GPG are determined based on each candidate’s composition, as depicted in Figure 2.
For candidate A, a sialylated complex type glycopeptide that does not contain fucose, the
GPG algorithm searches for the loss of a sialic acid residue in both the charge state of the
precursor and in the charge state below the precursor.  As the correct composition contains two
sialic residues (candidate A), GPG also searches for a loss of two sialic acid residues in the
precursor charge state.
The decoy composition in Figure 2B is classified as a complex/hybrid composition that
lacks sialic acid or fucose and contains more Hex than HexNAc residues.  Therefore, the GPG
software evaluates the presence or absence of the same [precursor – monosaccharide] product
ions that were described for candidates B and C in Fig. 1.  Likewise, as the decoy composition in
Figure 2C is classified as a high mannose type, the [precursor – monosaccharide] product ions
that GPG evaluates are neutral losses of hexose residues, as detailed in Fig. 1 for candidate
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composition A.  In comparison to the correct glycopeptide composition (candidate A), a lower
number expected ions evaluated by GPG are found in the MS/MS data for candidates B and C,
resulting in a lower GPG score.
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Figure 2. CID spectrum of a sialylated transferrin glycopeptide from the training set and
GlycoPep Grader’s scoring of candidate glycopeptides for m/z 1841.  (A) Shows the scoring of
the “correct” glycopeptide composition, while (B) and (C) show the GPG scoring mechanism
applied to two decoy candidates of the same nominal mass.  Arrows marked with X indicate ions
that were not present in the peak list for the spectrum shown.  GPG assigned a score of 75 % to
the actual glycopeptide composition of CGLVPVLAENYNK + [HexNAc]4[Hex]5[Neu5Ac]2,
candidate A.  GPG returned a score of score 7 % and 39 % to the two decoy compositions of
ETTRVNVSSSK + [HexNAc]5[Hex]9 and NLTEGEEYTFQVMAVNSAGRSAPR +
[HexNAc]2[Hex]4, candidates B and C, respectively.  Thus, GPG analysis determined the
correct glycopeptide candidate to be the most probable glycopeptide composition based on
presence or absence of calculated CID product ions expected to be present for each glycopeptide
scored.  A threshold of 2 % relative abundance was used as the cut-off for a matching ion
detected in the MS2 data peak list.
In Table 2, 45 test examples are provided that show GPG scores for glycopeptides
analyzed from experimental MS/MS data in the training data set.  For each example, the correct
composition is compared against at least two decoy compositions of the same nominal mass.  A
wide variety of glycopeptide compositional arrangements were tested.  Over 150 glycopeptide
spectra from the 45 unique glycopeptides in the training data set were scored using GPG, with
the correct candidate receiving the highest score in each test performed.
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Table 2. Score Results Calculated by GPG Software for Tests Performed on CID Spectra in the
Training Data Set.
1 2 + A 967.9252 SRNLTK + [HexNAc]2[Hex]5 91
2 + B 967.8831 NASHK + [HexNAc]2[Hex]6 95
2 + C 967.9336 WVRHNK + [HexNAc]3[Hex]3 20
2 2 + A 981.9227 NLTKDR + [HexNAc]2[Hex]5 91
2 + B 981.9125 NRSLTN + [HexNAc]3[Hex]4 26
2 + C 981.9550 RETQAVNWTK + [HexNAc]2[Hex]2 0
3 2 + A 1048.9516 SRNLTK + [HexNAc]2[Hex]6 97
2 + B 1048.9095 NASHK + [HexNAc]2[Hex]7 63
2 + C 1048.9600 WVRHNK + [HexNAc]3[Hex]4 20
2 + D 1048.9492 NVDSVVNGTCR4 + [HexNAc]3[Hex]2 23
4 2 + A 1103.4892 SRNLTKDR + [HexNAc]2[Hex]5 63
2 + B 1103.6655 NRSLTN + [HexNAc]5[Hex]3 0
2 + C 1103.4863 PFNQTKNRF + [HexNAc]2[Hex]4 38
5 2 + A 1129.9780 SRNLTK + [HexNAc]2[Hex]7 91
2 + B 1129.9756 NVDSVVNGTCR4 + [HexNAc]3[Hex]3 40
2 + C 1129.9674 AYANVSSK + [HexNAc]3[Hex]5 44
2 + D 1129.9864 WVRHNK + [HexNAc]3[Hex]5 44
6 2 + A 1143.9755 NLTKDR + [HexNAc]2[Hex]7 97
2 + B 1144.0078 RETQAVNWTK + [HexNAc]2[Hex]4 48
2 + C 1144.0129 NVTGTTSETIK + [HexNAc]4[Hex]2 30
2 + D 1143.9516 ANK + [HexNAc]5[Hex]4[Neu5Ac]1 27
7 2 + A 1184.5156 SRNLTKDR + [HexNAc]2[Hex]6 63
2 + B 1184.5127 PFNQTKNRF + [HexNAc]2[Hex]5 47
2 + C 1184.5015 VNVSSSK + [HexNAc]5[Hex]3[Fuc]1 0
8 2 + A 1211.0044 SRNLTK + [HexNAc]2[Hex]8 97
2 + B 1211.0128 WVRHNK + [HexNAc]3[Hex]6 38
2 + C 1211.0020 NVDSVVNGTCR4 + [HexNAc]3[Hex]4 33
9 2 + A 1225.0019 NLTKDR + [HexNAc]2[Hex]8 94
2 + B 1225.0207 NLTKDRGP + [HexNAc]3[Hex]4[Neu5Ac]1 21
2 + C 1225.0393 NVTGTTSETIK + [HexNAc]4[Hex]3 10
2 + D 1225.0342 RETQAVNWTK + [HexNAc]2[Hex]5 47
10 2 + A 1265.5420 SRNLTKDR + [HexNAc]2[Hex]7 82
2 + B 1265.5183 NRSLTN + [HexNAc]5[Hex]5 20
2 + C 1265.5309 VNVSSSK + [HexNAc]5[Hex]4[Fuc]1 25
11 2 + A 1292.0308 SRNLTK + [HexNAc]2[Hex]9 91
2 + B 1292.0284 NVDSVVNGTCR4 + [HexNAc]3[Hex]5 47
2 + C 1292.0392 AYANVSSK + [HexNAc]3[Hex]7 38
2 + D 1292.0392 WVRHNK + [HexNAc]3[Hex]7 38
12 2 + A 1306.0283 NLTKDR + [HexNAc]2[Hex]9 88
2 + B 1306.0654 NLTKDRL + [HexNAc]4[Hex]4[Neu5Ac]1 24
2 + C 1306.0781 LVINR + [HexNAc]6[Hex]3[Fuc]2 19
2 + D 1306.0606 RETQAVNWTK + [HexNAc]2[Hex]6 57
13 2 + A 1346.5684 SRNLTKDR + [HexNAc]2[Hex]8 76
Test1 Charge Candidate2 m/z Glycopeptide Composition GPG3
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2 + B 1346.5447 NRSLTN + [HexNAc]5[Hex]6 23
2 + C 1346.6205 LNVTLKWTK + [HexNAc]4[Hex]3[Neu5Ac]1 12
2 + D 1346.5913 DNGSPILGYWLEK + [HexNAc]2[Hex]4[Fuc]1 4
14 5 + A 1059.6808 RPTGEVYDIEIDTLETTCHVLDPTPLANCSVR +
[HexNAc]4[Hex]5
51
5 + B 1059.6980 IENTTTVLKSSATFQSTVAGSPPISITWLK +
[HexNAc]5[Hex]5[Neu5Ac]1
12
5 + C 1059.6567 CHYMTIHNVTPDDEGVYSVIARLEPR4 +
[HexNAc]5[Hex]6[Neu5Ac]1
12
5 + D 1059.6535 NAAGNFSEPSDSSGAITARDEIDAPNASLDPK +
[HexNAc]4[Hex]6[Fuc]2
17
15 5 + A 1132.7073 RPTGEVYDIEIDTLETTCHVLDPTPLANCSVR +
[HexNAc]5[Hex]6
61
5 + B 1132.6652 SCEPVPARDPCDPPGQPEVTNITR4 +
[HexNAc]6[Hex]7[Neu5Ac]2[Fuc]1
25
5 + C 1132.7244 IENTTTVLKSSATFQSTVAGSPPISITWLK +
[HexNAc]6[Hex]6[Neu5Ac]1
31
5 + D 1132.6708 HILVINDSQFDDEGVYTAEVEGK +
[HexNAc]6[Hex]7[Neu5Ac]2[Fuc]1
25
16 4 + A 1160.5442 VVHAVEVALATFNAESNGSYLQLVEISR +
[HexNAc]4[Hex]5
67
4 + B 1160.5187 TDTMRLLERPPEFTLPLYNK +
[HexNAc]4[Hex]5[Neu5Ac]2
29
4 + C 1160.5254 NVTVIEGESVTLECHISGYPSPTVTWYR4 +
[HexNAc]5[Hex]3
39
4 + D 1160.5186 LTPESTREFLCINGSIHFQPLK4 + [HexNAc]4[Hex]8 57
17 3 + A 1164.5188 KLCPDCPLLAPLNDSR + [HexNAc]4[Hex]5 48
3 + B 1164.5166 NLNVRYQSNATLVCK4 + [HexNAc]4[Hex]5[Fuc]1 9
3 + C 1164.4872 NSVGKSNCTVSVHVSDR4 + [HexNAc]2[Hex]8 5
3 + D 1164.5183 VNKSLLNALK4 + [HexNAc]5[Hex]4[Neu5Ac]2[Fuc]1 6
18 3 + A 1243.5312 LCPDCPLLAPLNDSR + [HexNAc]5[Hex]6 59
3 + B 1243.5766 DVTALENATVAFEVSVSHDTVPVK +
[HexNAc]2[Hex]4[Fuc]1
45
3 + C 1243.5153 YDSGKYTLTLENSSGTK + [HexNAc]2[Hex]9 38
3 + D 1243.5069 RETQAVNWTK + [HexNAc]4[Hex]5[Neu5Ac]3 13
19 3 + A 1286.2296 KLCPDCPLLAPLNDSR + [HexNAc]5[Hex]6 31
3 + B 1286.2375 EFLCINGSIHFQPLK4 + [HexNAc]8[Hex]3 5
3 + C 1286.1893 DSVNLTWTEPASDGGSK + [HexNAc]4[Hex]7[Fuc]1 4
3 + D 1286.1844 KAYATITNNCTK4 + [HexNAc]4[Hex]7[Neu5Ac]2 0
20 4 + A 1324.3492 RPTGEVYDIEIDTLETTCHVLDPTPLANCSVR +
[HexNAc]4[Hex]5
70
4 + B 1324.3458 TLKNLTVTETQDAVFTVELTHPNVK +
[HexNAc]4[Hex]5[Neu5Ac]3
16
4 + C 1324.3157 DSVNLTWTEPASDGGSKITNYIVEK +
[HexNAc]5[Hex]6[Neu5Ac]2
16
4 + D 1324.3101 LPYTTPGPPSTPWVTNVTR +
[HexNAc]6[Hex]6[Neu5Ac]3[Fuc]1
25
21 4 + A 1415.6259 RPTGEVYDIEIDTLETTCHVLDPTPLANCSVR +
[HexNAc]5[Hex]6
37
4 + B 1415.5982 NAAGNFSEPSDSSGAITARDEIDAPNASLDPK +
[HexNAc]5[Hex]7[Fuc]2
0
4 + C 1415.6288 TLKNLTVTETQDAVFTVELTHPNVK +
[HexNAc]5[Hex]6[Neu5Ac]3
0
22 3 + A 1547.0565 VVHAVEVALATFNAESNGSYLQLVEISR + 94
93
[HexNAc]4[Hex]5
3 + B 1547.0224 TDTMRLLERPPEFTLPLYNK +
[HexNAc]4[Hex]5[Neu5Ac]2
40
3 + C 1547.0223 LTPESTREFLCINGSIHFQPLK4 + [HexNAc]4[Hex]8 67
3 + D 1547.0314 NVTVIEGESVTLECHISGYPSPTVTWYR4 +
[HexNAc]5[Hex]3
52
23 3 + A 1668.7672 VVHAVEVALATFNAESNGSYLQLVEISR +
[HexNAc]5[Hex]6
85
3 + B 1668.7332 TDTMRLLERPPEFTLPLYNK +
[HexNAc]5[Hex]6[Neu5Ac]2
21
3 + C 1668.7370 LTPESTREFLCINSIHFQPLK + [HexNAc]5[Hex]9 57
3 + D 1668.7384 AMKDGVHDIPEDAQLETAENSSVIIIPECK4 +
[HexNAc]4[Hex]4[Neu5Ac]1
7
3 + E 1668.7950 ATAVVEVNVLDKPGPPAAFDITDVTNESCLLTWNPP4 +
[HexNAc]2[Hex]4
50
24 2 + A 1682.2271 LCPDCPLLAPLNDSR + [HexNAc]4[Hex]5 95
2 + B 1682.1743 SNCTVSVHVSDR4 + [HexNAc]4[Hex]5[Neu5Ac]1[Fuc]1 12
2 + C 1682.2459 LVINRTHASDEGPYK + [HexNAc]5[Hex]4 0
2 + D 1682.1895 VTNVTK + [HexNAc]7[Hex]7[Fuc]1 0
25 2 + A 1864.7932 LCPDCPLLAPLNDSR + [HexNAc]5[Hex]6 95
2 + B 1864.7574 DSGYYSLTAENSSGTDTQK + [HexNAc]6[Hex]3 0
2 + C 1864.7289 AYATITNNCTK4 + [HexNAc]4[Hex]7[Neu5Ac]2 0
2 + D 1864.7693 YDSGKYTLTLENSSGTK + [HexNAc]2[Hex]9 7
26 4 + A 848.3658 CGLVPVLAENYNK + [HexNAc]4[Hex]5[Neu5Ac]1 75
4 + B 848.3761 VNKTIIHDTQFK + [HexNAc]4[Hex]7 61
4 + C 848.3853 IRDAHLDDQANYNVSLTNHR + [HexNAc]2[Hex]3[Fuc]1 31
27 4 + A 921.1397 CGLVPVLAENYNK + [HexNAc]4[Hex]5[Neu5Ac]2 52
4 + B 921.1512 MSDAGKYTVVAGGNVSTAK + [HexNAc]5[Hex]5 38
4 + C 921.1133 DGFNITTSEK + [HexNAc]5[Hex]6[Neu5Ac]2 37
4 + D 921.1763 LLTQNSENITIENEHYTHLVMK + [HexNAc]2[Hex]4 30
28 5 + A 944.7902 QQQHLFGSNVTDCSGNFCLFR +
[HexNAc]4[Hex]5[Neu5Ac]2
36
5 + B 944.8100 GQVDLVDTMAFLVIPNSTR +
[HexNAc]6[Hex]7[Neu5Ac]1
26
5 + C 944.7862 NNTLVLQVR + [HexNAc]6[Hex]7[Neu5Ac]4[Fuc]1 10
5 + D 944.8017 NVTFTSVIRGTPPFK + [HexNAc]5[Hex]9[Neu5Ac]2 15
29 4 + A 1107.9621 QQQHLFGSNVTDCSGNFCLFR +
[HexNAc]4[Hex]5[Neu5Ac]1
46
4 + B 1107.9661 VNRLNVTLK + [HexNAc]6[Hex]7[Neu5Ac]3[Fuc]1 13
4 + C 1107.9878 ANDTLVRSTEYPCAGLVEGLEYSFR + [HexNAc]3[Hex]6 36
4 + D 1107.9765 NVTFTSVIRGTPPFK + [HexNAc]5[Hex]9[Neu5Ac]1 22
4 + E 1107.9609 NSILWTKVNK + [HexNAc]6[Hex]7[Neu5Ac]3 20
30 4 + A 1180.7359 QQQHLFGSNVTDCSGNFCLFR +
[HexNAc]4[Hex]5[Neu5Ac]2
42
4 + B 1180.7302 RANHTPESCPETKYK + [HexNAc]6[Hex]5[Neu5Ac]3 12
4 + C 1180.7608 HILVINDSQFDDEGVYTAEVEGK +
[HexNAc]6[Hex]3[Neu5Ac]1[Fuc]1
8
4 + D 1180.7617 ANDTLVRSTEYPCAGLVEGLEYSFR +
[HexNAc]3[Hex]6[Neu5Ac]1
15
31 3 + A 1227.8504 CGLVPVLAENYNK + [HexNAc]4[Hex]5[Neu5Ac]2 35
3 + B 1227.8153 DGFNITTSEK + [HexNAc]5[Hex]6[Neu5Ac]2 19
3 + C 1227.8591 QNATVQGLIQGK + [HexNAc]5[Hex]6[Neu5Ac]1[Fuc]1 4
94
3 + D 1227.8656 MSDAGKYTVVAGGNVSTAK + [HexNAc]5[Hex]5 12
3 + E 1227.9028 ATMRFNTEITAENLTINLK + [HexNAc]5[Hex]3 18
32 3 + A 1379.9152 QQQHLFGSNVTDCSGNFCLFR + [HexNAc]4[Hex]5 76
3 + B 1379.9344 NVTFTSVIRGTPPFK + [HexNAc]5[Hex]9 38
3 + C 1379.9085 NNTLVLQVR + [HexNAc]6[Hex]7[Neu5Ac]2[Fuc]1 8
3 + D 1379.8840 VHTNATIR + [HexNAc]6[Hex]7[Neu5Ac]3 8
33 4 + A 1434.3702 CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK +
[HexNAc]4[Hex]5[Neu5Ac]2
53
4 + B 1434.3555 LNGSAPIQVCWYRDGVLLR +
[HexNAc]6[Hex]7[Neu5Ac]4
25
4 + C 1434.4053 YTVTATNSAGTATENLSVIVLEKPGPPVGPVR +
[HexNAc]4[Hex]5[Neu5Ac]3
19
4 + D 1434.3639 DNKEIRPGGNYTITCVGNTPHLR +
[HexNAc]7[Hex]6[Neu5Ac]2[Fuc]1
14
34 3 + A 1476.9470 QQQHLFGSNVTDCSGNFCLFR +
[HexNAc]4[Hex]5[Neu5Ac]1
82
3 + B 1476.9160 VHTNATIR + [HexNAc]6[Hex]7[Neu5Ac]4 8
3 + C 1476.9793 HILVINDSQFDDEGVYTAEVEGK +
[HexNAc]6[Hex]3[Fuc]1
13
3 + D 1476.9800 GQVDLVDTMAFLVIPNSTR + [HexNAc]6[Hex]7 6
35 2 + A 1513.1582 CGLVPVLAENYNK + [HexNAc]3[Hex]4[Neu5Ac]1 96
2 + B 1513.1788 VNKTIIHDTQFK + [HexNAc]3[Hex]6 0
2 + C 1513.1711 QNATVQGLIQGK + [HexNAc]4[Hex]5[Fuc]1 13
2 + D 1513.1284 NNVTLK + [HexNAc]6[Hex]6[Fuc]1 0
36 3 + A 1525.6329 QQQHLFGSNVTDCSGNFCLFR +
[HexNAc]4[Hex]5[Neu5Ac]1[Fuc]1
52
3 + B 1525.6292 INNLTESDQGEYVCEISGEGGTSK + [HexNAc]5[Hex]6 0
3 + C 1525.6659 GQVDLVDTMAFLVIPNSTR +  [HexNAc]6[Hex]7[Fuc]1 0
3 + D 1525.6018 VHTNATIR + [HexNAc]6[Hex]7[Neu5Ac]4[Fuc]1 11
37 3 + A 1574.0003 QQQHLFGSNVTDCSGNFCLFR +
[HexNAc]4[Hex]5[Neu5Ac]2
76
3 + B 1574.0118 GQVDLVDTMAFLVIPNSTR + [HexNAc]6[Hex]7[Neu5Ac]1 33
3 + C 1573.9771 NSILWTKVNK + [HexNAc]6[Hex]7[Neu5Ac]4 17
3 + D 1574.0243 LLQNSENITIENTEHYTHLVMK + [HexNAc]4[Hex]7[Fuc]1 0
38 3 + A 1647.3437 QQQHLFGSNVTDCSGNFCLFR +
[HexNAc]5[Hex]6[Neu5Ac]1[Fuc]1
76
3 + B 1647.3598 CGPGEPAYVDEPVNMSTPATVPDPPENVK +
[HexNAc]3[Hex]6[Neu5Ac]1
48
3 + C 1647.3421 NSILWTKVNK + [HexNAc]7[Hex]8[Neu5Ac]3[Fuc]1 20
3 + D 1647.4079 AWTPVTYTVTRQNATVQGLIQGK +
[HexNAc]5[Hex]5[Neu5Ac]2
23
39 2 + A 1695.7243 CGLVPVLAENYNK + [HexNAc]4[Hex]5[Neu5Ac]1 71
2 + B 1695.7079 YILTVENSSGSK + [HexNAc]4[Hex]7[Fuc]1 0
2 + C 1695.6714 DGFNITTSEK + [HexNAc]5[Hex]6[Neu5Ac]1 43
2 + D 1695.7343 ANKTPIRMR + [HexNAc]6[Hex]4[Neu5Ac]1[Fuc]1 11
2 + E 1695.7485 DGQTLKETTRVNVSSSK + [HexNAc]2[Hex]7 0
40 3 + A 1695.6895 QQQHLFGSNVTDCSGNFCLFR +
[HexNAc]5[Hex]6[Neu5Ac]2
45
3 + B 1695.6829 NNTLVLQVR + [HexNAc]4[Hex]8[Fuc]1 15
3 + C 1695.7014 MSDAGKYTVVAGGNVSTAK + [HexNAc]8[Hex]9[Fuc]1 0
3 + D 1695.7225 WVRCNFTDVSECQYTVTGLSPGDR +
[HexNAc]4[Hex]6[Neu5Ac]1[Fuc]1
39
41 3 + A 1792.7213 QQQHLFGSNVTDCSGNFCLFR + 57
95
[HexNAc]5[Hex]6[Neu5Ac]3
3 + B 1792.7333 WVRCNFTDVSECQYTVTGLSPGDR +
[HexNAc]4[Hex]7[Neu5Ac]2
39
3 + C 1792.7783 CHYMTIHNVTPDDEGVYSVIARLEPR +
[HexNAc]6[Hex]4[Neu5Ac]1[Fuc]1
11
3 + D 1792.7840 LNWTKPEHDGGAKIESYVIEMLK + [HexNAc]7[Hex]8 12
42 3 + A 1815.1260 CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK +
[HexNAc]4[Hex]5[Neu5Ac]1
92
3 + B 1815.1366 VSDVSRDSVNLTWTEPASDGGSKITNYIVEK +
[HexNAc]4[Hex]6[Neu5Ac]1
52
3 + C 1815.1624 LLQNSENITIENTEHYTHLVMKNVQRK +
[HexNAc]6[Hex]6
4
3 + D 1815.1173 YTLTVKNASGTKAVSVMVK +
[HexNAc]7[Hex]8[Neu5Ac]2[Fuc]1
8
43 2 + A 1841.2720 CGLVPVLAENYNK + [HexNAc]4[Hex]5[Neu5Ac]2 75
2 + B 1841.2534 ETTRVNVSSSK + [HexNAc]5[Hex]9 7
2 + C 1841.3143 NLTEGEEYTFQVMAVNSAGRSAPR + [HexNAc]2[Hex]4 39
2 + D 1841.3346 TEIISTDNHTLLTVK + [HexNAc]6[Hex]3[Fuc]2 7
44 2 + A 1886.8030 QQQHLFGSNVTDCSGNFCLFR + [HexNAc]3[Hex]4 78
2 + B 1886.8111 VNRLNVTLK + [HexNAc]5[Hex]6[Neu5Ac]2[Fuc]1 6
2 + C 1886.8318 NVTFTSVIRGTPPFK + [HexNAc]4[Hex]8 66
2 + D 1886.8006 NSILWTKVNK + [HexNAc]5[Hex]6[Neu5Ac]2 0
45 3 + A 1912.1578 CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK +
[HexNAc]4[Hex]5[Neu5Ac]2
71
3 + B 1912.1382 LNGSAPIQVCWYRDGVLLR +
[HexNAc]6[Hex]7[Neu5Ac]4
17
3 + C 1912.1494 DNKEIRPGGNYTITCVGNTPHLR +
[HexNAc]7[Hex]6[Neu5Ac]2[Fuc]1
17
3 + D 1912.1546 TDTMRLLERPPEFTLPLYNK +
[HexNAc]7[Hex]8[Neu5Ac]2
39
1 For each test, candidate A is the actual glycopeptide composition that corresponds to the MS/MS data being
scored.
2 All candidate compositions have an m/z value, calculated in silico, within 50 ppm error of the monoisotopic mass
present in the experimental MS1 data.
3 The normalization threshold used for determining the presence or absence of the [peptide + core component]
product ions in all scoring by GPG was 2 % relative abundance. For Y1 ion evaluation included in the GPG scores
reported herein, a relative abundance threshold of 20 % was used for a spectral match to be considered valid.
Normalization thresholds applied to the detection of [precursor – monosaccharide] product ions vary according to
identity of the neutral loss being evaluated.
4 Denotes peptides where Cys residues were not derivatized by IAM.
3.3.3 GPG Validation: Application to Recombinant Gp120 HIV Envelope
Glycoprotein. As the GPG algorithm was designed after studying the fragmentation patterns
obtained for RNase B, asialofetuin, and transferrin, whose spectra comprise the training data set,
it was expected that the automated GPG tool would perform well when testing the training data
set. Therefore, after analysis of the training data set, the GlycoPep Grader software was used to
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analyze CID data collected on tryptic digests of the HIV envelope protein, CON-S gp140ΔCFI.
The resulting CID spectra from the CON-S gp 140ΔCFI glycopeptides (herein referred to as the
validation data set) contain MS/MS data on glycopeptides of varying N-linked glycan types and
compositional arrangements.  A total of over 100 CID spectra from 34 unique CON-S
gp140ΔCFI glycopeptides were tested using the GPG tool.  These results are summarized in
Table 3.
97
Table 3.  GPG Score Results of Tests Performed on CON-S gp140ΔCFI Glycopeptide CID
Spectra Comprising the Validation Data Set.
Test1 Charge Candidate2 m/z Glycopeptide Composition GPG3
1 2 + A 1071.5123 SNITGLLLTR + [HexNAc]2[Hex]4 83
2 + B 1071.4758 ANVTVEAR + [HexNAc]4[Hex]2 0
2 + C 1071.4695 MANISRYYEAPP + [HexNAc]2[Hex]2 8
2 3 + A 1156.4722 DGGNNNTNETEIFRPGGGDMR + [HexNAc]2[Hex]5 91
3 + B 1156.5238 YTLTVENNSGSKSITFTVK + [HexNAc]2[Hex]6 55
3 + C 1156.4895 VDQHEWTKCNTTPTK + [HexNAc]4[Hex]5 25
3 + D 1156.5225 NNLPISISSNVSISR + [HexNAc]6[Hex]4 0
3 2 + A 1160.4919 EANTTLFCASDAK + [HexNAc]2[Hex]3 83
2 + B 1160.4997 ANVTVEAR + [HexNAc]4[Hex]4 31
2 + C 1160.5104 YQSNATLVCK + [HexNAc]4[Hex]2 25
2 + D 1160.4567 ANK + [HexNAc]5[Hex]6 25
4 2 + A 1193.5653 SNITGLLLTR + [HexNAc]4[Hex]3 94
2 + B 1193.5372 LNWTKPEHDGGAK + [HexNAc]3[Hex]2 45
2 + C 1193.5239 YQSNATLPGKGN + [HexNAc]4[Hex]2 50
5 2 + A 1254.0784 SNITGLLLTR + [HexNAc]3[Hex]5 97
2 + B 1254.0502 LNWTKPEHDGGAK + [HexNAc]2[Hex]4 58
2 + C 1254.0503 ANVTVEAR + [HexNAc]5[Hex]3[Fuc]1 0
2 + D 1254.0399 YCVVVENSTGSR + [HexNAc]4[Hex]2 33
6 3 + A 1264.5074 DGGNNNTNETEIFRPGGGDMR + [HexNAc]2[Hex]7 97
3 + B 1264.5590 YTLTVENNSGSKSITFTVK + [HexNAc]2[Hex]8 56
3 + C 1264.5247 VDQHEWTKCNTTPTK + [HexNAc]4[Hex]7 30
3 + D 1264.5171 NASGSAKAEIK + [HexNAc]5[Hex]6[Neu5Ac]2[Fuc]1 0
7 3 + A 1268.8550 NNNNTNDTITLPCR + [HexNAc]6[Hex]4[Neu5Ac]1 53
3 + B 1268.8474 YTCQAKNESGVER + [HexNAc]5[Hex]5[Neu5Ac]1[Fuc]1 17
3 + C 1268.8582 QSDAGEYTFVAGRNR + [HexNAc]5[Hex]6[Fuc]1 5
3 + D 1268.8608 TKANVTVEAR + [HexNAc]5[Hex]6[Neu5Ac]2[Fuc]1 22
3 + E 1268.8474 YTCQAKNESGVER + [HexNAc]5[Hex]5[Neu5Ac]1[Fuc]1 17
3 + F 1268.8710 ANKTPIRMR + [HexNAc]7[Hex]8 25
8 3 + A 1272.8513 DGGNNNTNETEIFRPGGGDMR + [HexNAc]3[Hex]5[Fuc]1 91
3 + B 1272.8834 VDRNDAGNFTCRATNSVGSK + [HexNAc]5[Hex]3[Fuc]1 17
3 + C 1272.8393 VDRNDAGNFTCR + [HexNAc]5[Hex]4[Neu5Ac]2[Fuc]1 11
3 + D 1272.9008 KCSKTSFMVENLTGAIWYFR + [HexNAc]2[Hex]6 35
9 3 + A 1286.5269 DGGNNNTNETEIFRPGGGDMR + [HexNAc]4[Hex]4[Fuc]1 54
3 + B 1286.5201 QNLTVKDVTK + [HexNAc]7[Hex]8[Neu5Ac]1[Fuc]1 13
3 + C 1286.5467 INGSEPLQVSWYK + [HexNAc]6[Hex]6[Fuc]1 24
3 + D 1286.5430 MSDAGKYTVVAGGNVSTAK +
[HexNAc]3[Hex]5[Neu5Ac]2
0
10 2 + A 1298.5581 NCSFNITTEIR + [HexNAc]3[Hex]3[Fuc]1 84
2 + B 1298.5734 YTLTLENSSGTK + [HexNAc]4[Hex]2[Fuc]1 28
2 + C 1298.5453 YTCQAKNESGVER + [HexNAc]2[Hex]4 25
2 + D 1298.5733 YILTVENSSGSK + [HexNAc]4[Hex]3 29
11 3 + A 1318.5250 DGGNNNTNETEIFRPGGGDMR + [HexNAc]2[Hex]8 100
3 + B 1318.5804 CSKTSFKVENLTEGAIYYFR + [HexNAc]2[Hex]7 80
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3 + C 1318.5888 EKNSILWVKLNK + [HexNAc]6[Hex]6[Neu5Ac]1 41
3 + D 1318.5902 VQIEKGVNYTQLSIDNCDRNDAGK + [HexNAc]2[Hex]5 65
3 + E 1318.5457 KAYANVSSKCSK + [HexNAc]6[Hex]5[Neu5Ac]2 47
12 2 + A 1327.0688 NCSFNITTEIR + [HexNAc]4[Hex]3 40
2 + B 1327.0412 FTNITGEK + [HexNAc]3[Hex]7 17
2 + C 1327.0793 LNWTKPEHDGGAK + [HexNAc]2[Hex]4[Fuc]1 0
2 + D 1327.1003 RGRQNLTVK + [HexNAc]3[Hex]6 17
13 2 + A 1335.0606 EANTTLFCASDAK + [HexNAc]3[Hex]3[Fuc]1 96
2 + B 1335.0767 LNWTKPEHDGGAK + [HexNAc]2[Hex]5 31
2 + C 1335.0257 ANK + [HexNAc]6[Hex]6[Fuc]1 17
2 + D 1335.0284 CNITTTEK + [HexNAc]2[Hex]8 33
2 + E 1335.0684 ANVTVEAR + [HexNAc]5[Hex]4[Fuc]1 26
14 2 + A 1343.0580 EANTTLFCASDAK + [HexNAc]3[Hex]4 89
2 + B 1343.0658 ANVTVEAR + [HexNAc]5[Hex]5 39
2 + C 1343.0781 NNVTLK + [HexNAc]6[Hex]3[Fuc]2 0
2 + D 1343.0765 YQSNATLVCK + [HexNAc]5[Hex]3 22
15 2 + A 1367.0686 NCSFNITTEIR + [HexNAc]2[Hex]6 81
2 + B 1367.0867 YTFYAGENITSGK + [HexNAc]4[Hex]2[Fuc]1 0
2 + C 1367.0839 YTLTLENSSGTK + [HexNAc]3[Hex]5 31
2 + D 1367.0764 DGRQNLTVK + [HexNAc]2[Hex]8 31
16 3 + A 1372.5426 DGGNNNTNETEIFRPGGGDMR + [HexNAc]2[Hex]9 97
3 + B 1372.5980 CSKTSFKVENLTEGAIYYFR + [HexNAc]2[Hex]8 81
3 + C 1372.6064 EKNSILWVKLNK + [HexNAc]6[Hex]7[Neu5Ac]1 24
3 + D 1372.6078 VQIEKGVNYTQLSIDNCDRNDAGK + [HexNAc]2[Hex]6 62
3 + E 1372.5896 ESGTTAWQLVNSSVKR + [HexNAc]6[Hex]7 61
17 2 + A 1387.5819 NCSFNITTEIR + [HexNAc]3[Hex]5 96
2 + B 1387.6181 DNGSPILGYWLEK + [HexNAc]4[Hex]2[Fuc]1 0
2 + C 1387.5545 FTNITGEK + [HexNAc]2[Hex]9 11
2 + D 1387.6022 NGTEILKSK + [HexNAc]4[Hex]6 48
18 2 + A 1395.6179 SNITGLLLTR + [HexNAc]2[Hex]8 79
2 + B 1395.6060 NGINVTPSQR + [HexNAc]6[Hex]3 3
2 + C 1395.6156 DNGSPILGYWLEK + [HexNAc]4[Hex]3 4
2 + D 1395.5633 ANDTLVR + [HexNAc]3[Hex]5[Neu5Ac]2 6
19 2 + A 1400.0978 NCSFNITTEIR + [HexNAc]4[Hex]3[Fuc]1 96
2 + B 1400.0996 NNVTLK + [HexNAc]8[Hex]3 33
2 + C 1400.1051 TKANVTVEAR + [HexNAc]3[Hex]5[Neu5Ac]1 0
2 + D 1400.1312 YILKLENSSGSK + [HexNAc]4 + [Hex]4 59
2 + E 1400.1293 RGRQNLTVK + [HexNAc]3[Hex]6[Fuc]1 8
20 2 + A 1416.0820 EANTTLFCASDAK + [HexNAc]3[Hex]4[Fuc]1 80
2 + B 1416.1031 LNWTKPEHDGGAK + [HexNAc]2[Hex]6 57
2 + C 1416.0948 ANVTVEAR + [HexNAc]5[Hex]5[Fuc]1 23
2 + D 1416.0946 VNVSSSK + [HexNAc]8[Hex]3 28
21 3 + A 1451.2518 DGGNNNTNETEIFRPGGGDMR +
[HexNAc]5[Hex]4[Neu5Ac]1[Fuc]1
35
3 + B 1451.2582 EVNSTHWSRVNK + [HexNAc]5[Hex]8[Neu5Ac]1[Fuc]2 17
3 + C 1451.2824 NSLLWKRANK + [HexNAc]7[Hex]6[Neu5Ac]2[Fuc]1 13
3 + D 1451.2679 MSDAGKYTVVAGGNVSTAK +
[HexNAc]4[Hex]5[Neu5Ac]3
17
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3 + E 1451.2451 LVINR + [HexNAc]7[Hex]8[Neu5Ac]3[Fuc]1 7
3 + F 1451.2328 NNVTLK + [HexNAc]6[Hex]7[Neu5Ac]4[Fuc]1 6
22 2 + A 1436.6003 EANTTLFCASDAK + [HexNAc]4[Hex]3[Fuc]1 81
2 + B 1436.5998 YCVVVENSTGSR + [HexNAc]5[Hex]3 40
2 + C 1436.6186 RANHTPESCPETKYK + [HexNAc]2[Hex]4 8
2 + D 1436.6163 LNWTKPEHDGGAK + [HexNAc]3[Hex]5 17
23 2 + A 1476.6443 SNITGLLLTR + [HexNAc]2[Hex]9 82
2 + B 1476.6240 YTFYAGENITSGK + [HexNAc]5[Hex]3 0
2 + C 1476.6079 ANVTVEAR + [HexNAc]4[Hex]7[Fuc]1 0
2 + D 1476.6321 NGINVTPSQR + [HexNAc]6[Hex]4 3
2 + E 1476.6123 YQSNATLVCK4 + [HexNAc]5[Hex]5 17
24 2 + A 1481.1242 NCSFNITTEIR + [HexNAc]4[Hex]4[Fuc]1 80
2 + B 1481.1576 YILKLENSSGSK + [HexNAc]4[Hex]5 52
2 + C 1481.1687 QNATVQGLIQGK + [HexNAc]6[Hex]3 39
2 + D 1481.1392 YTVVAGGNVSTAK +
[HexNAc]3[Hex]4[Neu5Ac]1[Fuc]1
11
2 + E 1481.1443 NGTEILKSK + [HexNAc]5[Hex]5[Fuc]1 32
2 + F 1481.1423 VENLTEGAIYYFR + [HexNAc]3[Hex]3[Neu5Ac]1 0
2 + G 1481.1395 YTLTLENSSGTK + [HexNAc]5[Hex]3[Fuc]1 34
2 + H 1481.1394 YILTVENSSGSK + [HexNAc]5[Hex]4 44
2 + I 1481.1315 TKANVTVEAR + [HexNAc]3[Hex]6[Neu5Ac]1 0
2 + J 1481.1889 INETLELLSESPVYSTK + [HexNAc]2[Hex]3[Fuc]1 68
25 2 + A 1517.6265 EANTTLFCASDAK + [HexNAc]4[Hex]4[Fuc]1 72
2 + B 1517.6144 ANHTPESCPETK + [HexNAc]5[Hex]4 29
2 + C 1517.6162 ANDTLVR + [HexNAc]5[Hex]4[Neu5Ac]2 6
2 + D 1517.6388 YQSNATLVCK + [HexNAc]6[Hex]3[Fuc]1 40
26 2 + A 1568.1958 LINCNTSAITQACPK + [HexNAc]4[Hex]3[Fuc]1 100
2 + B 1568.1583 NASGSAKAEIK + [HexNAc]4[Hex]5[Neu5Ac]1[Fuc]1 11
2 + C 1568.2197 RESGTTAWQLVNSSVKR + [HexNAc]2[Hex]5 15
2 + D 1568.1898 LENSSGSKSAFVTVK + [HexNAc]3[Hex]6 17
27 2 + A 1583.1647 LDVVPIDDNNNSSNYR + [HexNAc]2[Hex]5 100
2 + B 1583.1998 VNRLNVTLK + [HexNAc]4[Hex]8 32
2 + C 1583.1425 VETNCNLSVEK + [HexNAc]3[Hex]6[Neu5Ac]1 0
2 + D 1583.1930 AYATITNNCTKTTFR + [HexNAc]3[Hex]4[Fuc]1 0
28 2 + A 1603.1722 NCSFNITTEIR + [HexNAc]6[Hex]3[Fuc]1 78
2 + B 1603.1885 TCILEILNSTK + [HexNAc]4[Hex]5[Neu5Ac]1 7
2 + C 1603.1644 YTCQAKNESGVER + [HexNAc]5[Hex]4 46
2 + D 1603.1973 QNLTVKDVTK + [HexNAc]4[Hex]5[Neu5Ac]1[Fuc]1 21
29 2 + A 1610.1478 NCSFNITTEIR + [HexNAc]2[Hex]9 89
2 + B 1610.1877 VFAENETGLSRPR + [HexNAc]3[Hex]7 25
2 + C 1610.1661 YTFYAGENITSGK + [HexNAc]4[Hex]5[Fuc]1 11
2 + D 1610.1137 NASGTK + [HexNAc]4[Hex]5[Neu5Ac]3[Fuc]1 13
30 2 + A 1669.7355 LINCNTSAITQACPK + [HexNAc]5[Hex]3[Fuc]1 95
2 + B 1669.6986 NDAGKYTLTVENNSGSK + [HexNAc]2[Hex]7 5
2 + C 1669.7664 DTGEYTLELKNVTGTTSETIK + [HexNAc]2[Hex]3[Fuc]1 42
2 + D 1669.6873 WVRHNK + [HexNAc]6[Hex]7[Fuc]1 24
31 2 + A 1697.2203 LDVVPIDDNNNNSSNYR + [HexNAc]4[Hex]3[Fuc]1 95
2 + B 1697.2139 TNKTINHDTQFK + [HexNAc]4[Hex]7 52
100
2 + C 1697.2194 LINCNTSAITQACPK + [HexNAc]2[Hex]8 4
2 + D 1697.1902 WVRHNK + [HexNAc]5[Hex]5[Neu5Ac]2[Fuc]1 8
2 + E 1697.2506 YTLTVKNASGTK + [HexNAc]8[Hex]3 33
2 + F 1697.2122 VDQHEWTKCNTTPTK + [HexNAc]3[Hex]4[Neu5Ac]1 0
2 + G 1697.1594 AYACITDNCTK4 + [HexNAc]6[Hex]6 68
32 2 + A 1728.2116 NCSFNITTEIR + [HexNAc]5[Hex]4[Neu5Ac]1[Fuc]1 70
2 + B 1728.1707 LNK + [HexNAc]6[Hex]7[Neu5Ac]2[Fuc]1 33
2 + C 1728.1988 YTCQAKNESGVER + [HexNAc]4[Hex]5[Neu5Ac]1 58
2 + D 1728.2150 QSDAGEYTFVAGRNR + [HexNAc]4[Hex]6 33
33 2 + A 1745.2175 LDVVPIDDNNNNSSNYR + [HexNAc]2[Hex]7 92
2 + B 1745.2268 CDPPVISNITK + [HexNAc]5[Hex]4[Neu5Ac]2 3
2 + C 1745.2541 VNTSPISGREYR + [HexNAc]8[Hex]3 4
2 + D 1745.2458 AYATITNNCTKTTFR + [HexNAc]3[Hex]6[Fuc]1 0
34 2 + A 1826.2439 LDVVPIDDNNNNSSNYR + [HexNAc]2[Hex]8 100
2 + B 1826.2596 GVNYTQLSIDNCDR + [HexNAc]6[Hex]3[ Fuc]2 0
2 + C 1826.2532 CDPPVISNITK + [HexNAc]5[Hex]5[Neu5Ac]2 3
2 + D 1826.2753 DSGYYSLTAENSSGTDTQKIK +
[HexNAc]3[Hex]3[Neu5Ac]1
0
2 + E 1826.1873 SVDNGHSGRYTCQAKNESGVER +
[HexNAc]2[Hex]4[ Fuc]l
0
1 For each test, candidate A is the actual glycopeptide composition that corresponds to the MS/MS data being
scored.
2 All candidate compositions have an m/z value, calculated in silico, within 50 ppm error of the monoisotopic mass
present in the experimental MS1 data.
3 The normalization threshold used for determining the presence or absence of the [peptide + core component]
product ions in all scoring by GPG was 2 % relative abundance.  For Y1 ion evaluation included in the GPG
scores reported herein, a relative abundance threshold of 20 % was used for a spectral match to be considered
valid.  Normalization values applied to the detection of [precursor – monosaccharide] product ions vary according
to the identity of the neutral loss being evaluated.
4 Denotes peptides where Cys residues were not derivatized by IAM.
A minimum of three candidate compositions were scored for each spectrum, with an
average of four to five glycopeptide candidates being evaluated in each test performed. In
agreement with the training data set results, the GPG algorithm assigned the highest score to
each correct candidate composition, for each CON-S gp140ΔCFI glycopeptide spectrum, scored
in the validation data set. An example of a scored fucosylated complex type structure from
CON-S gp140ΔCFI is shown in Figure 3.
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Figure 3. MS2 data from the validation set.  (A) GPG evaluation of the correct candidate
composition assignment for a fucosylated N-glycopeptide from CON-S gp140ΔCFI.  Scoring in
(B) and (C) shows evaluation of this spectrum against decoy candidate compositions with the
same nominal mass.  Arrows with an X indicate ions that were not present in the spectra.  A 2 %
relative abundance threshold was used for [peptide + core component] product ion matching to
decrease false positives from noise.  For the composition in (A), GPG generated a score of 95 %.
The decoy compositions in (B) and (C) were scored at 52 % and 68 % respectively, indicating
that GPG scored the correct compositional assignment as the most probable glycopeptide
composition from this pool of candidates.
The GPG scores for decoy compositions tested against this spectrum are also reported on
the spectra.  This example is Test 31 of Table 3.
While the data from both the training sets and validation sets were quite encouraging, one
might note that in each case, a limited number of decoys were tested against the true
composition.  To test the likelihood that this limited number of decoys was a required feature for
the correct candidate to get the top score, a glycopeptide spectrum from gp140 was tested against
nine alternate isobaric candidate compositions.  Scores are shown in Table 1, and the MS/MS
data is in Figure 4.
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Figure 4. CID spectrum of a glycopeptide from CON-S gp140ΔCFI scored by GPG, along with
nine alternate compositions, as shown in Table 1.  Even when an extensive number of candidates
share the same nominal mass, GPG scored the correct composition as the most probable
glycopeptide match for the MS2 data against all other potential assignments tested.
The correct composition of NCSFNITTEIR + [HexNAc]4[Hex]4[Fuc]1 was indicated
with the highest GPG score, 80 %, while the highest scoring decoy composition,
INETLELLSESPVYSTK + [HexNAc]2[Hex]3[Fuc]1 was assigned a GPG score of 68 %.
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Table 4. GPG Results for Candidate Compositions Tested Against the MS2 Data in Figure 4.
Candidate1 Mass (Da) Glycopeptide Composition2 Score3
A 2960.2338 NCSFNITTEIR + [HexNAc]4[Hex]4[Fuc]1 80
B 2960.3006 YILKLENSSGSK + [HexNAc]4 + [Hex]5 52
C 2960.3228 QNATVQGLIQGK + [HexNAc]6[Hex]3 39
D 2960.2638 YTVVAGGNVSTAK + [HexNAc]3[Hex]4[Neu5Ac]1[Fuc]1 11
E 2960.2740 NGTEILKSK + [HexNAc]5[Hex]5[Fuc]1 32
F 2960.2700 VENLTEGAIYYFR + [HexNAc]3[Hex]3[Neu5Ac]1 0
G 2960.2644 YTLTLENSSGTK + [HexNAc]5[Hex]3[Fuc]1 34
H 2960.2642 YILTVENSSGSK + [HexNAc]5[Hex]4 44
I 2960.2484 TKANVTVEAR + [HexNAc]3[Hex]6[Neu5Ac]1 0
J 2960.3632 INETLELLSESPVYSTK + [HexNAc]2[Hex]3[Fuc]1 68
1 Candidate A is the actual N-linked glycopeptide composition corresponding to the CID spectrum scored by GPG
and candidates B, C, D, E, F, G, H, I, and J are decoy compositions of nearly identical neutral mass.
2 All glycopeptide compositions have an m/z value, calculated in silico, that is within 50 ppm error of the
monoisotopic mass present in the experimental MS1 data.  Users may also utilize low resolution MS1 data to
determine glycopeptide candidates, though more compositions will result.
3 Denotes GPG scores at 2 % peptide normalization.
Although the score values and distribution varies from spectrum to spectrum, GPG
ranked the correct candidate composition as the most probable glycopeptide in each test
performed, including approximately 300 CID spectra from the training and validation sets.  A
screen shot of the GPG scoring output for a high mannose type CON-S gp140ΔCFI
glycopeptide, along with three decoy candidate compositions, is included in Figure 5.
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Figure 5. Screen shot of output showing GPG scoring of a glycopeptide from CON-S
gp140ΔCFI, along with three candidate compositions with a nearly identical neutral mass.  The
actual glycopeptide composition of SNITGLLLTR + [HexNAc]2[Hex]8 received a score of 79
%, while the three decoy compositions of NGINVTPSQR + [HexNAc]6[Hex]3,
DNGSPILGYWLEK + [HexNAc]4[Hex]3, and ANDTLVR + [HexNAc]3[Hex]5[Neu5Ac]2
received scores of 3 %, 4 %, and 6 %, respectively. The exact m/z values, calculated in silico, are
shown for each of the glycopeptide candidate compositions in Table 3, test #18.
3.4 CONCLUDING REMARKS
We have developed a novel software analysis tool, GlycoPep Grader, to increase the
speed and efficiency of assigning N-linked glycopeptide composition from MS/MS data.  This
novel spectral scoring approach relies heavily on the identification of the peptide-containing, or
[peptide + core component], product ions and neutral monosaccharide residue losses, or
[precursor – monosaccharide] product ions, across various charge states.  After developing and
testing the GPG software using a training set of CID data collected on glycopeptides from RNase
B, asialofetuin, and transferrin, GPG was then validated by scoring glycopeptide compositions
from the recombinant HIV envelope protein, CON-S gp140ΔCFI, against alternate candidate
compositions of the same nominal mass. Thus far, in approximately 300 tests performed across
spectra of differing quality, the novel scoring algorithm powering GPG identifies the correct
glycopeptide composition as the highest scoring candidate ion every time.
This tool has several useful features, compared to other existing glycopeptide analysis
tools: 1) It is the only available tool whose scoring algorithm was designed specifically for low
resolution CID data, 2) It does not require the user to first deconvolute the spectrum to singly
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charged ions, which is often difficult or impossible for low resolution CID spectra, 3) It has
unique scoring rules, depending on the types of glycans present in the candidate composition and
4) The user need not know the peptide composition in advance in order to use the tool, but rather
inputs potential candidate compositions obtained from available glycopeptide databases that
correspond to the precursor’s experimental mass.  Finally, GPG has shown unprecedented
success in accurately identifying of the correct glycopeptide composition in 79 unique test cases.
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CHAPTER 4
COMPUTATIONAL METHOD TO DETERMINE
PRECURSOR CHARGE STATE IN ETD MS/MS DATA OF
DISULFIDE-BONDED PEPTIDES
ABSTRACT
The analysis of peptides using electron transfer dissociation (ETD) is still in the early
stages, as is the development of methods and programs to elucidate a precursor’s charge state
from peptide ETD spectra.  Conversely, manual assignment of spectra is tedious and time-
consuming.  Still, accurate charge state assignment is necessary in order to determine mass of a
precursor ion. As low resolution instruments, such as the Thermo Scientific Velos LTQ, are
equipped with ETD capabilities, the availability of computational tools to assist in the
determination of precursor charge state directly from ETD MS/MS data is essential to advance
the study of disulfide-bonded peptides.
Although a few programs determine charge state from low resolution ETD data of
peptide precursors, the majority are not freely available to the public.  Additionally, no program
has been described or reported to be tested on peptides containing disulfide bonds.  To address
this need in automated MS/MS analysis, we have developed a method that utilizes simple
computational tools generated in Excel in order to identify charge state in disulfide-bonded
peptide precursors. One benefit of the computational tools is that the most likely precursor
charge state may be deciphered when more than one potential charge state exists, which greatly
reduces the amount of time it takes to perform subsequent protein database searches.
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4.1 INTRODUCTION
Disulfide bonds play a critical role in stabilizing protein structure.1, 2, 3, 4, 5 Experimental
studies show that in the absence of proper disulfide bond orientation, proper protein folding may
not occur.2, 6 As such, it is important to identify the disulfide bond arrangements in order to
evaluate structural features within a protein.  This described importance is magnified within the
pharmaceutical and biotechnology industries, where the mapping of disulfide bonds is critical to
ensuring drug quality and efficacy.2, 7, 8, 9 In the characterization of protein disulfide bond
formation, analysis by electron transfer dissociation tandem mass spectrometry (ETD MS/MS) is
emerging as a powerful technique.7, 9, 10, 11, 12, 13
At present, mass spectrometry is a common analysis route used to identify disulfide bond
arrangements in proteins and peptides.14 Nuclear magnetic resonance (NMR) 15, 16 and
crystallography 17, 18, 19 experiments can also be used to obtain disulfide bond information;
unfortunately, the instrumentation requires high amounts of high purity samples. In contrast,
LC-MS reveals disulfide bond patterns using small sample amounts,9, 10, 13, 14, 20, 21 even when the
sample is comprised of unknowns.  To obtain experimental MS/MS data on disulfide-bonded
peptides, a variety of fragmentation techniques may be utilized,14 including collision induced
dissociation (CID).21, 22, 23, 24, 25, 26 However, ETD MS/MS impart more extensive fragmentation
information for these species.11, 25
During ETD MS/MS experiments, Cα-N bond cleavage is induced through the transfer of
an electron from a radical anion, such as fluoranthene, to a protonated peptide.11, 27 The
mechanism of peptide backbone cleavage is analogous to the way in which fragmentation in
electron capture dissociation (ECD) occurs.11, 28, 29 When the backbone is fragmented, it
dissociates into c- and z-type product ions.11, 27, 30, 31 Like the b- and y-type ions generated
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during collision induced dissociation (CID),11, 27, 30 these product ions provide peptide sequence
information. However, in the study of disulfide-bonded peptides, ETD presents several
advantages over the more popular CID.  For example, although ETD generally preserves labile
post-translational modifications (PTMs),11, 27, 30 it is shown to preferentially cleave between
peptides containing a disulfide bond.10, 12, 13, 30 This provides valuable MS/MS information about
the individual chains that are bonded together to form a disulfide.  In contrast, although CID is
known to fragment labile PTMs,11, 27, 30 it does not typically fragment the covalent disulfide
bond.10, 11
Still, in order to utilize low resolution ETD MS instruments, the charge state of the
precursor ion must be known. This is a requirement for accurately determining mass, or for
identifying peptide sequence using automated database search tools such as MassMatrix.32, 33
For example, when the charge state is unknown, repeated searches must be performed on each
spectrum to evaluate all possible charge states.  These repeated searches result in analysis that is
inefficient and time-consuming, which becomes even more costly when larger peptides with a
higher charge state distribution are considered.
In the determination of precursor charge state directly from peptide ETD MS/MS data, a
few software tools have recently been described in the literature.34, 35, 36 Two of these programs
are accessible to only select users. These include the commercially available Charger, developed
by Sadygov et al. and distributed by Thermo Scientific, and Charge Prediction Machine (CPM)
by Carvalho et al., which is available to academic users to run on Linux through the Mono
Project.35, 36 The other program, developed by Sharma et al., utilizes support vector machine
(SVM) classifiers to deduce charge state from analyzing patterns in the intensity of the charge
reduced precursor ion peaks within an ETD spectrum.34 This program is publicly available,
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however, it  requires the use of other stand-alone programs, and is not intuitive to users
unfamiliar with vector analysis.
Although programs such as Charger, CPM, and the prediction tool using SVM classifiers
have been created to determine precursor ion charge state directly from low resolution ETD
MS/MS data, the fragmentation behavior of peptides containing disulfide bonds has shown
different predominant characteristics in comparison to peptides lacking these modifications. For
instance, limited fragmentation is observed and not as many c- and z-type product ions are
produced, as a majority of the ETD activation energy goes into cleaving the S-S bond.12 As it
stands, no program has been designed to analyze ETD MS/MS data of peptides containing inter
and intra disulfide bonds, nor has testing using the above automated programs been reported on
them.
We present herein a simple computational method that allows for the determination of
precursor ion charge state directly from MS/MS data of disulfide-bonded peptides. This method
is applicable to peptides containing both interchain and intrachain type disulfide bonds.  In
addition to being developed specifically for the interpretation of peptides containing disulfide
bonds, the novel computational method utilizes Excel-based tools to deduce the single most
probable charge state for a precursor ion.
4.2 EXPERIMENTAL
4.2.1 Materials and Reagents. Chicken lysozyme, bovine fetuin, bovine serum albumin
(BSA), human apo-transferrin (transferrin), formic acid, and acetic acid were purchased from
Sigma Aldrich (St. Louis, MO). HPLC grade methanol (CH3 OH) and HPLC grade acetonitrile
(CH3 CN) were purchased from Fisher Scientific (Fairlawn, NJ). Ammonium bicarbonate
(NH4HCO3) was purchased from Fluka (Milwaukee, WI) and sequencing grade modified trypsin
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was from purchased Promega (Madison, WI). Ultrapure water was obtained from a Millipore
Direct-Q® UV 3 system (Billerica, MA) with a resistance greater than 18 MΩ.
4.2.2 Protease Digestion. Lysozyme, fetuin, transferrin, and BSA were subjected to
proteolytic digestion.  Approximately 400 µg of each protein was dissolved in 100 mM
NH4HCO3 (pH 8.0).  Next, trypsin was added to in a 1:80 (w/w) protease to protein ratio and
incubated at 37 °C for 24 hr.  The protease digestion was stopped by the addition of 1 µL
concentrated acetic acid for every 100 µL solution. These samples were then analyzed by LC-
MS and subjected to MS/MS experiments, as described below.
4.2.3 Mass Spectrometry on an ESI-LTQ Velos. Peptides obtained from each tryptic
digest were loaded onto a C18 column (300 µm i.d., 5 cm length, and 3 µm particle size)
produced by CVC Microtech (Fontana, CA) at a final concentration of 15 µM after dilution with
ultrapure water.  The column was connected to a Waters Acquity UPLC system (Milford, MA),
directly coupled to an electrospray-linear ion trap mass spectrometer (ESI-LTQ Velos MS) from
ThermoScientific (San Jose, CA). The aqueous mobile phase was comprised of 99.9 % water
and 0.1 % formic acid (solvent A) and the organic mobile phase consisted of 99.9 % acetonitrile
and 0.1 % formic acid (solvent B).  The flow rate was set to 7 µL/min. For reversed phase
separation of peptides, the solvent conditions were as follows: 2 min at 2 % B, a 10 min linear
increase to 5 % B, another 10 min linear increase to 20 % B, a 20 min linear increase to 50 % B,
another 20 min linear increase to 60 % B, and a final 10 min linear increase to 95 % B before
being held at 95 % B for 10 min, followed by re-equilibration of the column. A 45 min wash
cycle and blank injection were used between each sample run to ensure no carry over between
samples occurred. For mass spectrometry, the electrospray source voltage was 3 kV and the
capillary temperature was 250 °C. For ETD MS/MS analysis of peptides, fluoranthene was used
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as the ETD reagent.  An activation time of 100 ms, and an isolation width of 2.5 Da was used.
Supplemental activation was enabled. LC-MS/MS was set up in data dependent scan mode
where the 5 most intense ions were chosen for MS/MS analysis with a 3 min dynamic exclusion
window.  MS/MS scans were collected in centroid mode.
4.2.4 Manual Data Analysis. To identify the peptides containing disulfide bonds in the
MS data, a prediction table of theoretical m/z values corresponding to disulfide-bonded peptides
for each of the protein digest samples was prepared. The amino acid sequences from lysozyme,
fetuin, transferrin, and BSA were obtained from Uniprot (www.uniprot.org) and imported into
Protein Prospector (http://prospector.ucsf.edu/prospector/mshome.htm), where a theoretical
tryptic digest was performed.  Tryptic miscleavages were not considered. The masses of the
peptides that contained both inter-and intra-bonded disulfides were calculated with their
modification. These masses were converted into m/z values corresponding to the disulfide-
bonded peptides in multiple charge states.  The MS/MS data for lysozyme, fetuin, BSA, and
transferrin were then searched to identify spectra that corresponded to the correct m/z value of
the calculated species.  The ETD spectra were carefully evaluated in order to verify each
assignment made.
4.3 RESULTS AND DISCUSSION
Various proteins with intact disulfide linkages were digested with trypsin and analyzed
by ETD-MS/MS in order to develop an automated approach for the determination of precursor
charge state directly from their tandem mass spectra.  Resultant peptides chosen for charge state
determination ranged in length from 2 to 61 amino acids, and contained an assortment of
disulfide bond arrangements.  Information on the selected proteins is given in Table 1.
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Table 1. Proteins Containing Disulfide Bonds Analyzed by ETD MS/MS.
Protein Mass (Da)                Length (AA) # Cys Residues               # Disulfide Bonds
Lysozyme 16,239 147 9 4
Fetuin 38,419 359 14 6
BSA 69,293 607 35 17
Transferrin 77,064 698 40 19
1 Lysozyme has 9 Cys located within the protein sequence, with 1 Cys in signal peptide and 8 Cys in protein chain.
Fetuin has 14 Cys located within the protein sequence, with 2 Cys in signal peptide and 12 Cys in protein chain.
BSA has 35 Cys located within the protein sequence, with 0 Cys in signal peptide and 35 Cys in protein chain.
Transferrin has 40 Cys located within the protein sequence, with 2 Cys in signal peptide and 38 Cys in protein
chain.
4.3.1 Low Resolution ETD MS/MS Data of Peptides Containing Disulfide Bonds. In
low resolution ETD MS data, the charge state of a precursor ion is not readily apparent.
Currently, there are a limited number of programs that exist to determine charge state from low
resolution ETD MS/MS data, and only one of these is publicly accessible.34 This program,
published by MacCoss and co-workers takes advantage of a characteristic feature found in ETD
spectra, the presence of intense peaks corresponding to charge reduced precursor species.34
However, this program has not been tested on precursor ions that contain disulfide linkages or
more than one peptide.  As it stands, all of the existing software programs that work to decipher
charge state from ETD MS/MS data were designed for the analysis of peptides absent of intact
disulfide bonds.  The direct application of these automated tools to disulfide-bonded peptides is
problematic in that peptides containing disulfide bonds have been shown to fragment differently
when subjected to ETD in comparison to peptides without this covalent modification.12, 30
Therefore, a program specifically intended for charge state determination of peptides containing
this common PTM is necessary.
In comparison to peptides, where the disulfide bonds have been reduced during sample
preparation, peptides containing intact disulfide linkages show prominent peaks for both the
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charge-reduced precursors and the individual peptides that comprise the disulfide-bonded
precursor.  Representative data from a lysozyme precursor with two peptides joined by one
disulfide bond is shown below in Figure 1.  In addition to the characteristic charge reduced
precursor peaks, peaks corresponding to the individual peptides are also present in high
abundance.  As a result, programs that determine charge state by evaluating a mass spectrum for
the relative abundance of those charge reduced precursors may not calculate charge state
properly if the most prominent peaks detected instead correspond to individual peptide
components.
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4.3.2 Method Development and Design.  Precursor charge state is not readily 
determined from low resolution ETD MS data, and no program is currently available to automate 
interpret ETD MS/MS data of disulfide-bonded precursors.  To overcome these limitations in 
analysis, we developed a method that utilizes simple Excel-based tools to determine charge state 
from ETD spectra of intact disulfide-bonded peptides, and is capable of handling both types of 
native disulfide bonding arrangements.  The premise of this method incorporates one accepted 
approach to deciphering charge state within a given mass spectrum; that is, by calculating the 
distance between adjacent peaks of the same compound that differ by a single charge (or one 
proton).
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  This is shown below by Equation 1.   
   GYSLGNWVCAAK (P5) 
        CK (P6) 
+ • •  
+ + •  
+ + +  
Figure 1. ETD MS/MS data collected at m/z 506.57 on a lysozyme precursor in the 3 + charge
state with one interchain disulfide bond.  Although peaks corresponding to the charge reduced
precursor species are present in this spectrum, the most abundant product ions detected are the
individual peptide chains that result from cleavage of the disulfide bond.
119
Equation 1. Charge State (z) of Peak 1 = Peak 1 / (Peak 2 – Peak 1) + 1
As charge reduced precursor ions are readily detectable within the ETD MS/MS data of
disulfide-bonded peptides,29 MS/MS peak space information may then be used to determine the
charge state of the precursor ion.  If the charge state of the charged reduced precursor ion
corresponding to one charge below that of the precursor ion is considered to be Peak 2, then the
charge state of Peak 1 can be calculated by designating the precursor ion to be Peak 1.
However, there is no way to know which of the numerous peaks correspond to the charge
reduced precursor species, and which correspond to other types of product ions generated,
including those formed from each of the individual peptide chains when peptides with interchain
disulfide bonds are present.  Therefore, each of the peaks present in a tandem mass spectrum
must be evaluated as potentially being Peak 2 and input separately into the charge state equation.
After each of these independent calculations is performed, discriminatory analysis is necessary to
determine which of the peaks corresponds to the actual charge reduced precursor species.
Specifically, the charge reduced precursor one charge state below the parent ion.  Using this
premise, two simple and straight forward computational tools that work to automate the steps of
this process were constructed in Excel.
To accomplish this, an ETD MS/MS peak list is first normalized to a 3 % relative
abundance cut-off in order to reduce spectral noise. Relative abundance thresholds of 1 %, 2 %,
3 %, 6 % and 10 % were tested during method development. Next, m/z values for the product
ions remaining in the normalized spectrum are imported into Excel.  Here, two computational
Excel-based tools work to determine the charge value associated with each of the MS/MS
product ions, and then the actual charge state of the precursor ion.
In the first tool, the raw charge value for each peak present within an experimental ETD
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spectrum, above the specified noise threshold, is calculated by evaluating the distance between
the m/z values present in the MS/MS peak list and the m/z of the precursor ion. The function
shown below by Equation 2 is input into an Excel spreadsheet to automate the charge value
calculation associated each remaining product ion, where the m/z of the selected precursor ion is
input into Column A and the MS/MS peak list data is input into Column B.  The raw charge
values are then output into Column C.
Equation 2. Fx (Column C) = Column A/(Column B – Column A)
Figure 2 provides an illustration of the first computational tool (constructed using
Equation 2), as applied to a single ETD spectrum collected at m/z 818.03 from a lysozyme
precursor.
Figure 2. Screen shot of computational tool 1 showing the Excel spreadsheet and charge value
output for each peak in the normalized MS/MS peak list from a lysozyme precursor ion at m/z
818.03 in the 4 + charge state.
Using the second tool, discriminatory analysis is performed to choose the most probable
Peak 1 Peak 2 Charge Value
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charge states based on constraints that were devised after extensive testing.  Discerning potential
charge values from all returned charge values is a two-step process.  First, as the charge
associated with a mass spectral peak must be an integer, the distance between each charge value
and the nearest whole number is calculated.  The following function shown by Equation 3 is
input into Excel to accomplish this, where Column A is the raw charge value for each of the
peaks in the MS/MS peak list (output from computational tool 1), and the distance between each
individual charge value and the nearest integer is output in Column B.
Equation 3. Fx (Column B) = ABS(Column A-ROUND(Column A, 0))
In the second step, values that are beyond a specified range are eliminated and set to zero,
and all charge values within a given error range are rounded to the nearest whole number.  After
extensive testing, the error threshold limit was set to 0.01, so any charge value that is greater than
0.01 away from an integer is eliminated.  To automate this process, the function shown below by
Equation 4 is input into Excel as Column C, and provides the final output of charge state for
those remaining integers that fall within the acceptable error range.  The integers that were
eliminated are shown as 0.  Finally, a custom sort function was used in Excel to sort the final
charge states returned (Column C) on the basis of the integer rounding distance (Column B).
Equation 4. Fx (Column C) = IF(ABS(Column B))>0.01,0,ROUND(Column A,0)
As this method determines the charge state (z) of the charge reduced precursor ion that is
one charge state below that of the precursor ion, the charge state of the precursor ion is equal to z
+ 1. The precursor charge state listed first in Column C of computational tool 2 is considered the
most probable charge state for that charge reduced precursor species, except in the cases where
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that number is one and another charge state of greater than 1 + is also returned. In these cases, if
another integer greater than 1 + is listed, that integer is considered more probable. If two
integers are given in the output list with equal or near equal rounding distances, a higher relative
abundance threshold may be applied to the MS/MS peak list, as described later.
Figure 3 shows an example a typical charge state output for computational tool 2.  In this
run, the charge values were those integers computed for the MS/MS data shown by computation
tool 1 in Figure 3.
Figure 3. Screen shot depicting computational tool 2.  The charge values shown in Column A
are the output from computational tool 2.  For the MS/MS data shown here, a charge state 3 + for
the charge reduced precursor species in the precursor – 1 charge state, the disulfide bonded
precursor is a 4 + charge state ion.
4.3.3 Precursor Charge State Assignment of Disulfide ETD MS/MS Data. Disulfide-
bonded precursors in various charge states from lysozyme, fetuin, BSA, and transferrin were
assigned charge state using the two computational tools from the method described in the
previous section.
Representative data from a fetuin precursor in the 4 + charge state is shown below in
Charge Value Rounding Distance Charge State
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Figure 4.  In this example, the total combined length of the two peptides comprising the 
precursor ion is 27 amino acids.  After the MS/MS peak list from an ETD spectrum collected at 
m/z 724.34 was tested, the precursor ion was determined to be in the 4 + charge state.  This 
assignment is correct, according to manual verification.  In Figure 4, peaks corresponding to 
individual chains of the disulfide bonded precursor are present in high abundance.  This agrees 
with previous research indicating the preferential cleavage of disulfide bonds during ETD.
10, 12, 13, 
30
 
 
 
 
 
One of the initial difficulties in designing a method for precursor charge state 
+ + + +  
+ + + •  
+ + • •  
      EPACDDPDTEQAALAAVDYINK (P1) 
        LCPGR (P2) 
Figure 4. ETD MS/MS data at m/z 724.34 collected on fetuin.  The fragmentation shown by the
spectrum is representative of a precursor ion with intact interchain disulfide bonding.  Product
ions resulting from the cleavage of the disulfide bond, and the characteristic charge reduced
precursors, are both present in high abundance.
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determination arose from the differences in the intensity of the charge reduced precursor peaks
that were observed for disulfide bonded precursors of different charge states.  This coincides
with the different degrees of accuracy that MacCoss and co-workers reported for precursor ions
of different charge state in their peptide ETD MS/MS program.34 The reported accuracy was
over 99 % for precursors of 2 +, 3 +, and 4 + charge states, but significantly lower for spectra
collected on peptide precursors with a higher charge state .34 Therefore, it was important to
ensure that the normalization level applied to the MS/MS peak list be applicable to all disulfide
bonded precursors, regardless of charge state.  An example of a spectrum collected on a 5 +
charge state transferrin precursor ion and scored using the devised charge state analysis method
is shown in Figure 5.  The spectrum was analyzed using computational tools 1 and 2, and the
precursor was correctly assigned as a 5 + charge state ion.
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Often, more than two individual chains are joined to form a precursor containing native 
disulfide bonding.  Therefore, it was important to ensure that our charge state determination tools 
were applicable to these disulfide-bonded peptides as well.  The ETD spectrum collected on a 
precursor from BSA that contains two disulfide bonds and three peptide chains is shown below 
in Figure 6.  In this case, a 5 + charge state assignment after the MS/MS data was evaluated 
using the computational tools described herein. 
 
 
+ + + + •  
+ + + + + 
+ + + • •  
+ + • • •  
DYELLCLDGTR (P27) 
KPVEEYANCHLAR (P28) 
Figure 5. ETD MS/MS data collected at m/z 565.67 on a transferrin precursor comprised of two
peptides joined together by one interchain disulfide bond.  In agreement with the tests of ETD
spectra obtained on disulfide bonded peptides in the 2 +, 3 +, and 4 + charge states, our
computational approach also identified the charge state for 5 + precursor ion.
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Further adding complexity to the ETD MS/MS analysis of disulfide bonded peptides are 
the differences reported for fragmentation reported for interchain and intrachain bonds types.
12
  
These include variations seen in both the amount, and type, of product ions formed.
12
  These 
differences have also been observed for experimental ETD data acquired in our lab.  For these 
reasons, it was important to develop a method for determining charge state that was applicable to 
both types of disulfide bond arrangements.  Experimental ETD MS/MS data of a transferrin 
peptide containing three intrachain disulfide bonds is depicted in Figure 7.  Using the same 
computational tools, this precursor was correctly identified as a 4 + charge state ion.  
 
+ + • • • 
+ + + + +  
+ + + + •  
GACLLPK (P3) 
LKPDPNTLCDEFK (P19) 
YNGVFQECCQAEDK (P21) 
+ + + • •  
Figure 6. ETD MS/MS data collected on bovine serum albumin at m/z 770.79, in the 5 + charge
state.  This precursor ion consists of three peptides joined together by two disulfide bonds.
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In total, over 70 ETD spectra from lysozyme, fetuin, BSA, and transferrin were assigned 
charge state using the Excel-based computational tools developed in our lab.  MS/MS data from 
precursors of various charge state and bonding arrangements were tested using this method, with 
an accuracy of over 90 % for all spectra combined.  A future direction of this project is to apply 
the computational tools to a validation set of spectra from a different protein.  
4.3.4 Number of Charge State Assignments Returned.  One of the limitations to 
current programs designed for charge state determination of peptide ETD MS/MS data is the 
inability to assign a single charge state to a precursor ion.  The number of charge states returned 
to a user per spectrum tested is referred to as the z: scan ratio, and attaining the lowest value 
AVANFFSGSCAPCADGTDFPQLCQLCPGCGCSTLNQYFGYSGAFK (P9) 
+ + + + 
+ + + •  
Figure 7. ETD MS/MS data at m/z 1161.26 from a 4 + charge state transferrin precursor with
three intrachain disulfide bonds.  The cysteine residues forming each disulfide bond are shown in
color within the peptide sequence.
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possible is reportedly a high priority goal for other programs aiming to decipher precursor charge
state.34 In short, the z: scan ratio of 1.00 is advantageous for researchers working to limit
analysis to the shortest time possible.
For example, the recommended user parameter for the previously mentioned SVM
classifier tool is a cut-off probability of 0.98, which corresponds to a z: scan ratio of 1.53, as
reported for the LTQ-ETD unique peptide data set.34 This means that the meaning SVM
classifier will aim to generate 1.53 charge state predictions for each spectral search performed.34
So, out of the six possible charge states considered by the tool (2 + through 7 +), close to two
charge state predictions are returned to a user for each query.34 Each additional charge state
assignment significantly increases analysis time for researchers using database searches to
identify peptide MS/MS data, as each one requires a separate database query to identify the
precursor ion using automated search algorithms.  One the other hand, accuracy typically
improves with a higher z: scan ratio, as all potential charge states are returned to a user for a
given spectrum.  Therefore, using the default parameters of this program for the described data,
the program achieves an accuracy of almost 99 %.34 This is significantly higher than the
accuracy reported for charge state assignment when a z: scan ratio of 1.00 is selected for the
same data, which was below 97 %.34
To overcome this limitation for researchers utilizing a database capable of processing
peptide ETD spectra with intact disulfides, we devised a computational method that predicts the
most probable charge state for a precursor ion.  As such, a charge state prediction return of 1.00
can be achieved for each spectrum tested. Other potential charge states are also returned to the
user, in order of decreasing probability. This is beneficial for users who are more interested in
accuracy than speed of analysis.
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As previously described, the top precursor charge state returned to a user is considered
the most probable charge state for that charge reduced precursor species, except in the cases
where that number is one.  For these, if a second integer greater than one is also returned, that
integer is considered more probable.  In cases where two integers are given in the output list with
equal or near equal rounding distances, it is suggested that a higher relative abundance threshold
of 10 % is applied to the MS/MS peak list, and the process repeated.  Figure 8 illustrates an ETD
spectrum of a 4 + transferrin precursor containing two disulfides, and shows typical product ions
that result from the cleavage of interchain bonds.  When this spectrum was initially analyzed
using our method, two different charge states were returned when the standard 3 % relative
abundance cut-off was applied.  When the normalization was increased to 10 %, a precursor
charge state of returned.  This assignment is in agreement with the manual assignment.
130 
 
 
limitations of current tools that work to determine precursor charge state from ETD MS/MS data.  
Although a few programs exist to aid in the interpretation of low resolution peptide ETD spectra, 
no method has previously been described for the assignment of disulfide-bonded peptide ETD 
spectra.  To overcome this need, we have created an algorithm that allows the determination of 
precursor charge state directly from low resolution ETD MS/MS data.       
This simple approach utilizes simple computational tools to allow a user to quickly 
access the most likely charge state directly from experimental MS/MS data, bypassing the need 
+ + • •  
DSSLCK (P26) 
FDEFFSEGCAPGSK (P24) 
LCMGSGLNLCEPNNK (P25) 
+ + + +  
+ + + •  
4.4 CONCLUDING REMARKS
The computational method presented herein is designed to overcome the most significant
Figure 8. ETD MS/MS data at m/z 941.48 collected on transferrin. A total of two interchain
disulfide bonds join the three peptide chains of this 4 + charge state precursor ion.  Individual
chains of the disulfide bonded precursor ion were readily detectable in the fragmentation profiles
of precursors containing interchain disulfide bonds.
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to rely on isotopic distribution patterns for deciphering charge state of disulfide-bonded peptides.
In addition, this method is advantageous in that no additional computer downloads are needed,
no Linux operating system is necessary, and no learning curve is required before use.
4.5 ACKNOWLEDGEMENTS
The author acknowledges financial support from an NSF CAREER Award (0645120) to
H.D., an NSF Fellowship (DGE-0742523) and Pfizer Scholarship to C.W., and a Seo
Scholarship to M.M.
The author also wishes to thank those who contributed to the work described herein:
Daniel Clark for providing some of the ETD MS/MS data, Morgan Maxon for her time and
contribution, and Heather Desaire for her time and leadership.
132
4.6 REFERENCES
(1) Fass, D. Disulfide bonding in protein biophysics. In Annual Reviews of Biophysics, Vol. 41,
Rees, D. C., Ed. 2012; Vol. 41, pp 63-79.
(2) Trivedi, M. V.; Laurence, J. S.; Siahaan, T. J. The role of thiols and disulfides on protein
stability. Curr. Protein Pept. Sci. 2009, 10, 614-625.
(3) Kang, T. S.; Kini, R. M. Structural determinants of protein folding. Cell. Mol. Life Sci.
2009, 66, 2341-2361.
(4) Wong, J. W. H.; Ho, S. Y. W.; Hogg, P. J. Disulfide bond acquisition through eukaryotic
protein evolution. Mol. Biol. Evol. 2011, 28, 327-334.
(5) Feige, M. J.; Hendershot, L. M. Disulfide bonds in ER protein folding and homeostasis.
Curr. Opin. Cell Biol. 2011, 23, 167-175.
(6) Wedemeyer, W. J.; Welker, E.; Narayan, M.; Scheraga, H. A. Disulfide bonds and protein
folding. Biochemistry. 2000, 39, 4207-4216.
(7) Chen, G.; Warrack, B. M.; Goodenough, A. K.; Wei, H.; Wang-Iverson, D. B.; Tymiak, A.
A. Characterization of protein therapeutics by mass spectrometry: Recent developments and
future directions. Drug Discov. Today. 2011, 16, 58-64.
(8) Zhang, L.; Chou, C. P.; Moo-Young, M. Disulfide bond formation and its impact on the
biological activity and stability of recombinant therapeutic proteins produced by Escherichia
coli expression system. Biotechnol. Adv. 2011, 29, 923-929.
(9) Wu, S. L.; Jiang, H.; Lu, Q.; Dai, S.; Hancock, W. S.; Karger, B. L. Mass spectrometric
determination of disulfide linkages in recombinant therapeutic proteins using online LC-MS
with electron-transfer dissociation. Anal. Chem. 2009, 81, 112-122.
(10) Wang, Y.; Lu, Q.; Wu, S. L.; Karger, B. L.; Hancock, W. S. Characterization and
comparison of disulfide linkages and scrambling patterns in therapeutic monoclonal antibodies:
Using LC-MS with electron transfer dissociation. Anal. Chem. 2011, 83, 3133-3140.
(11) Mikesh, L. M.; Ueberheide, B.; Chi, A.; Coon, J. J.; Syka, J. E. P.; Shabanowitz, J.; Hunt,
D. F. The utility of ETD mass spectrometry in proteomic analysis. BBA-Proteins Proteomics.
2006, 1764, 1811-1822.
(12) Cole, S. R.; Ma, X.; Zhang, X.; Xia, Y. Electron transfer dissociation (ETD) of peptides
containing intrachain disulfide bonds. J. Am. Soc. Mass Spectrom. 2012, 23, 310-320.
(13) Clark, D. F.; Go, E. P.; Desaire, H. Simple approach to assign disulfide connectivity using
extracted ion chromatograms of electron transfer dissociation spectra. Anal. Chem. 2013, 85,
1192-1199.
133
(14) Gorman, J. J.; Wallis, T. P.; Pitt, J. J. Protein disulfide bond determination by mass
spectrometry. Mass Spectrom. Rev. 2002, 21, 183-216.
(15) Sharma, D.; Rajarathnam, K. 13C NMR chemical shifts can predict disulfide bond
formation. J. Biomol. NMR. 2000, 18, 165-171.
(16) Mobli, M.; King, G. F. NMR methods for determining disulfide-bond connectivities.
Toxicon. 2010, 56, 849-854.
(17) McGeehan, J. E.; Bourgeois, D.; Royant, A.; Carpentier, P. Raman-assisted
crystallography of biomolecules at the synchrotron: Instrumentation, methods and applications.
BBA-Proteins Proteomics. 2011, 1814, 750–759.
(18) Qiu, W.; Dong, A.; Pizarro, J. C. Botchkarsev, A.; Min, J.; Wernimont, A. K.; Hills, T.;
Hui, R.; Artz, J. D. Crystal structures from the Plasmodium peroxiredoxins: New insights into
oligomerization and product binding. BMC Struct. Biol. 2012, 12.
(19) Hwang, S.; Hilty, C. Folding determinants of disulfide bond forming protein B explored
by solution nuclear magnetic resonance spectroscopy. Proteins. 2011, 79, 1365-1375.
(20) Yen, T. Y.; Joshi, R. K.; Yan, H.; Seto, N. O. L.; Palcic, M. M.; Macher, B. A.
Characterization of cysteine residues and disulfide bonds in proteins by liquid
chromatography/electrospray ionization tandem mass spectrometry. J. Mass Spectrom. 2000,
35, 990-1002.
(21) Wu, S. L.; Jiang, H.; Hancock, W. S.; Karger, B. L. Identification of the unpaired cysteine
status and complete mapping of the 17 disulfides of recombinant tissue plasminogen activator
using LC-MS with electron transfer dissociation/collision induced dissociation. Anal. Chem.
2010, 82, 5296-5303.
(22) Clark, D. F.; Go, E. P.; Toumi, M. L.; Desaire, H. Collision induced dissociation products
of disulfide-bonded peptides: Ions result from the cleavage of more than one bond. J. Am. Soc.
Mass Spectrom. 2011, 22, 492-498.
(23) Chen, J.; Shiyanov, P.; Zhang, L.; Schlager, J. J.; Green-Church, K. B. Top-down
characterization of a native highly intralinked protein: Concurrent cleavages of disulfide and
protein backbone bonds. Anal. Chem. 2010, 82, 6079-6089.
(24) Janecki, D. J.; Nemeth, J. F. Application of MALDI TOF/TOF mass spectrometry and
collision-induced dissociation for the identification of disulfide-bonded peptides. J. Mass
Spectrom. 2011, 46, 677-688.
(25) Mentinova, M.; Hongling, H.; McLuckey, S. A. Dissociation of disulfide-intact
somatostatin ions: The roles of ion type and dissociation method. Rapid Commun. Mass
Spectrom. 2009, 23, 2647–2655.
134
(26) Mormann, M.; Eble, J.; Schwöppe, C.; Mesters, R. M.; Berdel, W. E.; Peter-Katalinić, J.;
Pohlentz, G. Fragmentation of intra-peptide and inter-peptide disulfide bonds of proteolytic
peptides by nanoESI collision-induced dissociation. Anal. Bioanal. Chem. 2008, 392, 831-838.
(27) Molina, H.; Matthiesen, R.; Kandasamy, K.; Pandey, A. Comprehensive comparison of
collision induced dissociation and electron transfer dissociation. Anal. Chem. 2008, 80, 4825-
4835.
(28) Zubarev, R. A. Electron-capture dissociation tandem mass spectrometry. Curr. Opin.
Biotechnol. 2004, 15, 12-16.
(29) Sun, R. X.; Dong, M. Q.; Song, C. Q.; Chi, H.; Yang, B.; Xiu, L. Y.; Tao, L.; Jing, Z. Y.;
Liu, C.; Wang, L. H.; Fu, Y.; He, S. M. Improved peptide identification for proteomic analysis
based on comprehensive characterization of electron transfer dissociation spectra. J. Proteome
Res. 2010, 9, 6354-6367.
(30) Wiesner, J.; Premsler, T.; Sickmann, A. Application of electron transfer dissociation
(ETD) for the analysis of posttranslational modifications. Proteomics. 2008, 8, 4466-4483.
(31) Good, D. M.; Wirtala, M.; McAlister, G. C.; Coon, J. J. Performance characteristics of
electron transfer dissociation mass spectrometry. Mol. Cell. Proteomics. 2007, 6, 1942-1951.
(32) Xu, H.; Zhang, L.; Freitas, M. A. Identification and characterization of disulfide bonds in
proteins and peptides from tandem MS data by use of the MassMatrix MS/MS search engine. J.
Proteome Res. 2008, 7, 138-144.
(33) Xu, H.; Hsu, P. H.; Zhang, L.; Tsai, M. D.; Freitas, M. A. Database search algorithm for
identification of intact cross-links in proteins and peptides using tandem mass spectrometry. J.
Proteome Res. 2010, 9, 3384-3393.
(34) Sharma, V.; Eng, J. K.; Feldman, S.; von Haller, P. D.; MacCoss, M. J.; Noble, W. S.
Precursor charge state prediction for electron transfer dissociation tandem mass spectra. J.
Proteome Res. 2010, 9, 5438-5444.
(35) Sadygov, R. G.; Hao, Z.; Huhmer, A. F. R. Charger: Combination of signal processing and
statistical learning algorithms for precursor charge-state determination from electron-transfer
dissociation spectra. Anal. Chem. 2008, 80, 376-386.
(36) Carvalho, P. C.; Cociorva, D.; Wong, C. C. L.; Carvalho, M. D. D.; Barbosa, V. C.; Yates,
J. R. Charge prediction machine: Tool for inferring precursor charge states of electron transfer
dissociation tandem mass spectra. Anal. Chem. 2009, 81, 1996-2003.
(37) Chassaigne, H.; Vacchina, V.; Łobiński, R. Elemental speciation analysis in biochemistry
by electrospray mass spectrometry. Trac-Trends Anal. Chem. 2000, 19, 300-313.
135
CHAPTER 5
FUTURE DIRECTION: GLYCOPEP GRADER UPDATES
ABSTRACT
GlycoPep Grader (GPG) is a publicly available tandem mass spectrometry (MS/MS) data
analysis tool that scores glycopeptide candidate compositions by evaluating two types of product
ions: 1) Ions that contain the peptide plus some portion of the pentasaccharide core, referred to as
[peptide + core component] ions, and 2) Ions formed via the neutral loss of monosaccharide
residues from the precursor ion, or [precursor – monosaccharide] ions.  Although GPG has
shown unprecedented success in identifying the correct glycopeptide candidate composition for a
given CID spectrum, a number of vital updates that should work to create a larger separation in
scores among the correct and incorrect compositional assignments have been identified.
Specifically, there are adjustments in the scoring algorithm that could be made for the
[peptide + core component] product ions, which are applicable to all N-linked glycopeptide
types, as well as a number of changes for glycopeptides containing complex or hybrid type
glycans.  The new rules proposed for grading the [precursor – monosaccharide] product ions for
these species would affect both the glycopeptide marker ions and precursor neutral losses
currently searched by GPG.  These results are so far untested and based on observations made
for the original collection of CID data that was used train and validate the software. Most
notable are suggested improvements to account for complex and hybrid type glycopeptide
arrangements that contain sialic acid residues.
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5.1 INTRODUCTION
The interpretation of glycopeptide data from tandem mass spectrometry (MS/MS)
experiments remains challenging today, even with the advent of automated tools to assist in the
elucidation of these spectra.  When glycopeptides containing sialic acid are considered,
glycopeptide identification tends to become even more difficult, due to the inherent problems
associated with the characterization of these negatively charged residues when using positive ion
mode collision induced dissociation (CID).1, 2, 3, 4 Although the negative charges add complexity
to their analysis, these acidic glycans play major functional roles in biological processes.4, 5, 6, 7, 8
In addition, sialic acids have proven critical to the development of efficacious and safe
glycoprotein therapeutics.6, 9, 10, 11, 12, 13 For example, the presence of sialic acid residues in
complex or hybrid glycans has been shown to increase the circulatory half-life of erythropoietin
in comparison to the asialo erythropoietin counterpart.6, 9, 10, 11, 12
To date, one of the current restrictions to publicly available glycopeptide software is the
inability to accommodate the distinctive CID features imparted by glycopeptides containing
sialic acid.  Although the MS/MS data collected on glycopeptides of high mannose or
complex/hybrid asialo type glycans generally contain more identifying fragmentation features
than those containing sialic acid, most automated programs fall short in their analysis as well.
One of the ways to improve the automation of glycopeptide identification is to make use of CID
product ion intensity information, which limited algorithms are equipped to do.14 More
challenging still, recent studies have shown that the charge state of a precursor ion is a critical
component to accurately identifying many of the product ions expected to be present upon
fragmentation of a given glycopeptide.14, 15 This applies to all glycopeptides, though it is
amplified for sialylated species.
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Few of the currently available automated MS/MS data analysis programs were
specifically intended for the characterization of glycopeptide spectra; they were instead, designed
for glycans. Accordingly, these programs lack the capacity to investigate the fragmentation
profiles of both the peptide and glycan portions of a glycopeptide.15 This is problematic in
glycopeptide analysis because many arrangements of these two unknowns (peptide and glycan
portions) combine to form a nearly identical neutral mass.16 It was with the goal of overcoming
these debilitating limitations that GlycoPep Grader (GPG) was originally constructed.  GPG’s
unique capabilities ultimately allow a user to discriminate between isobaric N-linked
glycopeptide compositions.  The correct composition is determined by scoring experimental
MS/MS data in a highly specific manner that depends on the fragmentation patterns typical of
each type of glycan substituent attached to a peptide.15
Although GPG has shown unprecedented success in the identification of N-linked
glycopeptide compositions, a number of potential improvements to the program have been
identified. The most important of which should greatly improve the scoring of sialylated
glycopeptides.  These proposed changes are based on the recent discovery of additional
fragmentation patterns found to be present in CID spectra of N-linked glycopeptides containing
sialic acid. In addition, the detailed findings described herein are not only essential for the
enhancement of GPG, but are also significant because they lend further insight into charge state
dependent fragmentation of glycopeptides, which has not been studied in much detail.17, 18
Additional updates to GPG are also discussed below.  One of these comes from an
important observation made for all MS/MS data collected on N-linked glycopeptides containing
hybrid or complex type glycans. Specifically, a change in a typical glycopeptide marker ion, or
commonly observed oxonium ion, is prosed for future versions of GPG.  The oxonium ion is
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significant for the software because the currently used marker ion, at m/z 366, is often out of the
scan range, and therefore not evaluated by GPG for a majority of CID spectra. Herein, we
change this marker ion to m/z 528, which is more likely to be detected because it has a greater
probability of being within the MS/MS scan range.
Overall, the potential improvements that have been identified since the release of GPG
should decrease variations in scoring, especially in the case where complex glycopeptides are
modified by sialic acid.  To this end, these improvements should work to increase user
confidence in the results for those tests where scores between alternate compositional
assignments are not as pronounced as in most cases.
5.2 EXPERIMENTAL
5.2.1 Materials and Reagents. Bovine asialofetuin, bovine ribonuclease B (RNase B),
human apo-transferrin (transferrin), urea, dithiothreitol (DTT), iodoacetamide (IAM), formic
acid, acetic acid, Sepharose® CL-4B, HPLC grade ethanol, and HPLC grade 1-butanol were
purchased from Sigma Aldrich (St. Louis, MO). HPLC grade methanol (CH3OH) and HPLC
grade acetonitrile (CH3CN) were purchased from Fisher Scientific (Fairlawn, NJ). Ammonium
bicarbonate (NH4HCO3) was purchased from Fluka (Milwaukee, WI) and sequencing grade
modified trypsin was from purchased Promega (Madison, WI). Ultrapure water was obtained
from a Millipore Direct-Q® UV 3 system (Billerica, MA) with a resistance greater than 18 MΩ.
5.2.2 CID MS/MS Data of RNase B, Asialofetuin, and Transferrin Glycopeptides.
Detailed information on the preparation and MS analysis of RNase B, asialofetuin, and
transferrin samples can be found in Chapter 2 of this dissertation.  Briefly, samples of RNase B,
asialofetuin, and transferrin were each prepared by Rebecchi and Woodin on multiple occasions,
using an enrichment method for the RNase B glycopeptides that was developed by Rebecchi et
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al.19 This collection of CID spectra, obtained for each sample by Rebecchi and Woodin, results
from the compilation of experiments published in the original GPG article, therein referred to as
the glycopeptide training data set.15
5.2.3 CON-S gp140ΔCFI Preparation and CID MS/MS Data. The CON-S gp
140ΔCFI CID spectra shown herein are from the glycopeptide validation data set of the original
GPG article, which was originally analyzed and reported on by Go et al.15, 20 Sample preparation
for the CON-S gp140ΔCFI glycopeptides was also performed by Go and co-workers, as
previously described.20 Detailed information on the experimental procedures and MS analysis is
also given in Chapter 3 of this dissertation.
5.2.4 Manual Data Analysis. To identify the glycopeptides from these samples in the
MS data, a prediction table of theoretical m/z values corresponding to glycopeptide compositions
for RNase B, asialofetuin, and transferrin was prepared.  The amino acid sequences from the
proteins were obtained from Uniprot (www.uniprot.org) and their sequences were imported into
Protein Prospector (http://prospector.ucsf.edu/prospector/mshome.htm). In the Protein
Prospector programs, settings were used to indicate peptides containing Cys residues were
modified with carbamidomethylation, and a theoretical tryptic digest was performed to consider
up to two tryptic miscleavages.  Peptide masses containing potential N-linked glycosylation sites
were added to the mass values of known, biologically relevant glycans, in order to obtain
glycopeptide masses.  These theoretical glycopeptide masses were converted into m/z values
corresponding to the glycopeptides existing in multiple charge states.  The MS/MS data for
RNase B, asialofetuin, and transferrin were then searched to identify spectra that contained m/z
values for ion fragments that correspond to the theoretical m/z values for a given glycopeptide
composition.  The CID spectra were carefully (manually) evaluated in order to verify the
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glycopeptide assignment, and subjected to analysis by GPG.
5.3 RESULTS AND DISCUSSION
The novel GPG software developed in our lab is a great advancement for researchers
working to decipher glycopeptide composition from MS/MS data. Although they have not yet
been tested, changes to the original GPG algorithm that could improve scoring for all N-linked
glycopeptides have been identified.  A summary of the major product ions for each glycopeptide
type is shown in Figure 1, as a reminder.  This figure is also shown in Chapter 2 of this
dissertation, where the basis for these devised glycan categories and their illustrated product ions
is described in great detail.
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   A.  [Peptide + Core Component] Ions            B.  [Precursor – Monosaccharide] Ions  
 
 
 
Figure 1.  Schematic of (A) [peptide + core component] and (B) [precursor – monosaccharide] 
product ions expected for each of the eight group types, described in the text.  In (A), the six 
different [peptide + core component] product ions detected for a glycopeptide, regardless of 
glycan type, are displayed.  In (B), the monosaccharide neutral losses evaluated for group 1 are 
shown in the purple oval; for group 2, the relevant losses are shown in both the purple oval and 
the yellow circle; group 3, the relevant losses are shown in the blue oval; group 4, in the blue 
oval and yellow circle; group 5, in the orange oval and yellow circle; group 6, in the green oval 
and yellow circle; and group 7 and group 8 neutral losses are presented by the orange oval, and 
the green oval, respectively.  This figure is adapted from the original ACS publication on GPG.
15 
 
The impact of the scoring differences is expected to be dependent upon the 
monosaccharide arrangements comprising the appended glycan, which the most pronounced 
differences expected for complex and hybrid type glycans, especially for those containing sialic 
acid.  This is hypothesized because there is not always a large difference in GPG scores between 
the actual and decoy candidate compositions for these compositions, as evidenced by some test 
cases shown in Chapter 3, Tables 2 and 3, of this dissertation.  For a few specific examples, see 
Tests 27, 28, and 29 of Chapter 3, Table 2.  Other updates should improve scoring for all N-
linked glycopeptides regardless of glycan substituent, such as those pertaining to the [peptide + 
core component], or peptide-containing, product ions.  The proposed updates that have been 
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formulated, but not yet tested, to improve scoring in future GPG software versions are described
below.
5.3.1 Peptide-Containing Glycopeptide Product Ions. In order to minimize the
contribution of random peak matches during the MS/MS data search by GPG, the following
update to the GPG algorithm is proposed. Currently, each match identified within the MS/MS
peak list that corresponds to those [peptide + core component] ions expected to be present for a
given glycopeptide is assigned a uniform score.  Instead, the algorithm could be updated to
incorporate an additional scoring factor for each consecutive hit by GPG for these ions.  This
update would increase the TotalRawPeptideScore (theoretical points possible) associated with
each composition.  Then, when each of these respective product ions found in series after the
first one is detected, an incrementally higher point value would be assigned to each candidate’s
respective ActualRawPeptideScore (actual points awarded).  The implementation of this scoring
factor would affect the overall PeptideScore (ActualRawPeptideScore/TotalRawPeptideScore)
associated with each candidate glycopeptide composition, though the final GlycopeptideScore
would still be weighed the same.  That is, the PeptideScore would still account for 67 % of the
total GlycopeptideScore.  The way the scoring of these terms are calculated is detailed in the
original GPG algorithm, as shown in Chapter 2, Table 2, of this dissertation.
Essentially, the longest number of consecutive [peptide + core component] product ions
that could be detected for each candidate composition would be added to their respective
TotalRawPeptideScore, and the number of these found in series would be added to their
ActualRawPeptideScore. This would be done for both the charge state of the precursor ion and
for the charge state below the precursor ion, as long as the calculated product ions are within
scan range.  For example, if matches were detected for a candidate composition that
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corresponded to the [peptide + HexNAc], [peptide + 2HexNAc], [peptide + 2HexNAc + Hex],
and [peptide + 2 HexNAc + 2Hex] ions, but no product ions was detected for the calculated
[peptide] or [peptide + 2 HexNAc + 3Hex] ions, the longest number of consecutive matches for
the peptide-containing product ions would be 4.  Therefore, 4 points would be added to that
glycopeptide’s ActualRawPeptideScore. However, since there were a total of 6 peptide-
containing product ions possible, 6 points would be added to that candidate’s
TotalRawPeptideScore. The purpose of this would be to decrease the impact of random peak
matches, especially in the case of spectra containing high noise levels.
5.3.2 Sialylated Glycopeptides. Recent studies suggest that fragmentation of
glycopeptides containing sialic acid is profoundly impacted by precursor charge state, and that
more than one dissociation pathway may to take place for these species under different charge
states.14, 15, 17, 21 Although a charge that is imparted during the electrospray ionization process
may reside in one of two distinct locations within the glycopeptide, namely the peptide backbone
or the attached glycan moiety, it is assumed that a glycan will not support more than one charge
due to a lack of basic (proton accepting) sites and inherent Coulomb repulsion between
charges.14 However, glycosidic cleavages may result from two distinct mechanisms, charge-
remote pathway or charge-directed pathway.14, 17 Proton distribution is shown to affect the
probability of each pathway, especially in the case of sialylated glycopeptide precursors.14 For
these species, it has recently been shown that precursor charge state determines which of the
cleavage pathways will dominate.14
Through extensive CID MS/MS data analysis performed in our lab, it was demonstrated
that fragmentation patterns in sialylated glycopeptides are dependent on charge state.  For
precursor ions with a charge state greater than or equal to 3 +, a different fragmentation profile
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was observed in the experimental data of those N-linked glycopeptides containing sialic acid, in
comparison to those precursors in the 1 + and 2 + charge states. These two fragmentation
patterns are depicted below in Figure 2. In A, the most likely point of cleavage is the glycosidic
bond joining sialic acid, or Neu5Ac, to the rest of the glycan substituent.  This leads to the loss of
individual sialic acid residues from the glycopeptide precursor.  In B, the most likely point of
cleavage is the glycosidic bond after the HexNAc residue of the glycan antennae, which results
in the loss of the entire branch, or the combined residues of Neu5Ac + Hex + HexNAc  from the
precursor ion.
Figure 2. Illustration of the two different fragmentation pathways observed in CID spectra of
sialylated glycopeptides.  In (A) the predominant cleavage observed for glycopeptide precursors
in the 1 + and 2 + charge states is shown, whereas the most likely point of cleavage detected for
glycopeptides in charge states higher than 3 + is shown in (B).  According to experimental CID
spectra, glycopeptide precursor ions with a charge state of 3 + were found to frequently
dissociate by either pathway.
The experimental data obtained in our lab corroborates the mathematical predictions of
Zhang, who recently extended a peptide fragmentation model to experimental CID MS/MS data
of N-linked glycopeptides.14, 22, 23 In these studies, Zhang and Shah demonstrate that sialylated
glycopeptides will dissociate according to charge-remote or charge-directed cleavage depending
on charge state, with characteristic losses for each matching the fragmentation pathway shown in
Figure 2A and Figure 2B, respectively.14 However, they report that sialic acid residues with a
CGLCPVLAENYNK CGLCPVLAENYNK 
A B 
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charge state equal to 3 + were found to dissociate by the charge-remote cleavage indicative of
lower charge state species.  In comparison, according to our collection of CID MS/MS data,
these 3 + glycopeptide species dissociate by both the charge-remote and charge-directed
pathways.
To illustrate the charge-directed cleavage of a 3 + precursor ion containing sialic acid,
MS/MS data of a transferrin glycopeptide is shown in Figure 3.  Here, the predominant neutral
losses detected within a CID spectrum are different than those expected for sialylated
glycopeptides of lower charge state.14 Specifically, a peak corresponding to the loss of an entire
branch, or the combined residues of HexNAc + Hex + Neu5Ac from the precursor ion, was
found to be present in high abundance for those species of higher charge states.
146
Figure 3. CID data collected on a transferrin glycopeptide at m/z 1227.9 in the 3 + charge state.
The most abundant product ion in this spectrum is detected in the 2 + charge state, resulting from
a combined loss of HexNAc + Hex + Neu5Ac residues from the precursor.  A very intense peak
at m/z 657 is also present in the spectrum, and is indicative of these species. Although the losses
of individual sialic acid residues are also present within the MS/MS data, these product ions are
much less abundant than they are for sialylated glycopeptide precursors of charge states lower
than 3 +. The current version of GPG scores the loss of individual sialic residues, and does so at
a relative abundance threshold that is above the detection limit for those charge states greater
than or equal to 3 +.
In contrast, the most predominant neutral fragment for a precursor ion of lower charge
state species was found to result from a loss of individual sialic acid residues, in both the charge
state of the precursor and the charge state below the precursor ion.15 These losses are illustrated
in Figure 4.  Evaluation of glycopeptide candidate compositions in future versions of GPG
should benefit by incorporating both fragmentation pathways into the scoring algorithm.
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Figure 4. MS/MS data at m/z 1841.8 of a sialylated glycopeptide from transferrin in the 2 +
charge state. For the CID data shown here, the most product ions are formed from individual
losses of sialic acid from the precursor, which are detected in the 2 + charge state. A peak at m/z
657 is present in the spectrum as well, but is less prominent than the same marker ion depicted in
Figure 3.
The spectra of the higher charge state species are also shown to contain an intense
glycopeptide marker ion at m/z 657, which is also depicted in Figure 3.  This marker ion is
present in the spectra of most compositions that contain sialic acid, regardless of charge state.21,
24, 25, 26 However, the relative abundance of the peak may vary.  Another proposed update to
GPG scoring is to score the presence of this marker ion for all sialylated glycopeptides,
regardless of precursor charge state.
5.3.3 Glycopeptide Marker Ion Detection for Complex/Hybrid Type Glycans. The
algorithm behind GPG could be improved if an update was made to score the glycopeptide
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marker ion of m/z 528, as opposed to the glycopeptide marker ion of m/z 366.  One of the reasons
for this is ambiguity of the m/z 366 ion that arises when scoring complex/hybrid type
glycopeptides against CID spectra of high mannose type glycopeptides, as the MS/MS data
collected on these species generally contains the m/z 366 marker ion as well.  This trend is also
shown by Huddleston et al. who concluded that CID data of glycopeptides with high mannose
and complex branching give rise to an intense peak at this molecular weight, due to the loss of
HexNAc + Hex from the charged precursor ion.27 Furthermore, from the experimental MS/MS
data acquired in our lab, glycopeptides containing sialic acid were also shown to possess a peak
at m/z 366.  The presence of this marker ion in the CID spectra of sialylated glycopeptides has
been also reported by Conboy and Henion.28
Often, because of the low molecular weight scan cut-off used, the marker ion at m/z 366
is out of scan range when glycopeptide MS/MS data is acquired on tryptic digests of
glycoproteins.  This occurs because the lowest mass range is limited on an ion trap instrument to
approximately 1/3 of the precursor ion’s m/z.29 GPG currently searches for the loss of this
specific product ion for glycopeptide compositions that contain more terminal Hex than HexNAc
residues, as shown in Figure 5.  Therefore, in many instances, the glycopeptide marker ion’s
score is not factored into the overall candidate score.  This adversely affects scoring for a number
of compositions.
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[Precursor – Monosaccharide] Product Ions Currently Scored by GPG
Figure 5. Schematic of the [precursor – monosaccharide] product ions searched by GPG for
each of the eight glycopeptide group types, previously detailed in Chapter 2 of this dissertation.
The glycopeptide marker ion at m/z 366 is currently searched for complex and hybrid type
glycans belonging to group 6 (which include those glycan compositions that contain at least one
fucose, and more terminal Hex than HexNAc residues) and group 8 (which include those glycan
compositions with no appended fucose, and more terminal Hex than HexNAc residues).  The
characteristic product ions for group 6 are depicted by the yellow circle and green oval, whereas
the characteristic product ions for group 8 are shown in the green oval.  This figure is adapted
from the original ACS publication on GPG.15
In Figure 6, representative MS/MS data collected on an asialofetuin glycopeptide with a
scan range of 500-2000 m/z is given.  The composition of the glycan in this case contains more
terminal Hex than HexNAc residues.  Although m/z 366 is out of range, the spectrum shows the
presence of a peak at m/z 528, which corresponds to the oxonium ion that results by the loss of
Hex + HexNAc + Hex from a complex type glycopeptide precursor.
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Figure 6. CID spectrum from a complex type asialofetuin N-linked glycopeptide precursor in
the 2 + charge state. An intense marker ion at m/z 528 is shown to be present in the spectrum.
The current version of GPG evaluates the presence of a marker ion at m/z 366.  This product ion
is often out of scan range for MS/MS data taken on tryptically digested glycopeptides, whereas
m/z 528 is more likely to be within the scan range.
Originally, the algorithm was designed to search for a peak at m/z 366 for only those
complex and hybrid type glycans, absent of sialic acid residues, that contain an appropriate
number of Hex versus HexNAc residues.  The expected fragmentation for glycopeptides of these
glycan categories is shown by groups 6 and 8 of Figure 1.  The characteristic [precursor –
monosaccharide] product ions for these glycan compositions is shown again in Figure 5,
although a more thorough discussion on each of the devised glycan categories (including their
respective monosaccharide arrangements) is provided in Chapter 2 of this dissertation.  After
extensive analysis of experimental CID MS/MS data, it became apparent that both of these
151
marker ions (m/z 366 and m/z 528) are detected in the spectra of most complex and hybrid N-
linked compositions, regardless of the ratio of terminal residues.  Therefore, future versions of
GPG should score the presence of this ion for all complex and hybrid type arrangements that do
not contain sialic acid, regardless of whether they contain more HexNAc or Hex residues after
the common pentasaccharide core.  The original fragmentation evaluated for these glycans,
which this new rules will now extend to, is illustrated in groups 5 and 7 of Figure 1.
In CID experiments fucose is considered labile, and numerous instances of rearrangement
events have also been documented for fucosylated species.17, 30 For complex/hybrid type
glycopeptides appended with fucose, GPG not only evaluates the presence or absence of the
product ions formed by the loss of this monosaccharide, but the remaining glycan portion as
well.  As such, it was important to verify the formation of the oxonium ion at m/z 528 for
fucosylated complex type glycopeptides to ensure that this update would be applicable to these
more labile compositions.  In Figure 7, the presence of this marker ion is shown to be readily
detectable for an N-linked glycopeptide from CON-S gp140ΔCFI containing one fucose residue.
In contrast to the data shown in Fig. 6, the glycan substituent in this instance contains more
terminal HexNAc than Hex residues.
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Figure 7. MS/MS data collected on a fucosylated N-linked glycopeptide from CON-S
gp140ΔCFI. An intense marker ion at m/z 528 is shown to be present for complex/hybrid
compositions whether or not fucose is present.  This is significant because GPG evaluates the
remaining portion of a glycopeptide independently after the expected product ions resulting from
loss of fucose are scored.
Due to the issues discussed above, the glycopeptide marker ion at m/z 528 is presumed to
be a more logical choice for the identification of complex or hybrid type glycopeptides over the
marker ion at m/z 366, which is currently evaluated by GPG when scoring appropriate [precursor
– monosaccharide] product ions.  A schematic of future GPG scoring encompassing all of the
proposed updates to the [precursor – monosaccharide] product ions, including the changes in
glycopeptide marker ion evaluation, is given in Figure 8.
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[Precursor – Monosaccharide] Product Ions Proposed for Future GPG Scoring 
 
 
 
Figure 8.  Proposed schematic of [precursor – monosaccharide] product ions searched by future 
versions of GPG for scoring each of the eight glycopeptide group types.  The monosaccharide 
neutral losses evaluated for group 1 are shown in the purple oval; for group 2, the relevant losses 
are shown in both the purple oval and the yellow circle; group 3, the relevant losses are shown in 
the blue oval; group 4, in the blue oval and yellow circle; group 5, in the orange oval and yellow 
circle; group 6, in the green oval and yellow circle; and group 7 and group 8 neutral losses are 
presented by the orange oval, and the green oval, respectively.  Expected product ions for group 
1 and group 2 remain unchanged if these updates are incorporated into the current algorithm, but 
change for complex/type glycans with (groups 3 and 4) and without (groups 5, 6, 7, 8) sialic 
acid.  This figure is adapted from the original ACS publication on GPG.
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5.3.4 Other Potential Future Updates.  One of the more obvious improvements to 
future versions of GPG is the incorporation of a scoring function designed to handle 
glycopeptide precursors containing common adducts, such as sodium or potassium.  These 
adducts are often found in CID MS/MS data of N-linked glycopeptides, especially those samples 
extracted from biological matrixes.
21, 31, 32
  However, other updates have been identified as more 
vital at this time.  In addition, as the development of GPG is complex and heavily based in 
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mathematical calculations, the incorporation of scoring designed for glycopeptide adducts would
take a long time to implement.
Another future update to GPG centers on analysis of glycopeptide branching
characteristics.  Although the software only identifies composition at this point, future versions
may allow users the ability to decipher basic structural information such as the number of glycan
branches. One of the recent observations made in our laboratory for CID spectra of complex or
hybrid type glycans is a difference in intensity for two common product ions.  Specifically, a
comparison in the intensity of product ions formed by loss of 1) HexNAc, and 2) HexNAc +
Hex, from the glycopeptide precursor.  A comparison between the intensity of these two product
ions may lend potential insight into glycopeptide branching, including whether a glycoform is bi-
or tri-antennary.
Finally, a potential future direction of GPG could be to incorporate an algorithm into the
software that is specific to O-linked glycopeptides.  Currently, no automated analysis program
has been designed to evaluate MS/MS data and determine the identity of both the peptide and
glycan portions of O-linked glycopeptides.  Some of the challenges associated with the
automation of O-linked glycopeptide MS/MS data analysis are given in Chapter 1 of this
Dissertation.  The inclusion of a GPG algorithm designed specifically for MS/MS scoring of O-
linked species would be a major project, as a new set of fragmentation rules would first need to
be devised using CID MS/MS data collected on O-linked glycopeptides.
5.4 CONCLUDING REMARKS
Recently, we developed an automated analysis tool, GlycoPep Grader (GPG) to
determine the N-linked glycopeptide composition for a given CID spectrum. After extensive
testing of the program, a number of improvements that could render the GPG more effective
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have been identified.  In addition, although the GPG program has shown to be highly accurate, a
limited number of spectra collected on glycopeptides containing sialic acid, or both sialic acid
and fucose, have been evaluated for improved data analysis.
When testing MS/MS data of N-linked glycopeptides containing these labile
modifications, the scores between actual and decoy glycopeptide compositions of nearly
identical neutral mass were found to be closer in value than the scores acquired for glycopeptide
precursors possessing other N-glycan arrangements, as shown in Tables 2 and 3 from Chapter 3
of this dissertation. After further analysis, an alternate predominant fragmentation pathway was
identified for glycopeptide precursor ions containing sialic acid appearing in the 3 + charge state
or higher.  This pathway demonstrates the consistent loss of a sialylated glycan branch. The
incorporation of this pathway, along with other described improvements to the algorithm, should
improve the scoring margin of GPG when discriminating the actual glycopeptide composition
from a pool of decoy candidates corresponding to the same m/z.
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CHAPTER 6
CONCLUSION
6.1 SUMMARY OF DISSERTATION CONTENT.
Protein glycosylation and disulfide bond formation are two common post-translational
modifications (PTMs) that are widespread among all three taxonomic domains.1, 2, 3 The
characterization of these and other PTMs are routinely performed using mass spectrometry (MS)
and tandem mass spectrometry (MS/MS) experiments,4, 5 and the availability of reliable
automated tools greatly increases the amount of data that can be processed in a given amount of
time.6
In the analysis of glycopeptides, a lack of publicly available programs to evaluate the two
individual components they are comprised of, the peptide and glycan portions, has hampered the
speed at which collision induced dissociation (CID) MS/MS data interpretation is
accomplished.6, 7 To overcome this limitation, we developed the GlycoPep Grader (GPG)
program to automate the compositional determination of N-linked glycopeptides from CID
spectra.7 The algorithm that powers GPG was designed using a set of glycopeptide
fragmentation rules derived from careful analysis of experimental CID MS/MS data collected on
glycopeptides with various N-linked glycan arrangements.7
The ability to map a protein or peptide’s disulfide bonds through MS/MS experiments is
plagued with challenges similar to those encountered in the elucidation of glycopeptide MS/MS
data. That is, automation of applicable programs to process MS data of peptides containing
disulfide bonds is still in the infancy stage.  Furthermore, software for newly developed
dissociation techniques such as electron transfer dissociation (ETD) MS/MS were not designed
to interpret data collected on proteins or peptides with intact disulfide linkages.8 As a result,
160
analysis tools to assist in the extraction of even basic information from a mass spectrum, such as
precursor charge state, are currently lacking for these species.  To this end, we have devised an
automated approach that works to assign precursor charge state from ETD MS/MS data of
disulfide-bonded peptides using two Excel-based computational tools.
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